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  ------ ------ ------  — SUMMARY ------    —  ------ -----  ------
Following oral adm inistration of a nephrotoxic dose (200mg/kg) of 
hexachloro-l:3-butadiene (HCBD) to  male ra ts , b ile  was the princ ipa l 
route of excretion, 17-20% of the dose being elim inated on each of 
the f i r s t  two days. Faecal excretion over th is  period was less than 
5% of the dose per day, suggesting enterohepatic re c ircu la tio n  of 
b i l ia ry  metabolites. Urinary excretion was small, not exceeding 3.5% 
of the dose during any 24hr period.
Incubation of HCBD with ra t l iv e r  microsomes in v it ro  gave a product 
which was chromatographically (TLC) s im ila r to  the major b i l ia ry  
metabolite of HCBD. The in v it ro  and major b il ia ry  metabolite were 
id e n tif ie d  as S -(l,l,2 ,3 ,4 -pen tach lo ro -l,3 -bu tad ieny lJg lu ta th ione  which 
demonstrated a d irec t conjugation reaction without p r io r  oxidation.
The cyste inylg lycine conjugate o f HCBD was also found in b ile .
Evidence has been obtained to  show that b il ia ry  metabolites o f HCBD 
are reabsorbed and excreted via the kidneys. Whole body 
autoradiography demonstrated a high concentration of ra d io a c tiv ity  
in  the outer medulla of the kidney on dosing [1 4 C]-HCBD. The 
glutathione conjugate, i ts  mercapturic acid derivative  and b ile  
containing HCBD metabolites are a ll nephrotoxic when dosed o ra lly  to  
ra ts . In common with HCBD, these metabolites cause loca lised damage 
to the kidney with minimal e ffects in  the l iv e r .  Rats f i t te d  w ith 
a b il ia ry  cannula were completely protected from kidney damage when 
dosed with HCBD, demonstrating that hepatic metabolites are so le ly 
responsible fo r the nephrotoxicity of th is  compound.
I t  i  s proposed tha t the hepatic g lu ta th i one conjugate o f HCBD was 
degraded to i ts  equivalent cysteine conjugate which was cleaved by the 
renal cytoso lic  enzyme 8 -lyase to give a tox ic  th io l which caused 
localised kidney damage. A urinary sulphenic acid metabolite o f HCBD 
has been id e n tif ie d  which is  consistent with th is  hypothesis. The 
mode of activa tion  o f HCBD conjugates in the kidney is  believed to  
be analogous to that proposed fo r  S -( l,2 -d ich lo ro -v in y l)-L -cys te in e .
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INTRODUCTION
1.1 HCBD i ts  Uses and the Risk o f Human Exposure
Hexachloro-1,3-butadiene (HCBD) is a chlorinated a lip h a tic  
unsaturated hydrocarbon with the fo llow ing s truc tu re :-
/
Cl
Cl
\
Cl Cl 
I /
c = c -  c = c 
I \  
Cl Cl
MW 260.76
I t  is  a colourless non fTamable liq u id  w ith the odour of tu rpentine. 
I t  is  read ily  soluble in alcohol, ether, hexane and other organic 
solvents but sparingly soluble in water (0.0005%) (Gauntley et al 
1975). HCBD is produced as a by-product in the manufacture of 
tetrachloroethylene, trich lo roethy lene and carbon te trach lo ride  
(IARC, 1979) and is also found in association with the fungicide
hexachlorobenzene (Laska et al 1976).
Although HCBD is  a by-product i t  has some commercial uses in the 
p lastics industry and in the recovery of chlorine during the 
manufacture of hydrochloric acid. In Russia, i t  has been used as a 
vineyard fumigant (Laseter et al 1975), to  tre a t grape phylloxera 
(EPA 1975), and has been suggested fo r  use as an insectic ide  and
herbicide (Laseter et al 1975 and Davis et al 1980).
Due to manufacturing processes and the disposal methods used fo r
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chlorinated compounds HCBD has been detected as an environmental 
po llu tan t in Liverpool Bay (McConnell et al 1975), in the inland 
lakes fed by the River Rhine (Goldbach et al 1976) and in the lower 
M ississippi r iv e r  (Laska et al 1976). Concentrations up to  1.5ppb 
have been detected in the water, and up to 300ppb in so il samples 
from the levee of the M ississippi r iv e r  between Baten Rouge and New 
Orleans, LA. HCBD has also been detected in various aquatic 
organisms. However the Environmental Protection Agency do not 
believe tha t there is  a s u ff ic ie n t basis to fin d  tha t the current 
manufacture, d is tr ib u tio n , processing, use or disposal o f HCBD 
presents an unreasonable r is k  to the environment (Federal Register 
1982). As well as environmental exposure, man could p o te n tia lly  be
exposed to HCBD in his occupational environment when disposing of 
the "heavies" produced in the production o f t r i -  and 
tetrachloroethylenes. The suggested maximum permissable level fo r  
exposure to HCBD is 0.0009ppm (0.01mg/m^) (Poteryaeva 1972).
Current le g is la tio n , the Health and Safety at Work Act, requires 
tha t chemicals be tested in animals to  enable assessment o f human 
r is k . The current lite ra tu re  available on HCBD is  presented in the 
next section.
1.2 The Toxicology o f HCBD in Animals
Most studies on the e ffects  of HCBD have been carried out using the 
rodent species, ra t, mouse, hamsters and guinea pigs, although some 
data is  available on cats and avian species. Studies have been 
carried out using various routes of adm inistration and using acute, 
subacute or chronic dosing.
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Acute
The oral LD100 and LD50 fo r  mice have been reported at 1200mg/kg and 
200mg/kg respective ly (Poteryaeva 1972). Other studies have 
reported LD50 values o f llOmg/kg and 87mg/kg (Murzakaev 1963), 
80mg/kg and 65mg/kg (Gradiski et al 1975) fo r males and females 
respective ly.
In the study done by Gradiski et al (1975), anatomopathological, 
haematological and biochemical tests revealed hepatic and renal 
disorders. The mice showed tubular necrosis, modifications in the 
number of leucocytes, erythrocytes and to ta l haemoglobin.
Biochemical tests in the female a fte r ip administration o f HCBD 
showed s ig n ifica n t changes in serum alanine aminotransferase, 
aspartate aminotransferase and urea.
The oral LD50 values fo r ra ts vary, values have been reported as 
580mg/kg in male Sprague-Dawley rats and 200-400mg/kg in female ra ts 
(Kociba et al 1977a) whereas LD50 values o f 250 ± 30mg/kg and 
270±20mg/kg have also been reported (Gradiski et al 1975) fo r  males 
and females respective ly.
In traperitoneal in jec tion  of HCBD gave LD50 values of 216 ± 6  and 
175 ± 25mg/kg fo r  male and female ra ts  (Gradiski et al 1975).
HCBD is  tox ic  on acute dermal adm inistration, the LD50 in ra ts being 
4330mg/kg (Chernokon 1971) and in New Zealand rabbits 12000mg/kg. 
During exposure the rabbits displayed a moderate depression o f the
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central nervous system. In animals dying w ith in  24hr, macroscopic 
examination revealed tha t the main lesions were in the lungs, l iv e r  
and in the kidneys. Microscopic examination demonstrated tha t the 
lesions in the kidney were in the proximal convoluted tubules 
(hydropic changes and vacuo lisa tion ). Those animals surviving 
longer showed weakness and anorexia, fa t ty  degeneration of the 
l iv e r ,  and the cortex of the kidney was so ft and pulpy. Within 3 or 
5 days the rabbits died from nephrosis. In a ll animals the skin in 
the area of exposure was haemorrhagic and necrotic (Duprat and 
Gradiski 1978). As a skin i r r i t a n t  HCBD has been described as both 
a mild (Gradiski et al 1975) and medium i r r i t a n t  (Duprat et al 1976) 
in the ra bb it. Gradiski et al (1975) also noted a marked skin 
reaction on guinea pigs exposed to HCBD. I r r ita t io n a l e ffects  on 
the occular mucous membranes o f rabb its  have also been reported in 
these studies.
Single inha la tiona l exposures of ra ts to atmospheres containing 133- 
500ppm HCBD fo r 4-7 hours resulted in death of some or a ll o f the 
exposed animals. Rats survived exposure to 161ppm fo r  0.88hr or 
34ppm fo r  3.5hr. Guinea pigs and cats were more sensitive and most 
died on exposure to HCBD at 161ppm fo r  0.88hr or 34ppm fo r  3.5hr 
(Gehring and MacDougall 1971). The LC50 fo r  mice has been reported 
to be 235ppm fo r  4 hours (Gage 1970) or lOppm fo r  6  hours (Gradiski 
et al 1978). In th is  la s t study, HCBD was ranked as the most to x ic  
o f the chlorinated solvents tested.
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Sub-acute
Both male and female rats fed HCBD at 450ppm and 150ppm in d ie ts fo r  
14 days showed a decreased weight gain which was associated with a 
decreased food consumption. The re la tiv e  kidney weights increased 
in males and females at both doses o f HCBD. H istopathological 
changes were found only in the kidney at 50ppm HCBD and above.
These changes were characterised by degeneration of tubular 
e p ith e lia l ce lls  which occurred in a dose-dependent manner, 
especia lly in the s tra ig h t portion o f the proximal tubules in the 
outer zone of the medulla (Harleman and Seinen 1979). In a 
d iffe re n t study (Kociba et al 1977b), the kidney was also noted as 
the organ which was most sensitive to the deleterious e ffects  of 
HCBD. An increase in kidney : body weight ra tio ,  tubular 
degeneration, necrosis and regeneration was observed in rats 
receiving 30, 65 and lOOmg HCBD/kg/day fo r  30 days. Other e ffec ts  
observed were decreased food consumption, body weight gain and 
haemoconcentration at lOmg/kg/day and above and hepatocellu lar 
swelling at lOOmg/kg/day.
Inhalational exposure to HCBD at lOOppm fo r  6 hr/day fo r  12 days 
produced severe to x ic ity  including resp ira to ry  d i f f ic u l t y ,  decreased 
weight gain and pathological in ju ry  to  the tubular epithelium  of the 
kidney (Gage 1970).
Chronic
Rats given d a ily  doses o f HCBD by gavage fo r  13 weeks showed reduced
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body weight gain and increased kidney weight at 6.3 and 15.6mg/kg in 
both male and females. Degeneration o f proximal renal tubules 
occurred at doses of 2.5 and 6.3mg/kg or more in females and males 
respective ly. At 15.6mg/kg in females, changes were noted in the 
convoluted and s tra igh t portion o f the proximal tubules. E p ith e lia l 
ce lls  of the proximal tubules showed large hyperchromatic nucle i. 
H yperce llu la rity  o f the e p ith e lia l lin in g  was the most prominent 
feature in the s tra igh t segment o f the proximal tubules, the 
e p ith e lia l ce lls  were small, more basophilic and f in e ly  vacuolated. 
Necrotic ce lls  were observed and nuclear d e tritu s  was found in the 
lumen. The brush border of the e p ith e lia l lin in g  was th inner or 
absent. C a lc ified  casts were found in the loops of Henle and 
co llec ting  ducts. In males, changes were less pronounced. Urine 
concentrating a b i l i t y  was reduced in females at greater than 
2.5mg/kg HCBD and in males at 15.6mg/kg HCBD. Increased cytoplasmic 
basophilia of hepatocytes associated w ith an increased l iv e r  weight 
occurred in males at 6.3 and 15.6mg/kg. An increase in female l iv e r  
weight was observed only at 15.6mg/kg (Harleman and Seinen 1979).
In a s ix month study, d a ily  doses o f HCBD at 7mg/kg given to ra ts 
produced morphological changes in l iv e r ,  kidney and myocardium in 
the form of parenchymatous dystrophic lesions and c ircu la tio n  
disturbances. Decreased SH groups in blood and cerebral cortex were 
noted (Murzakaev 1967).
L ifetim e ingestion of 20mg/kg/day HCBD in the d ie t caused m u ltip le  
tox ico log ica l e ffects in ra ts . These e ffects  included increased 
m o rta lity  (males) decreased body weight gain, increased urinary
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excretion of coproporhyrin and increased terminal kidney weight in 
males and females. Pathological examination revealed changes in the 
kidneys, including hyperplasia and neoplasia o f renal tubular 
epithelium. Some of these neoplasia were noted grossly as nodules 
in the kidneys and were m icroscopically diagnosed as renal tubular 
adenomas or adenocarcinomas. 23% of males and 15% of the females at 
th is  dose had renal tubular neoplasma, some of which metastasized to 
the lungs (Kociba et al 1977a; Kociba et al 1977b; Kociba et al 
1977c). The life tim e  study (Kociba et al 1977a and b) indicated a 
clear dose-response fo r  HCBD-induced to x ic ity .
Reproductive studies with HCBD have fa ile d  to fin d  any e ffe c t on 
reproduction in terms of percent pregnancy and neonatal survival 
(Kociba et al 1977a; Schwetz et al 1977) and except fo r  decreased 
body weight at b ir th  and weaning (Harleman and Seinen .1979) the 
pregnancies developed normally.
1.3 The Kidney and i ts  S u sce p tib ility  to Chemical Damage
Anatomy of the nephron with regard to HCBD induced nephrotoxic ity
The nephrotoxin HCBD is  known to damage a spec ific  part o f the 
kidney nephron structure , the so called Sg segment (pars recta) or 
s tra ig h t portion o f the proximal tubules, situated in the outer 
s trip e  of the outer medulla of the ra t kidney. The nephron is  the 
functional un it o f the kidney and consists o f the Malpighian 
corpuscle (glomerulus and Bowman's capsule), proximal tubule, th in  
limbs, the d is ta l tubule and the connecting segment or in i t ia l
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segment of the co rtica l co lle c ting  duct (Fig 1 .1). Each nephron 
possesses a loop of Henle, the length of which depends on the 
position of i ts  glomerulus in the cortex. The loop of Henle is  
composed of the s tra igh t portion o f the proximal tubule (pars 
rec ta ), the th in  limb segment, and the s tra ig h t portion of the 
d is ta l tubule (pars rec ta ). In the ra t there are two types of 
nephron, the c o rtica l which have short loops of Henle, and the 
juxtamedullary nephrons which have long loops of Henle with well 
developed descending and ascending th in  limb segments tha t enter the 
inner medulla. Based on the anatomical d is tr ib u tio n  of regions of 
the nephrons at various levels in the medulla, i t  is possible to 
d ivide the medulla in to  an inner and outer zone, w ith the la t te r  
fu rth e r subdivided in to  inner and outer s trip es . The inner 
medullary zone contains both descending and ascending th in  limbs and 
large co lle c ting  ducts. The inner s trip e  of the outer medullary 
zone contains descending th in  limbs and ascending th ick  limbs in 
addition to the co lle c tin g  ducts. The outer s tr ip e  of the outer 
medullary zone contains the terminal segments of the proximal 
tubule, the ascending th ick  limbs of the d is ta l tubule and 
co llec ting  ducts.
The in i t ia l  portion of the proximal tubule, the convoluted segment 
is  usually refered to as the pars convoluta and the more d is ta l 
s tra igh t segment, as the pars recta. In the ra t,  three d is t in c t 
morphological segments have been id e n tif ie d  (Tisher 1976). The 
s truc tu ra l features tha t d istingu ish  these segments have been 
described in d e ta il by Maunsbach (1964 and 1966). The f i r s t  
segment, S^ 9 corresponds to the f i r s t  portion of the pars convoluta.
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Figure 1.1
Diagram of the s truc tu ra l organisation of the mammalian kidney 
to demonstrate the relationships between the various segment 
of the nephron and the zones of the kidney.
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The second segment, S2  includes the la s t part o f the pars convoluta 
and the in i t ia l  portion of the pars recta. The th ird  segment, S3 ,
comprises the remainder of the pars recta and extends to the
tra n s itio n  with the th in  descending limb o f Henle. The epithelium  
of the pars recta is  generally cuboidal; the apical c e ll surface is 
convex and is  covered by a well developed brush border composed o f
elongated m ic ro v ill i measuring up to 4 .Op in length. The brush
border is  more extensively developed in the S3  segment than in or 
S2  segments. S3  ce lls  are smaller in height, number and have 
smaller more randomly organised mitochondria than in S-^  or S2  c e lls .  
There is  a marked absence of la te ra l in te rd ig ita tio n s . Microbodies 
are increased in size and number in the S3  c e lls . The sign ificance 
of these s tructu ra l differences is presently unknown, however, i t  is 
believed tha t th is  portion of the kidney tubule is  less involved 
w ith sodium and water reabsorption (requ iring  active transport) than 
is  e a r lie r  regions of the proximal tubule, but the ra te  of energy 
dependent secretion of organic acids, such as para-aminohippuric 
acid is  greatest in the pars recta.
S u sce p tib ility  o f the kidney to chemical damage
Maintenance o f normal kidney functions, excretion of wastes, 
regulation of homeostasis, hormone synthesis and biochemical and 
metabolic processes requires de live ry o f large amounts o f metabolic 
substrates and oxygen to the kidney, th is  requires a high blood 
flow . Although the two kidneys comprise less than 1% of the to ta l 
bodyweight, they normally receive about 25% of the resting  cardiac 
output.
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Because of the high blood flow , any chemical in the c ircu la tio n  w i l l  
be delivered in high amounts to  th is  organ. Appoximately one-th ird 
of the plasma reaching the kidney is f i l te re d .  As the glomerular 
f i l t r a t e  passes down the nephron, approximately 98-99% of the s a lt 
and water are reabsorbed, concentrating both the urine and any 
f i l te re d  xenobiotics in the tubular lumen. Thus, a non-toxic 
concentration of a chemical in the plasma could reach a tox ic  
concentration w ith in  the nephron. The high luminal concentration 
creates a steep concentration gradient between tubular f lu id  and 
plasma. Small water soluble molecules or l ip id  soluble compounds 
which have high membrane perm eability, may then d iffuse  back in to  
plasma. During passive reabsorption of the xenobiotic chemical from 
the tubular urine in to  the blood i t  w i l l  pass through tubular ce lls  
in high concentration, p o te n tia lly  leading to in tra c e llu la r  
to x ic ity .
Active transport systems also play a s ig n ific a n t ro le  in the 
excretion of chemicals by the kidney. These systems secrete some 
chemicals in to  the tubular lumen and thus increase th e ir  excretion 
in urine. Two major transport systems are p rim a rily  responsible fo r  
the secretion of fore ign chemicals, the organic anion and the 
organic cation systems (Weiner, 1973). Their major function appears 
to be the rapid e lim ination of compounds, e ithe r endogenous or 
exogenous in o r ig in , which might prove to x ic  to the organism. Both 
systems transport a broad range of compounds, in general requ iring  
only tha t the molecule is  organic and tha t i t  carries a charge at 
physiological pH. Since so many foreign chemicals and/or th e ir  
metabolites possess these cha rac te ris tics , these transport systems
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play a dominant ro le  in co n tro llin g  the rate at which many 
environmental chemicals are elim inated (P ritchard, 1981). A 
xenobiotic ac tive ly  secreted in to  the tubular urine w il l  pass 
through the ce lls  of the proximal tubule and could lead to to x ic ity  
w ith in  these c e lls .
Normally, plasma binding o f xenobiotics renders them unavailable fo r  
fu rth e r d isposition  however, the active transport secretory systems 
can e ffe c tiv e ly  s tr ip  xenobiotics from plasma proteins (Weiner,
1973) and hence plasma protein bound xenobiotics may become to x ic  to 
the kidney.
The kidney is  a m etabolically competent organ in tha t i t  can carry 
out both phase I and phase I I  metabolic processes, and therefore i t  
has the potentia l to metabolise xenobiotics to h igh ly reactive 
intermediates which may be responsible fo r  the observed acute kidney 
in ju ry , a point which w i l l  be considered in more d e ta il in section 
1.4.
S ite o f in ju ry  produced by HCBD in the ra t
Pattern of pathological changes: HCBD has been shown to
s p e c if ic a lly  damage the pars recta of the proximal tubule of the ra t 
kidney and in p a rticu la r the S3  segment (Ishmael et al 1982). 
Administration of HCBD ip at 300mg/kg caused u ltra s tru c tu ra l changes 
as early as one hour a fte r dosing. Mitochondrial swelling was seen 
in the S^  and S2  segments of the proximal tubules a fte r 1-4 hours.
By 8  hours, the major pathological changes were la rge ly  confined to
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the Sg segment and consisted o f loss o f brush border, mitochondrial 
swelling, d ila tio n  of the endoplasmic reticulum and c e llu la r  
necrosis. This was the e a rlie s t time tha t morphological changes 
were detected by lig h t  microscopy. In animals dosed with HCBD at 
2 0 0 mg/kg ip , several proximal tubules showed necrosis at sixteen 
hours when a d is t in c t band o f necrosis was seen in the outer s trip e  
of the outer medulla. One and two days a fte r dosing proximal 
tubular necrosis was s t i l l  evident, whereas d is ta l tubules were 
unaffected. By three days, vacuo!ation was observed in the pars 
convoluta o f some tubules, and the pars recta of many of the tubules 
were f i l le d  with amorphous necrotic material while others appeared 
empty and were lined by fla ttened  c e lls . Tubular regeneration was 
apparent by day f iv e . By day fourteen, substantial recovery had 
occurred.
Effects on renal func tion : Twenty four hours a fte r a single
in traperitonea l in jec tio n  of HCBD (200mg/kg) there was a reduction 
in the renal clearances of in u lin  (a measure of glomerular 
f i l t r a t io n  ra te ), the organic cation te trae thy l ammonium bromide 
(TEA), the organic anion p-aminohippuric acid (PAH) (ind ica to rs  o f 
renal active transport mechanisms). The urinary excretion o f urea 
was also reduced and was accompanied by an increase in plasma urea 
concentration. Urine flow was s ig n if ic a n tly  reduced. These changes 
suggested a general reduction in renal function (Lock and Ishmael 
1979).
A decrease in PAH but not TEA accumulation was seen in renal 
co rtica l s lices from rats treated with HCBD 24hr previously, which
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demonstrated se lective  damage to  the renal anion transport system 
without damaging the cation system. The renal anion transport 
system is located w ith in  the proximal tubule, with the most active 
system being in the s tra ig h t portion (Tune et al 1969).
Biochemical detection o f HCBD induced renal damage: The damage
produced by HCBD can be detected using various biochemical markers. 
Twenty four hours a fte r dosing lOOmg/kg HCBD, Lock and Ishmael 
(1979) noted an increase in plasma urea concentration, an increase 
in the urinary excretion o f a lka line  phosphatase, N -acetyl-8 -D- 
glucosaminidase and pro te in . Urinary glucose has also been shown to 
be a valuable parameter in assessing renal damage due to HCBD (Gore 
et al 1981; Berndt and Mehendale 1978).
1.4 Metabolic Considerations and Possible Mechanisms of 
Nephrotoxicity
Introduction
I t  is  well known tha t the liv e r  and kidney together serve to 
elim inate xenobiotics from the body. Expressed simply, xenobiotic 
molecules too large or too l ip id  soluble fo r  e ffe c tive  renal 
excretion can be excreted in the b ile . In addition hepatic 
metabolism has the a b i l i t y  to convert many of the l ip id  soluble 
xenobiotics to more polar metabolites, which may then be excreted by 
the kidney. However, while the ro le  o f the kidney as an excretory 
organ fo r  drugs, chemicals and th e ir  polar metabolites is  well
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described, the involvement of the kidneys in the biotransformation 
of xenobiotics is  re la t iv e ly  poorly understood. The 
biotransformation of xenobiotics can occur in two steps, termed 
phase I and phase I I  (Williams 1959). Phase I reactions, include 
oxida tive , reductive and hydro ly tic  reactions. Phase I I  reactions 
include synthetic (conjugation) reactions including, fo r  example, 
glucuronidation, sulphation and the formation o f glutathione 
conjugates. These phases reduce the 1ipophi1ic i t y  o f the parent 
compounds and in the case of tox ic  or pharmacologically active 
compounds th is  frequently reduces th e ir  to x ic ity .  However, examples 
e x is t where the reverse is true . The kidney is  known to carry out 
both phase I and I I  metabolic reactions.
B iological fa te  of HCBD
Limited lite ra tu re  was available on the metabolic fa te  o f HCBD when 
s ta rtin g  th is  thesis. In order to pred ict possible routes of 
metabolism, one could only draw s truc tu ra l comparisons of HCBD with 
compounds upon which metabolic data was ava ilab le .
The halogenated ethylene series most c lose ly resemble HCBD in th a t, 
although not possessing a diene s tructu re , they do have an o le f in ic  
structure . The examples which w il l  be discussed are v iny l ch lo ride , 
vinylidene chloride ( 1 , 1 -d ich loroethylene), trich lo roe thy lene  and 
te trach 1 oroethylene (perch1 oroethylene).
-  16 -
Nephrotoxic po tentia l o f the chioroethylenes
The chioroethylenes are p rim a rily  known fo r  th e ir  hepatotoxic 
e ffe c ts , however some are known to be weak nephrotoxins, producing 
kidney damage at high doses or on prolonged exposure. Repeated 
inhalational exposure to v iny l chloride over periods of several 
weeks produced proximal tubular in ju ry . Exposure of guinea-pigs to 
100,000ppm v iny l chloride fo r  90 days increased to ta l kidney weight 
and produced severe or moderate e p ith e lia l degeneration in the 
tubular and glomerular epithelium respective ly (Prodan et a l , 1975). 
In rats Viola (1970) reported only s lig h t degeneration of the 
tubular epithelium in males exposed to 30,000ppm viny l ch loride fo r  
up to 12 months. However other workers (Torkelson et al 1961) 
reported tubular changes a fte r 6  months o f exposure to 500ppm v iny l 
ch loride. In the case o f vinylidene ch loride, Prendergast et al 
(1967) have reported tha t the nuclei in proximal tubular ce lls  were 
enlarged fo llow ing prolonged exposure of ra ts to  46ppm vinylidene 
ch loride. Vinylidene chloride has also been reported to be injurous 
to the kidney when administered o ra lly  (Jenkins and Andersen 1978). 
In male ra ts given 400mg/kg vinylidene chloride vacuolation and 
necrosis o f the renal tubular epithelium as well as generalised 
tubular d ila tio n  was shown. The biochemical markers serum urea 
nitrogen, creatin ine and absolute kidney weight were also elevated.
Tetrachloroethylene at 2.5ml/kg i.p .  has been reported to be a weak 
nephrotoxin in mice (Plaa and Larson, 1965) producing necrosis and 
swelling of the proximal convoluted tubules and a small increase in 
urinary prote in . Inhalation or ingestion of tetrachloroethylene 
produces a lesion characterised by degeneration, desquamation,
- 17 -
atrophy and/or necrosis of the renal tubular epithelium (Kluwe, 
1981).
Metabolism of the chloroethylenes in re la tio n  to HCBD
The primary metabolic step in the biotransformation o f chlorinated 
ethylenes is  epoxidation by a cytochrome P-450-catalysed oxidative 
reaction. A general scheme fo r the biotransformation of chlorinated 
ethylenes is  shown in Fig 1.2. The formation of the epoxides 
depends on the extent o f chlorine substitu tion  in the parent 
compound. Chemically the rate o f formation o f epoxides decreases 
from v iny l chloride to tetrachloroethylene (Henschler, 1977). The 
s ta b i l i ty  and re a c tiv ity  of the epoxides, at least chemically varies 
widely and also depends on the number of chlorine substitu tions and 
on the re la tiv e  position o f the substituents in the molecule (Greim 
et a l , 1975). Symmetrically substituted epoxides from 
tetrachloroethylene and isomeric 1 , 2 -dichloroethylene are more 
stable than v iny l chloride and trich lo roe thy lene  epoxide, in which 
the p o la r ity  resu lts  in lesser s ta b i l i ty  and induces intram olecular 
rearrangement. The most polar and unstable epoxide is  tha t formed 
from vinylidene chloride ( 1 , 1 -d ich loroethylene).
In addition to the ethylenes, 2-chlorobutadiene a known nephrotoxin 
(Nystrom, 1948; Von Oettingen et a l , 1936), is  presumed to form 
e ithe r one or both of the two isomeric epoxides, 2 -c h lo ro - l, 2 - 
epoxybut-3-ene and 2-chloro-3,4-epoxybut-l-ene. (Bartsch et a l , 
1979). This assumption is based on observations tha t the formation 
of an a lky la ting  intermediate, which has been trapped by 4-(4- 
n itrobenzyl)pyrid ine, is  dependent on microsomes, cofactors and a ir  
or oxygen.
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I f  one speculates tha t HCBD may be activated by cytochrome P-450 to 
produce a strongly e le c tro p h ilic  epoxide intermediate in a s im ila r 
manner to those produced from the chloroethylenes or 2 - 
chlorobutadiene which would be capable of a lky la ting  nucleophilic  
s ites  in tissue macromolecules, thus causing damage in the kidney. 
The s ite -s p e c if ic  nephrotoxicity produced by HCBD seemed to  argue in 
favour of th is  type of mechanism as the kidney possesses the 
components of the cytochrome P-450 dependent mixed function oxidase 
system, (Benedetto et a l , 1976) which would be necessary fo r  the 
production of an epoxide. Cytochrome P-450 a c t iv ity  is  not 
homogenous throughout the kidney and P-450 concentrations e xh ib it a 
cortica l-m edullary gradient (highest in the cortex and outer 
medulla, lowest in the pa p illa ) (Zenser et a l , 1978). Anatomically 
the d is tr ib u tio n  o f mixed function oxidase a c t iv it ie s  grossly 
corresponds to the in trarena l d is tr ib u tio n  o f ce lls  (Fowler et al 
1977), the concentration o f these ce lls  being greatest in the pars 
recta o f the proximal tubule (Venkatachalam et al 1978). I t  is  th is  
part o f the nephron which is  most susceptible to  HCBD-induced 
damage.
Manipulation of the mixed function oxidase system metabolising the 
haloethylenes to  epoxides has been used extensively and has been 
shown to a lte r  hepatotoxic ity o f v iny l chloride (Jaeger et al 1976), 
vinylidene chloride (Jaeger et al 1974), trich lo roe thy lene  and 
tetrachloroethylene (Moslen et al 1977).
The contribution o f the mixed function oxidase system in 
metabolising HCBD to reactive metabolites was investigated by Hook
- 20 -
et al (1982) and by Lock and Ishmael (1981) by modifying hepatic and 
renal cytochrome P-450's and looking fo r  the extent o f l iv e r  and 
kidney in ju ry . Treatment o f ra ts with the hepatic cytochrome P-450 
in h ib ito rs , SKF 525A or piperonyl butoxide, did not a lte r  the 
response of the liv e r  or kidney to  in ju ry . Treatment of animals 
with inducers of cytochrome P-450, phenobarbitone, B-naphthoflavone, 
or isosafro le also did not a lte r e ithe r l iv e r  or kidney in ju ry . 
However, Arochlor-1254 was reported in one study (Lock et a l , 1981) 
to increase nephrotoxicity o f HCBD s lig h t ly  w h ils t in the other no 
such e ffec t could be found. These studies generally indicated tha t 
e ithe r metabolic activa tion  by cytochrome P-450 was not necessary 
fo r  the nephrotoxicity o f HCBD or tha t the inducers and in h ib ito rs  
did not e ffe c t the relevant cytochrome P-450 isoenzymes fo r  the 
metabolism o f HCBD.
In addition to a lky la ting  nucleophilic s ites  of macromolecules, the 
epoxides of chloroethylenes have another important route o f 
metabolism. They can rearrange by in tra c e llu la r  chlorine m igration, 
to chlorinated aldehydes (eg cis-and t ra n s - l, 2 -d ichloroethylenes, 
v iny l chloride and trich lo roe thy lene) or acyl chlorides (eg 
tetrachloroethylene and vinylidene chloride (Henschler, 1977).
The aldehydes are fu rth e r metabolised to chloroacids and 
chloroalcohols. C is-and trans-l,2-d ich loroethylenes give r ise  to 
d ichloroacetic acid formed by oxidation of the aldehyde and 
dichloroethanol by reduction o f the aldehyde (Henschler, 1977).
Vinyl chloride gives chloroacetic acid as a minor metabolite (Green 
and Hathway, 1975) and has been suggested to arise from
-  21 -
chloroacetaldehyde (Henschler, 1977). The rearrangement product of 
trich lo roe thy lene , trichloroacetaldehyde (ch lo ra l) gives 
tr ich lo ro a ce tic  acid and trich lo ro e th a n o l.
The acylchlorides are also fu rth e r metabolised to chloroacids. In 
the case of tetrachloroethylene, hydrolysis o f tr ic h lo ro a c e ty l-  
chloride gives tr ich lo ro a ce tic  acid (Bonse et a l , 1975; Daniel, 
1963). Vinylidene chloride also gives chloroacetic acid from 
ch ioroacety l-ch loride.
For v iny l ch loride, both the epoxide and chloroacetaldehyde have 
been proposed as the agents responsible fo r  covalent binding to 
c r i t ic a l  c e llu la r  ta rgets, leading to necrosis (and carcinogenesis) 
(Macdonald, 1982). Trich loroacetyl ch lo ride, derived from 
tetrachloroethylene has been suggested to be responsible fo r  
covalent binding to macromolecules (Henschler, 1977). 
Trichloroethylene oxide formation is thought to give r ise  to  the 
reactive metabolites of trich lo roe thy lene . Proposed reactive 
metabolites tha t could bind irre v e rs ib ly  to protein and nucleic 
acids are trich lo roethylene oxide, formyl ch loride, glyoxyl ch loride 
and possibly dichloroacetyl chloride (Macdonald, 1982). S im ilar 
metabolites derived from HCBD may be responsible fo r the observed 
nephrotoxicity.
The rearrangement products o f the chloroethylene epoxides (except 
trich lo roethylene a metabolite of which, trich lo roethano l is 
extensively conjugated to glucuronic acid) appear to be conjugated 
to glutathione. The epoxides per se can also be conjugated with
-  22 -
glutath ione, or cysteine and subsequently be transformed according 
to  established metabolic pathways to mercapturic acid derivatives 
(Henschler and Hoos, 1982). The sulphur-containing metabolites 
account fo r  a large proportion of the metabolites of v iny l ch loride 
and vinylidene chloride (Green and Hathway 1975 and 1977; Jones and 
Hathway, 1978a and 1978b) and vinylidene chloride depletes l iv e r  
non-protein sulphydryl content (Hefner et al 1975; Jaeger et a l ,
1974).
Glutathione conjugation w ith fore ign compounds is  a well documented 
event, and is  considered a de tox ifica tion  pathway to protect v ita l 
nucleophilic s ites in tissues from e le c tro p h ilic  attack by 
a lky la ting  metabolites o f xenobiotics (Chasseaud, 1979). A number 
o f glutathione-S-transferases (E.C. 2 .5 .1 .18), catalysing the
transfe r o f glutathione to a wide va rie ty  o f xenobiotic substrates 
are known (Hutson, 1976; Chasseaud, 1973), however glutathione can 
react non-enzymically with some substrates. Any observed depletion 
o f tissue glutathione a fte r the adm inistration o f a to x ic  compound 
has been taken as ind ica tive  of the formation o f p o te n tia lly  to x ic  
metabolites (M itchell et al 1976). Lock and Ishmael (1981) 
demonstrated tha t a single i .p .  in je c tion  o f HCBD to male ra ts  at 
300mg/kg produced a reduction in the to ta l non-protein sulphydryl 
content of the l iv e r ,  the maximum reduction (60% of con tro l) 
occurring at 6 hr a fte r dosing, whereas renal non-protein sulphydryl 
remained unchanged. This reduction in l iv e r  non-protein sulphydryl 
was dose dependent up to doses of 900mg/kg HCBD.
In an attempt to explain the depletion of l iv e r  non-protein 
sulphydryl on dosing HCBD, i f ,  one presumes tha t HCBD is metabolised
-  23 -
via  a cytochrome P-450-dependent reaction to an e le c tro p h ilic  
metabolite (epoxide), in a manner analogous to  v iny l chloride and 
vinylidene ch loride, then the epoxide may react d ire c tly  with 
glutathione or be conjugated via  glutathione S-epoxide transferase 
(Boyland and W illiams, 1965; F je lls te d t et al 1973).
HCBD could also be conjugated to glutathione v ia  glutathione alkene 
transferase an enzyme which is  present in various tissues in the ra t 
(Boyland and Chasseaud, 1967), including liv e r  and kidney.
The ro le  of glutathione in the to x ic ity  o f HCBD is not c lear 
because, although HCBD produces a reduction in l iv e r  non-protein 
sulphydryl which would be consistent with the production of a 
reactive metabolite in the liv e r  and its  subsequent d e to x ifica tio n , 
depletion of l iv e r  non-protein sulphydryl by diethylmaleate fa ile d  
to produce any hepatotoxic ity . (Lock and Ishmael, 1982). As the 
kidney is  the ta rget organ fo r  HCBD to x ic ity  fa ilu re  of kidney non­
protein sulphydryl to  be depleted on administering HCBD to male 
ra ts , seemed to argue against the production of reactive 
e le c tro p h ilic  metabolites in th is  organ. This is  a d i f f ic u l t  
concept to understand, as the term "reactive" implies tha t the 
metabolite so described is  chemically unstable and would qu ick ly  
react with su itab le molecules in close proxim ity to produce a more 
stable product. The reactive metabolite would thus have a short 
h a lf l i f e  and formation of the kidney-damaging "reactive" metabolite 
elsewhere in the body such as the l iv e r  is  excluded. On the other 
hand depletion of non-protein sulphydryl w ith diethylmaleate did 
increase the to x ic ity  o f HCBD to the kidney (Lock and Ishmael,
- 24 -
1982), which suggested tha t glutathione plays a ro le  in the 
d e to x ifica tio n  o f HCBD in th is  organ.
The ro le  tha t cytochrome P-450 plays, i f  any, in the metabolism of 
HCBD is  unclear as is the ro le  o f g lutath ione.
1.5. Objectives of th is  Study
From the foregoing, i t  can be seen tha t although a great deal is  
known about the toxicology o f HCBD, nothing is  known about the 
mechanism of the nephrotoxic ity. This mechanism may be re lated to 
the metabolism o f HCBD. Related chemicals, the chloroethylenes are 
metabolised by cytochrome P-450 to reactive e lectroph iles which 
u ltim a te ly  produce hepatotoxic ity , w ith very l i t t l e  nephro toxic ity . 
However in contrast the target organ fo r  HCBD to x ic ity  is  not the 
l iv e r  but the kidneys. The lite ra tu re  evidence to date suggests 
tha t HCBD may be metabolised d if fe re n tly  from the chloroethylenes 
and th is  may explain the d iffe r in g  ta rge t organ to x ic ity .  The aim 
of th is  study was to elucidate the structure  of HCBD metabolites, to 
determine th e ir  s ite  o f formation and route o f excretion and by 
means o f detailed to x ic ity  studies to determine th e ir  relevance to 
the nephrotoxicity o f hexachloro-l:3-butadiene.
- 25 -
MATERIALS AND METHODS
MATERIALS
2.1 Animals
Adult male, Wistar derived A lderley Park albino ra ts , approximately 
2 months old weighing 170-200g were used fo r  a ll studies. The 
animals were maintained on a standard p e lle t d ie t (PCD d ie t, Special 
Diet Services Lim ited, Witham, Essex, UK - fo r  composition see 
Appendix) and allowed access to water ad lib itum  unless otherwise 
stated. A temperature o f 22°C and re la tiv e  humidity o f 50% was 
maintained in the room where the animals were housed. A lte rnating  
periods of 1 2  hours l ig h t  and 1 2  hours dark were maintained with 
a r t i f i c ia l  l ig h t .
2.2 Chemicals
a) Proprietary chemicals
Hexachloro-1:3-butadiene (HCBD) w ith p u rity  of 99% (Spectrosol 
grade) was obtained from BDH Chemicals Lim ited, Poole, Dorset, UK.
Other chemicals were of the highest grade available comrnercially.
b) Non-proprietary chemicals
Conjugates o f hexachloro-l:3-butadiene were synthesised according to 
the fo llow ing methods:
- 26 -
i ) N -ace ty l-S -(l,l,2 ,3 ,4 -pen tach lo ro -l:3 -bu tad ieny l)-L -cys te ine : 
Dry N-acetyl-L-cysteine (50g, 0.3mole) was added to a so lution of 
sodium (0.6mole) in methanol (1 l i t r e ) .  HCBD (8 8 g, 0.33mole) was 
added slowly w ith s t ir r in g  over 30 min. A fte r 90 m in., the so lu tion 
was evaporated to approximately 500ml, 300ml of water was added and 
the pH adjusted to 5-6. Unchanged HCBD was removed by extracting  4 
times with equal volumes of n-hexane. The solution was adjusted to 
pH 1 with sulphuric acid and extracted 4 times with ethyl acetate. 
The ethyl acetate extracts were washed twice with water and 
evaporated to dryness. The residue was re crys ta llise d  from 
a c e to n itr ile  a fte r treatment with decolourizing charcoal to y ie ld  
38g of product. M.pt.70°C. (Found C, 29.9; H, 2.6; N, 5.7; S, 7.7; 
Cl, 41.2%, CgHgOgNSClg requires C, 27.9; H, 2.1; N, 3.61; S, 8.3;
Cl, 45.8%). The probe insertion  mass spectrum of the product was
consistent with the expected structure (Fig 2 .1).
i i )  S -(l,l,2 ,3 ,4 -p en ta ch lo ro -l:3 -bu tad ie ny l)-g lu ta th io ne :
This conjugate was prepared from HCBD and glutathione in the 
presence of sodium and liq u id  ammonia by a method analogous to tha t 
described by McKinney and Biester (1959). The crude product was 
re crys ta llise d  from ethanol/water to give a white c ry s ta llin e  
material M.pt.l86-187°C. (Found C, 32.0; H, 3.2; N, 7.7; S, 6.3;
Cl, 33.1% ci 4 Hi 5 ° 5 N3 ^Cl^ requires C, 31.6; H, 3.0; N, 7.9; S, 6.0; 
Cl, 33.4%). The f ie ld  desorption mass spectrum was consistent w ith
the expected structure (Fig 2 .2).
i i i ) S -(l,l,2 ,3 ,4 -p e n ta ch lo ro -l:3 -b u tad ie n y l)-cys te iny lg lyc in e :
This conjugate was prepared b io lo g ic a lly  by trea ting  chemically 
synthesised S -(l,l,2 ,3 ,4 -p e n ta ch lo ro -l:3 -b u ta d ie n y l) -g lu ta th ione
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(2.5mM) with 20 units of Y-glutamyltransferase from hog kidney 
(Sigma Chemical Co) in 50mM Tris-HCl bu ffe r pH8.5 fo r  16hr at 25°C.
2.3 Radiochemicals
i )  [ 14C]HCBD:
[U- C]HCBD with a spec ific  a c t iv ity  o f 0.16 mCi/mraole (in  house 
synthesis) with a chemical and radiochemical p u rity  exceeding 99% as 
assessed by gas chromatography, th in  layer chromatography and mass 
spectrometry was used fo r  excretion and tissue d is tr ib u tio n  studies.
14[U- C]HCBD with a spec ific  a c t iv ity  o f lO.lmCi/mmole was supplied 
by Imperial Chemical Industries PLC, Physics and Radioisotopes 
services, (Billingham, Cleveland, UK) in lmCi batches d ilu ted  in 
0.5ml ethanol. The chemical and radiochemical p u rity  was checked by 
gas chromatography with radiochemical detection using a 1.5m x 2mm 
glass column packed with 20% 0V101 on 100-120 mesh supelcoport and 
exceeded 99% in a ll cases. A ll rad io labelled HCBD was stored at 
-20°C.
35i i )  [ S]Cysteine hydrochloride:
35L-[ S]Cysteine hydrochloride w ith a spec ific  a c t iv ity  o f 
6 8 mCi/mmole was supplied by Amersham In ternationa l Lim ited,
(Amersham, Buckinghamshire, UK) as an aqueous solution containing 
0.55mCi in a to ta l volume of 0.11ml.
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i i i ) [ 1 4 C] S -(l,l,2 ,3 ,4 -pe n ta ch lo ro -l:3 -bu tad ie ny l)-g lu ta th io ne :
This conjugate was prepared b io lo g ic a lly . [ * 4 C]HCBD (2.8mM;5pCi) 
was incubated w ith reduced glutathione (lOmM), glutathione reductase 
( 1 . 2 units /m l) and hepatic microsomes ( 2 mg prote in/m l) in 0 . 1 M 
phosphate buffe r pH 7.4 fo r  60 min at 37°C. The f in a l incubation 
volume was 10ml. At the end of the incubation, the sample was 
cooled in ice-cold water and unchanged HCBD removed by extraction 
with d ie thyl ether ( 6  x 10ml). The aqueous phase was freeze dried 
and then redissolved in 1ml water. A liquots of the clear 
supernatant were used as the standards.
-  31 -
METHODS
2.4 Excretion and D is tribu tio n  Studies
a) Preparation o f HCBD dosing solutions
Solutions of HCBD in corn o i l  fo r  dosing to animals were prepared 
vo lum etrica lly . The correct volume of HCBD and [^ 4 C]HCBD to prepare 
a known volume of dosing solution at the required dose was 
calculated from the spec ific  g rav ity  of HCBD (1 . 6 8 g/m l). The 
required volumes of cold HCBD and [ * 4 C]HCBD were added to corn o i l  
(K ra ft and Wesson Ltd) and made to volume. The dosing so lution was 
checked fo r  ra d io a c tiv ity  by liq u id  s c in t i l la t io n  counting p r io r to 
dosing.
b) Urinary and faecal excretion of HCBD
A group of s ix  male rats were each given a single oral dose of 
[^ 4 C] HCBD 200mg/kg (46.4yCi/kg) as a so lution in corn o i l  
(5ml/kg). Animals were housed in d iv id u a lly  in p la s tic  metabolism 
cages (Forth Tech Ltd) designed fo r the separate co llec tion  o f urine 
and faeces. Urine and faeces samples were collected d a ily  fo r  5 
days. The samples were collected over so lid  CC^  (-70°C) and the 
co llec ting  vessels were covered to reduce exposure to l ig h t .
(c) B ilia ry  Excretion of HCBD by Rats a fte r a Single Oral Dose.
( i )  Surgical procedure: Surgical anaesthesia was induced w ith 5%
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halothane (Fluothane,ICI PLC,Macclesfield,Cheshire) in oxygen 
and maintained w ith 1-2% halothane in oxygen using a Fluotec 3 
(Cyprane Keighley, England) and Aldosorber system (0 W Turner 
Ltd, L iverpool). The b ile  ducts were exposed by a m idline 
abdominal inc is ion  (down the linea nigra) and the common b ile  
duct cannulated with polythene tubing (Portex, Hythe, England 
0.8mm o.d. 0.4mm i.d )  a l i t t l e  below the junction of the r ig h t 
and le f t  hepatic ducts. The cannula was externalised by 
passing i t  subcutaneously w ith the aid of a trochar to  emerge 
through an inc is ion  in the dorsal cervica l area. The in te rna l 
m idline inc is ion  was closed w ith suture (Mersilk braided s i lk  
3/0, 16mm cu tting  needle, Ethicon Ltd, Edinburgh, Scotland) 
and the skin wound closed with surgical c lip s  (9mm Autoclips 
Clay Adams, Parsippany NJ USA).
( i i )  Animal dosing and sample co lle c tio n : Three animals were
b il ia r y  cannulated. On regaining consciousness, ra ts  were 
dosed o ra lly  w ith HCBD 200mg/kg (250pCi/kg) in corn o i l  
(5ml/kg). Immediately a fte r dosing, the ra ts were placed in 
res tra in ing  cages (Bollman, 1948) fo r  the co lle c tio n  o f b ile  
and urine samples over the time periods 0-24hr and 24-48hr. 
During the co llec tion  o f samples, animals had access to 
lim ited  supplies of pelleted laboratory d ie t and unlim ited 
drinking water containing 1% dextrose, 0.9% NaCl and 0.05% KC1 
(w/v).
(d) D is tribu tion  of a single oral dose of HCBD in the ra t
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( i )  The d is tr ib u tio n  of ra d io a c tiv ity  in the ra t at 2,4,8 and 16hr 
a fte r a single oral dose of [^C]HCBD was studied by whole 
body autoradiography. One animal fo r  each o f the time points 
2,4, 8 hr was dosed a t, 200mg/kg (213pCi/kg) in corn o i l
(5ml/kg) and one animal fo r  the 16hr time point was dosed at
200mg/kg (250yCi/kg). Animals were k il le d  at the time points 
by exposure to excess halothane, and were rap id ly  frozen at 
-70°C in a hexane/solid CO2  m ixture. The frozen carcass was 
embedded in 2 % (w/v) carboxymethylcellulose and long itud ina l 
sa g itta l sections were cut w ith an LKB PMV type 450 MP cryo-
microtome. Apposition autoradiograms were made by pressing
the freeze-dried sections against S truc tu rix  D7 X-ray f i lm  
(Agfa Gevaert) in l ig h t - t ig h t  cassettes (U llberg, 1962). 
Autoradiograms were developed a fte r 19 days exposure in the 
case of the 2, 4 and 8 hr time points and a fte r 14 days fo r  the 
16hr time po in t. The amounts o f radiolabel in various organs 
was determined sem iquantita tive ly using a lig h t  box and 
densitometer.
( i i )  Determination of the form o f ra d io a c tiv ity  from [^ C ]  HCBD in 
the gut:
Four rats were each dosed o ra lly  w ith [^C]HCBD 200mg/kg 
(2.18yCi/kg) in corn o i l  and k il le d  with halothane at 2, 4, 8  
and 16 hr a fte r dosing. The small and large in testines were 
removed, washed exte rna lly  with water and then homogenised in 
water with a polytron (Kinematica GmbH, Switzerland). The 
homogenate was extracted with hexane to remove unchanged
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[■^CjHCBD and the aqueous fra c tio n  was centrifuged at 10,000g 
fo r  30 min (MSE High Speed 18). The aqueous supernatant and 
the hexane extract were assayed fo r  ra d io a c tiv ity  by liq u id  
s c in t i l la t io n  counting.
Measurement of ra d io a c tiv ity :
Aliquots of liq u id  samples such as urine (1ml) and b ile
(lOOpl) were admixed with 10ml standard s c in t i l la to r
(Instagel-Packard or F isofluor-Fisons Ltd) and counted
d ire c tly . Samples of faeces were freeze dried, weighed,
ground to  an homogenous powder and samples (lOOmg) combusted
in a Packard tissue ox id ise r. [^ C ]  carbon dioxide from the
samples was automatically absorbed in 2 -methoxyethylamine and
mixed with a toluene based s c in t i l la to r  p r io r to counting.
A ll counts were corrected fo r  oxidation e ffic ie n cy  determined 
14with [ C] hexadecane.
A ll samples were counted using a T ri-carb  460 CD s c in t i l la t io n  
counter (Packard Instruments Ltd, UK). The values obtained
were automatically corrected fo r  background. Counting
226e ffic ie n cy  was determined using a Ra external standard and 
the dpm values were derived from appropriate quench curve data 
stored in the instrument computer.
Metabolism Studies
Hepatic Microsomal Metabolism of HCBD
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( i )  Preparation o f hepatic microsomal fra c tio n :
Rats were fasted fo r  24hr p r io r to preparation o f microsomes. 
The ra ts were k il le d  by cervica l d is loca tion , the l iv e r  
removed and a 25% (w/v) homogenate made in ice-cold 0.154M KC1 
(adjusted to pH7.4 w ith 0.1M phosphate buffe r) using a Potter 
homogeniser. The homogenate was centrifuged at ll,000g  (av) 
fo r  20min at 4°C using an MSE high speed 18 centrifuge. The 
p rec ip ita te  was discarded and the supernatant transferred to 
fresh tubes and centrifuged at 160,000g (av) fo r  40min at 4°C 
(MSE Super Speed 75 cen trifuge). The fa t ty  layer and the 
supernatant (cytoso lic  fra c tio n ) were removed and discarded. 
The microsomal p e lle t was washed once by resuspending in ice - 
cold 0.154M KC1 and centrifug ing  at 80,000g (av) fo r  30 min. 
F in a lly , the p e lle t was resuspended in 20mM Tris-HCl bu ffe r pH
7.4 containing 0.25M sucrose and 5.4mM EDTA to give a prote in 
concentration o f 20-30mg/ml.
Protein concentration were determined by the method of Lowry 
et al (1951).
( i i )  Iso la tion  and id e n tif ic a tio n  o f the microsomal m etabolite:
HCBD (5mM), reduced glutathione (4mM), [^C]HCBD (lOpCi) and 
microsomal protein (7.5mg/ml) were incubated in 0.1M phosphate 
buffe r pH 7.5 fo r  75 min at 37°C. The to ta l volume o f the 
incubation was 40ml. At the end of the incubation, unchanged 
HCBD was removed by extracting with hexane (3x40ml). Two 
volumes of ice-cold ethanol were added to the aqueous
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fra c tio n  and the p rec ip ita ted  microsomal protein removed by 
cen trifuga tion  at 10,000g fo r  30 min. The supernatant was 
decanted and evaporated under reduced pressure at 25°C to 
0.5ml. This concentrate was chromatographed on s i l ic a  gel GF 
th in -la ye r plates using n-butanol: acetic acid:water (12:3:5 
v/v) as the developing solvent. The major radioactive band 
(Rf 0.33) was removed and eluted from the s i l ic a  w ith water. 
The eluate was again concentrated (1ml) and hydrolysed w ith 6 M 
HC1 at 100°C fo r  20hr. Under these conditions, complete 
hydrolysis of the material w ith Rf 0.33 occurred to give a 
single radioactive product, Rf 0.57 in the same system. The 
hydrolysate was evaporated to dryness and methylated w ith an 
ethereal solution of diazomethane. The methylated sample was 
fu rth e r chromatographed on th in -la ye r plates (s i l ic a  gel GF) 
using chloroform methanol (9:1 v /v) as the solvent system.
The major radioactive band, Rf 0.75, which was strong ly UV- 
absorbing and ninhydrin pos itive  was eluted w ith ether, 
concentrated and analysed by GC-RCD using a 1.5m x 2mm glass 
column which was packed with 5.2% 0V101 on 100-120 mesh 
Supelcoport. The column was operated at 200°C with an
Argon:C0 2  (95:5) c a rrie r gas flow  rate of 25ml/min. Two
radio labelled mass peaks were id e n tif ie d  using an LKB 2091 gas
chromatograph EI/CI mass spectrometer operated under the same
chromatographic conditions.
(b) Metabolism of HCBD in the Rat
( i )  Iso la tion  of b i l ia r y  metabolites:
For the purpose o f id e n tif ic a tio n  o f b i l ia r y  metabolites, a
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male ra t was b i l ia r y  cannulated under halothane-anaesthesia. 
The ra t was allowed to recover from the anaesthetic and then 
dosed o ra lly  w ith [^C]HCBD, 200mg/kg (250pCi/kg). The ra t 
was restrained (Bollman, 1948) and b ile  was collected fo r  24h.
B ile  (14ml) was freeze-dried and extracted with 5ml ethyl 
acetate:acetic acidimethanol:water (60:15:15:10). The b ile  
extract was compared with an a liquo t o f the o rig in a l b ile  
sample by chromatography on th in -la y e r plates (S ilic a  Gel GF) 
(20cm x 5cm x 0.25mm) using ethyl acetate:acetic 
acid:methanol:water (60:15:15:10) and butanol: acetic 
acid:water (12:3:5). Areas o f ra d io a c tiv ity  were located 
using a th in -la ye r radiochromatogram scanner (Berthold Model 
LB 2723) and by autoradiography using s tru c tu r ix  07 X-ray f i lm  
(Agfa Gevaert).
Preparative separation of larger amounts of b ile  extract was 
achieved by column chromatography o f 1ml samples using a Lobar 
size B Lichroprep Si 60 column (E. Merck Darmstadt) and 
e lu ting  w ith ethyl acetate:acetic acid:methanol:water at 
lm l/m in. The eluate was monitored w ith a radiochemical 
detector (Berthold Model LB503) f i t te d  w ith a lOOpl f lo w -c e ll 
and 2ml frac tions were collected w ith an LKB U ltrorac fra c tio n  
co lle c to r. Three bands of ra d io a c tiv ity  were eluted w ith 
re tention times of 92, 174 and 204min. Fractions 
corresponding to each of these bands were pooled and 
concentrated under reduced pressure. The concentrated bands 
were compared to the b ile  extract and a biosynthetic standard 
HCBD-glutathione conjugate ( 2 .3 i i i )  by TLC on S ilic a  gel
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layers using the two solvent systems described previously.
The plates were subjected to  radiochromatogram-scanning and 
autoradiography.
The most polar column fra c tio n  (Rt 204 mins), containing the 
major metabolite as assessed by th in  layer chromatograms, was 
hydrolyzed overnight w ith 6 M HC1 at 100°C. The hydrolysate 
was evaporated to dryness and the methyl ester, N- 
tr if lu o ro a c e ty l deriva tive  prepared using ethereal 
diazomethane and tr if lu o ro a c e tic  anhydride respective ly. The 
derivatised sample was analysed by GC-RCD and by gas 
chromatography -mass spectrometry (GC-MS).
The material e lu ting  from the column with a retention time of 
174min was analysed by th in -la ye r chromatography alongside an 
authentic sample of S - ( l ,1 ,2 ,3 ,4-pentach loro-l:3 -butad ienyl) -  
cyste iny lg lyc ine  ( 2 .2 b i i i ) .  S ilic a  gel GF th in -la y e r plates 
were used with ethyl acetate: acetic acid: methanol: water and 
butanol: acetic acid: water solvent systems. Spots on the
chromatograms were located under u.v. l ig h t  (254nm), by 
spraying with ninhydrin so lution or by radiochromatogram 
scanning.
The material e lu ting  from the column with a retention time of 
92min was reconstituted in 2ml ethyl acetate: acetate acid: 
methanol: water (60:15:15:10) and applied to  two preparative 
s i l ic a  gel TLC plates (20cm x 20cm x 2mm). The plates were 
developed in ethyl acetate: acetic acid: methanol: water
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(60:15:15:10) and the radioactive bands were located by 
radiochromatogram-scanning. Two radioactive bands Rf 0.61 and 
0.93 were removed and the ra d io a c tiv ity  eluted from the 
s i l ic a  gel w ith methanol. The eluates were concentrated by 
ro ta ry  evaporation under reduced pressure. The concentrates 
were analysed by GC-RCD using a 0.9m x 2mm glass column packed 
with 5.2% 0V101 on 100-120mesh Supelcoport.
( i i )  Id e n tif ic a tio n  of sulphur containing metabolites in b ile :
35Two ra ts were each dosed o ra lly  w ith [ Sjcysteine (23yg, 
lOyCi) in water fo r  f iv e  consecutive days and a fu rth e r ra t 
was dosed s im ila r ly  w ith 23yg/day non-radiolabelled cysteine 
hydrochloride (Sigma Chemical Co) in the same volume of water. 
The doses were not adjusted fo r  body weight.
A fte r the cysteine dosing regime, a ll animals were f i t t e d  w ith
an exterio rised b i l ia r y  cannula as previously described.
Immediately on recovery from the anaesthetic, the 
35[ S]cysteine -dosed ra ts were given a fu rth e r 50yCi ( 115ug)
35[ S]cysteine and the ra t previously dosed cysteine
hydrochloride was given a fu rth e r dose, of cysteine
35hydrochloride (115yg). Then one [ S]cysteine-dosed ra t was 
dosed i .p .  w ith HCBD (200mg/kg) in corn o i l  and the other 
dosed i.p .  w ith corn o i l .  The ra t previously dosed non- 
rad io labelled cysteine hydrochloride was dosed i .p .  w ith 
C^C]-HCBD, 200mg/kg (250pCi/kg). B ile  was collected fo r  
24 hr.
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B ile  was chromatographed on s i l ic a  gel th is  layers using ethyl 
acetate: acetic acid: methanol: water (60:15:15:10) and
i
butanol: acetic acid: water (12:3:5) systems. TLC plates were 
examined fo r  radioactive areas by autoradiography.
( i i i )  Iso la tion  o f urinary metabolites:
Observations by Davis et al (1980) and in th is  laboratory have 
shown a dose-dependent urinary excretion of HCBD m etabolites. 
In order to  optimise the recovery o f ra d io a c tiv ity  and mass 
from treated ra ts , both high and low doses o f HCBD were used 
to generate metabolites. Twelve ra ts were each dosed o ra lly  
w ith [^C]HCBD, 200mg/kg (50yCi) and a fu rth e r four ra ts  at a 
dose level o f 20mg/kg (50pCi). Animals were housed 
in d iv id u a lly  fo r  the separate co llec tion  of urine and faeces. 
Urine was collected fo r  24hr (200mg/kg dose group) or 48hr 
(20mg/kg dose group). The urine samples were combined and 
f i l te re d  through a glass f ib re  f i l t e r  (Whatman GF/F) under 
vacuum. Two volumes of ice-cold ethanol were added to the 
combined sample and the p rec ip ita ted  prote in removed by 
centrifugation  at 10,000g. The supernatant was removed, 
evaporated under reduced pressure to  approximately h a lf volume 
(390ml), and extracted 4 times w ith 250ml volumes of d ie thy l 
ether at neutral pH. The aqueous fra c tio n  was then adjusted 
to pH 1 w ith 3M HC1 and extracted repeatedly w ith equal 
volumes o f d ie thy l ether (11 x 250ml) u n t il no fu rth e r 
ra d io a c tiv ity  was extracted. The ether extract obtained at 
pH 1 was evaporated to  dryness, reconstitu ted in d is t i l le d  
water (10ml) and 2ml aliquots chromatographed on a Lobar size 
B Lichroprep RP- 8  reverse phase column with
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methanol:water:form ic acid (60:40:1 v /v) as the e lu ting  
solvent. R ad ioactiv ity  was monitored in the eluate using a 
Berthold LB503 Radiochemical detector and frac tions collected 
with an LKB 7000 U ltrorac fra c tio n  c o lle c to r. Three peaks 
were evident, these were labelled Ul, U2 and U3 in order of 
e lu tion . Fractions corresponding to  ind iv idua l peaks o f 
ra d io a c tiv ity  were combined and evaporated to dryness under 
reduced pressure.
The least polar peak, U3 was analysed underivatised and as i ts  
TMS deriva tive  by GC-RCD and GC-MS using 1.5m x 2mm glass 
columns packed with 20% or 5.5% 0V101 on 100-120 mesh 
Supelcoport. The TMS derivative  was also subjected to 
accurate mass measurement by high resolution GC-MS.
Band U2 was rechromatographed on the preparative RP- 8  column 
using methanol:water (3:7) + 1% formic acid as the e lu ting  
solvent fo r  60min followed by a lin e a r gradient to methanol + 
1% formic acid over 60min. The flow  rate was 2ml/min and 2ml 
frac tions  were co llected. R ad ioactiv ity  was monitored in the 
eluate. Fractions corresponding to the single radioactive 
peak were combined and evaporated to dryness under reduced 
pressure. The dry sample was recovered in methanol. An 
a liquo t o f the sample was taken to  dryness with a stream o f 
nitrogen dissolved in dry pyrid ine and treated w ith Regisil 
(BSTFA + 1% TMCS, Phase Separations Ltd, UK). The treated 
sample was analysed by GC-RCD on a 1.5m x 2mm glass column 
packed with 5.5% 0V101 on 100-120 mesh Supelcoport.
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A fu rth e r a liquo t ( 2 0 0 u l) o f the methanol extract was taken to 
dryness in a 25ml round bottomed fla s k . The flask  was 
attached to  a water condenser and 50pl dimethyl formamide and 
2ml th iony l chloride were added. The resu lting  so lution was 
refluxed fo r  2hr. The sample was cooled, d ilu ted  w ith an 
equal volume o f dichloromethane and f i l te re d  under vacuum 
through a GF/F (Whatman) glass f ib re  f i l t e r .  Excess th iony l 
chloride was removed by ro ta ry  evaporation under reduced 
pressure. The residue was dissolved in 50pl carbon 
te trach lo ride  and subjected to GC-RCD analysis on a 1.5m x 2mm 
glass column packed with 20% 0V101 on 100-120 mesh 
Supelcoport. This la te r  de riva tisa tion  method was adapted 
from those published by Kirkland (1960) fo r  the preparation o f 
sulphonyl chloride deriva tives.
The most polar fra c tio n , Ul, was rechromatographed on the 
preparative RP- 8  column using a gradient system of 
ace ton itrile :w a te r (3:7) + 1% formic acid fo r  70min r is in g  to 
a c e to n itr ile  + 1 % formic acid over 1 2 0 min and maintaining th is  
solvent fo r  60min. Fractions corresponding to ra d io a c tiv ity  
peaks were combined and concentrated under reduced pressure. 
Samples were treated with Regisil and analysed by GC-RCD.
( iv )  Gas-liquid chromatography of metabolites:
Radioactive metabolites were analysed by gas chromatography 
using a Pye series 104 instrument equipped with flame 
ion isa tion  and radiochemical detection (ESI Nuclear 504 
Radiogas Detector). The column e fflu e n t was s p l i t  in the
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ra tio  of 1 0 : 1  between the radiochemical detector and the flame 
ion isa tion  detector. In each case the c a rrie r gas was a 
mixture o f argon/C^ (95:5) at a flow  ra te  of 25-30ml/min. 
Microsomal metabolites were analysed on a 1.5m x 2mm glass 
column packed with 5.2% 0V101 on 100-120 mesh Supelcoport 
operated at 200°C. The s p l i t te r  ra tio  in th is  case was 1:1. 
B il ia ry  metabolites were analysed on a 0.9m x 2mm glass column 
packed with 5.2% 0V101 on 100-120 mesh Supelcoport, 
temperature programmed from 150°C (3 min) to 250°C at 
10°C/min, w ith an in je c tio n  temperature o f 200°C. Urinary 
metabolites were analysed on a 1.5m x 2mm glass column packed 
with 5.5% 0V101 on 100-120 mesh Supelcoport and on a 1.5m x 
2mm glass column packed with 20% 0V101 on 100-120 mesh 
Supelcoport. Both columns were programmed from 100°C (1 min) 
to 300°C at 15°C/min w ith an in je c to r temperature o f 150°C. 
Mass peaks corresponding to ra d io a c tiv ity  were id e n tif ie d  and 
analysed by GC-MS using the same columns and conditions, but 
with helium as the ca rrie r gas ( 2 0 ml/min).
(v) Mass spectrometry o f metabolites:
An LKB 2091 EI/CI gas chromatograph-mass spectrometer was used 
to obtain spectra o f metabolites. El spectra were obtained 
with the fo llow ing instrument se ttings: ion source temperature 
240°C, electron energy 70eV, trap current 50pA, accelerating 
voltage 3500V and scan speed 3. Cl spectra were obtained 
using methane as the reagent gas.
Accurate mass measurement and f ie ld  desorption spectra were
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obtained on a Jeol D300 GC-MS. This instrument was f i t te d  
w ith a 2.7m x 2mm glass column packed with 3% 0V101 on 100-120 
mesh Supelcoport and programmed from 150°C to 300°C at 
15°C/min.
The T ox ic ity  o f B il ia ry  HCBD Metabolites and HCBD 
Conjugates
The T ox ic ity  o f B i l ia ry  HCBD Metabolites:
Thirteen rats were f i t te d  w ith in traperitonea l glass
reservoirs under halothane anaesthesia as described by Johnson
and Rising (1978). Following recovery from the anaesthetic,
14the animals were given a single i.p .  dose of [ CjHCBD 
(200mg/kg) in corn o i l .  B ile  samples were collected fo r  24hr 
and stored at -20°C. The volume of each b ile  sample was 
determined by weight (lm l= lg) and assayed fo r  ra d io a c tiv ity  by 
liq u id  s c in t i l la t io n  counting. The weight (mg equivalents) of 
HCBD metabolites was calculated fo r  each residual b ile  sample. 
The b ile  samples were pooled, freeze dried and reconstitu ted 
in 10ml of d is t i l le d  water. A s im ila r volume o f contro l b ile  
obtained from corn o i l  dosed-rats was concentrated to the same 
volume. B ile  was checked q u a lita t iv e ly  by TLC-autoradiography 
and q u a n tita tive ly  by liq u id  s c in t i l la t io n  counting fo r  
possible losses during concentration and recovery.
A group of 3 ra ts were dosed o ra lly  w ith the reconstituted 
b ile  collected from [^C]HCBD-treated ra ts at a dose level 
equivalent to 107mg/kg HCBD, based on the ra d io a c tiv ity
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content o f the b ile .  Further groups of 3 rats were dosed with 
an equivalent amount of control b ile ,  with [^C]HCBD 
(lOOmg/kg) in corn o i l  or w ith corn o i l  vehicle alone 
(5ml/kg). The rats were housed in d iv id u a lly  in metabolism 
cages fo r  the separate co llec tion  of urine and faeces. Twenty 
four hours a fte r dosing, the rats were sacrificed  with 
halothane and blood and the 24hr urine samples taken fo r  
biochemical analysis. Urine was also assayed fo r  
ra d io a c tiv ity . Kidneys and liv e r  were removed fo r  the 
measurement of organ body to weight ra tio s  and water content 
and fo r  h istopathological assessment.
(b) The T o x ic ity  o f HCBD Conjugates:
The synthesised HCBD conjugates, N -acetyl-S -(1 ,1 ,2 ,3 ,4 - 
pentachloro-l:3-butadienyl)-L-cyste ine and S - ( l, l ,2 ,3 ,4 -  
pentachloro-l:3 -butad ienyl)-g lu ta th ione were examined fo r  in 
vivo to x ic ity .  A dose-response study was undertaken fo r  each 
compound in order to determine an e ffe c tive  nephrotoxic dose, 
followed by a detailed examination of th e ir  to x ic ity  using 
biochemical and histopathological markers.
( i )  Dose-response:
Groups of 3 ra ts were given single oral doses of N- 
acetylcysteine conjugate of HCBD in polyethylene glycol 400 at 
10,25,50 and lOOmg/kg (5ml/kg), and in a separate s tud y ,* 
s im ila r groups of ra ts were given single oral doses of the 
glutathione conjugate of HCBD as the hydrochloride in water at 
50,100,150 and 200mg/kg (10ml/kg). Twenty four hours a fte r 
dosing, the rats were sacrificed  w ith halothane and blood
- 46 -
samples obtained by cardiac puncture fo r  determination of 
plasma urea.
( i i )  T o x ic ity :
N -acetyl-S -(1 ,1 ,2 ,3 ,4-pentach loro-l: 3-butadienyl)-L-cyste ine: 
Groups o f 6  ra ts were dosed o ra lly  with e ithe r N- 
acetylcysteine conjugate o f HCBD lOOmg/kg in polyethylene 
glycol 400 or HCBD 200mg/kg in polyethylene glycol 400.
Control animals received polyethylene glycol 400 alone.
S-(1 ,1 ,2 ,3 ,4-pentach loro-l:3 -butad ienyl)-g lu ta th ione 
Groups of 6  ra ts  were dosed o ra lly  w ith e ithe r the glutath ione 
conjugate of HCBD 138mg/kg as the hydrochloride in water or 
HCBD 200mg/kg in Polyethylene glycol 400. Control animals 
received water alone (lOml/kg) or polyethylene glycol 400 
(5ml/kg).
Animals were housed in d iv id u a lly  in p la s tic  metabolism cages 
fo r  the separate co llec tion  o f urine (preserved with addition 
o f 50vil 10% aqueous sodium azide) and faeces. A fte r 24hr, the 
animals were weighed, k il le d  w ith halothane and blood was 
sampled by cardiac puncture in to  Monovette Lithium/Heparin 
Syringes (Sarstedt W. Germany) fo r  biochemical measurements.
The kidneys were removed and weighed; the r ig h t kidney was 
used fo r  h istopathological examination and the le f t  kidney fo r  
determination of kidney water content. The liv e rs  were 
removed, weighed and samples taken fo r  histopathology. A
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portion of each liv e r  (approximately Ig) was used fo r  the 
determination of l iv e r  water content. Tissue water content 
was determined as a weight loss on drying to  constant weight 
at 105°C. Urine samples were subjected to biochemical 
measurements.
(c) The e ffe c t o f b i l ia r y  cannulation on HCBD to x ic ity
Two groups o f ra ts , 3 per group, were f i t te d  with exterio rised
b il ia r y  cannulae as previously described. One group was dosed 
o ra lly  with HCBD (200mg/kg) as a solution in polyethylene 
glycol 400 (5ml/kg), the other group received the vehicle 
alone. A th ird  group of 3 ra ts  underwent part of the surgical
procedure in tha t the abdominal cav ity  was opened under
anaesthesia and immediately closed again with sutures. A 
b i l ia r y  cannula was not f i t te d  to these ra ts , the b ile  duct 
was not disturbed and remained f u l ly  func tiona l. These ra ts 
then received a single oral dose of HCBD (200mg/kg) in 
polyethylene glycol 400. Animals were restrained and treated 
as previously except tha t urine was collected w ith the 
addition of 50pl 10% sodium azide. The animals were 
sacrificed  with halothane a fte r twenty four hours and blood 
sampled by cardiac puncture. The blood and urine samples were 
submitted fo r biochemical analysis.
(d) Biochemical assays
Plasma urea was determined by an automated method with a 
V ita tron PA 800 analyser using SKI k i t  No. 86245. (Smith
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Kline Instruments). Plasma a lka line  phosphatase (E.C .3.1.3.1) 
and plasma alanine aminotransferase (E.C.2.6.1.1) were 
determined by automated methods with a V ita tron AKES analyser 
using BCL k its  Nos. 123862, 124656 and 124508 respective ly 
(Boehringer Corporation L im ited). Urinary glucose was 
determined using BCL test-combination No 124346. Total 
urinary prote in was determined by a modified method of Pesce 
and Strande (1973).
\
The a c t iv it ie s  or urinary alanine aminopeptidase andY- 
glutamyltransferase (E.C.2.3.2.2) were determined by the 
methods o f Mondorf e t al (1978), and Szasz (1969), 
respective ly. The a c t iv ity  or urinary a lka line  phosphatase 
was determined by the method o f Fernley and Walker (1965) and 
the a c t iv ity  o f N -acetyl-8 -D-glucosaminidase (E.C.3.2.1.30) 
according to Leaback and Walker (1961).
(e) Histopathology
Portions of l iv e r  and kidney were fixed  in 10% buffered formol 
saline, and pa ra ffin  sections (5ym) cut and stained with 
haematoxylin and eosin.
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RESULTS
3.1 Excretion and D is tribu tio n  o f HCBD in the Rat.
The excretion p ro f ile  fo r  each of these routes has been investigated 
fo llow ing a single oral nephrotoxic dose of HCBD. The d is tr ib u tio n  
of HCBD in the ra t has been examined by whole body autoradiography. 
The absorbtion o f an oral dose of HCBD has been investigated.
(a) Excretion o f [^ 4 C]-HCBD
A single oral dose o f [^C]HCBD at 200mg/kg produced an excretion 
pattern in which the faecal route o f e lim ination predominated (Fig 
3 .1 ). Over the f iv e  day period studied, approx 40% o f the dose was 
excreted in faeces, the bulk of the ra d io a c tiv ity  was excreted on 
days 3-5. The decreased faecal production observed during the f i r s t  
two days may be a contribu tory fac to r to th is  delayed excretion.
Experiments in ra ts f i t te d  w ith a b i l ia r y  cannula demonstrated tha t 
approximately 17% o f the ra d io a c tiv ity  was excreted in both the 
f i r s t  24 hours and in the fo llow ing 24 hours suggesting tha t b i l ia r y  
metabolites accounted fo r  most i f  not a ll o f the ra d io a c tiv ity  in 
faeces. The faecal excretion o f ra d io a c tiv ity  in the non-cannulated 
ra ts fo r  these two periods was low, approximately 1 % and 2 % 
respective ly of the radioactive dose, suggesting extensive re - 
absorbtion and enterohepatic re c ircu la tio n  o f b i l ia r y  metabolites.
An estimate of th is  re c ircu la tion  can be made from these figu res ; 
approximately 15% o f the radiolabel excreted in b ile  over 24hr was 
re-absorbed from the gut.
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The excretion o f ra d io a c tiv ity  in the urine was low; 10% of the dose 
excreted over the 5 days, with a maximum o f 3.5% of the dose 
elim inated in any one 24hr period (Fig 3 .1).
b) The d is tr ib u tio n  o f a single oral dose of HCBD in the ra t
Whole body autoradiograms of ra ts k il le d  at in te rva ls  of 2, 4, 8  and
16hr a fte r a single oral dose of [^CjHCBD at 200mg/kg (250pCi/kg)
demonstrated a s im ila r pattern of d is tr ib u tio n  at a ll time points
(Fig 3 .2 ). Quantitation of the autoradiograms with a densitometer
(Table 3.1) demonstrated tha t the organs containing most
ra d io a c tiv ity  were the large and small in tes tines , kidney and the
l iv e r .  Where a determination was made the bladder also contained a
large amount of ra d io a c tiv ity . The low amount of ra d io a c tiv ity  in
the stomach, but high amounts in the small in tes tine  indicates
e ithe r rapid absorption of HCBD from the stomach followed by
excretion v ia  the b ile  in to  the gut or passage of HCBD d ire c t ly  from
the stomach to the small in tes tine . In order to investigate th is
fu rth e r, the gut and contents were extracted with hexane at 2, 4, 8
and 16hr a fte r a single oral dose o f C^CjHCBD at
200mg/kg(2.18yCi/kg). The quantity o f hexane-extractable m ateria l,
assumed to be unchanged HCBD, decreased with time w h ils t the amount
remaining in the aqueous phase, assumed to be metabolites, increased
(Table 3.2 ). Thus the ra d io a c tiv ity  shown in the in tes tin e  on
14autoradiograms is  due to unchanged [ C]HCBD, both from d ire c t
passage of [^C]HCBD from the stomach, and to the presence of
[^C]HCBD metabolites from the b ile . B i l ia ry  excretion of
ra d io a c tiv ity  was noted as early as lh r  in the b ile  from ra ts  dosed
lOOmg/kg HCBD (resu lts  not shown).
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At 2hr unchanged HCBD accounted fo r  most of the ra d io a c tiv ity , 
whereas by 16hr the ra d io a c tiv ity  was present as water soluble 
material ind ica ting  tha t absorption of HCBD was v ir tu a l ly  complete 
by th is  time.
The kidney contained ra d io a c tiv ity  at a ll time points, the greatest 
amount being noted at 4hr, coinciding with the e a rlie s t time noted 
fo r  HCBD-induced renal necrosis (Ishmael et al 1982). The 
autoradiograms showed a d e fin ite  in trarena l d is tr ib u tio n  of 
ra d io a c tiv ity , the outer s tr ip e  o f the outer medulla, the s ite  o f 
damage produced by HCBD, being p a rt ic u la r ly  well labelled (Fig 3 .3 ).
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2 hr.
16hr.
Figure 3.2 Whole body autoradiograms of longitudinal saggital sections
of rats showing the d is tr ib u tio n  of radiolabel a fte r a single 
oral dose of C-14 hexachloro-1:3-butadiene in corn o il 
(200 mg/kg : 250 uCi/kg) and sacrificed  a fte r 2, 4, 8  and 
16 hr.
Table 3.1
The re la tive  quantities of radiolabel associated with 
various tissues in whole body autoradiogram sections as 
determined by densitometry
Light transmission (%) at various
Tissue times (hr) a fte r dosing
2 4 8 16
Adrenal 95 97 97 ND
Bladder 52 ND ND ND
Blood 95 98 95 95
Large In testine ND ND 1 1 1 0
Testes ND 98 ND ND
Myocardium 95 98 96 96
Kidney Cortex 92 8 8 85 77
Medulla 82 32 57 60
Pelvis 98 95 97 92
Liver 87 87 92 85
Small In testine 4 1 0 18 0
Stomach contents 90 92 95 45
Note 100% = No ra d io a c tiv ity  
ND = not determined
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Table 3.2 The d is tr ib u tio n  of radiolabel between aqueous and
hexane extract phases from the gastro in testina l tra c t of 
ra ts given [^CJHCBD and k ille d  at 2, 4, 8  and 16 hr 
a fte r dosing.
Time (hr) Radioactivity recovered in  each phase expressed 
as a % of the to ta l rad ioa c tiv ity  recovered.
Hexane Aqueous
2 92.8 7.2
4 85.4 14.6
8 58.8 41.2
16 9.5 90.5
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Figure 3.3 An autoradiogram of a section of kidney showing the
loca lisa tion  of rad ioa c tiv ity  in the cortico-medullary region 
from an animal given [ 1 4 C]HCBD, o ra lly  200 mg/kg; 213 uCi/kg 
and k ille d  4 hr a fte r dosing.
3.2 Id e n tif ic a tio n  of the in v it ro  Microsomal Metabolite o f HCBD
This work arose from observations by Dr C R Wolf which demonstrated 
tha t HCBD caused a marked reduction in glutathione concentration 
when incubated w ith male and female hepatic microsomal or cy toso lic  
frac tions  fo r t i f ie d  w ith g lu tath ione. Studies with the cytochrome 
P-450 in h ib ito rs , carbon monoxide and SKF 525A, demonstrated tha t 
the glutathione depletion was not dependent on cytochrome P-450. 
Although cytoso lic  and microsomal frac tions  could produce a 
glutathione depletion w ith HCBD, the microsomal fra c tio n  was more 
e f f ic ie n t  at producing th is  e ffe c t, and resulted in the formation of 
a single product (Wolf et a l , 1984).
Hexane extractions of the microsomal incubation removed 7.4yCi 
(9.7mg) o f the to ta l 13.1yCi o f ra d io a c tiv ity , leaving 2.6pCi 
(3.4mg) of product in the aqueous phase. Preparative TLC of the 
aqueous products gave a single radioactive band at Rf 0.33 (butanol: 
acetic acid: water) which was ninhydrin pos itive . Acid hydrolysis 
of th is  band gave a single ninhydrin sta in ing product w ith Rf 0.57 
(butanol: acetic acid: water). Methyl ation of th is  product w ith 
diazomethane and subsequent TLC using chloroform:methanol (9:1) gave 
two radioactive bands, a minor one on the o rig in  and the major one 
at Rf 0.75 which was strongly u.v absorbing ind ica ting  the presence 
of diene double bonds. GC-RCD analysis of the major band gave two 
radiolabelled mass peaks in the ra tio  of 9:1 w ith re tention times of 
2.4 and 2.7 min respective ly. Both peaks gave iden tica l mass 
spectra, which were interpreted as tha t of the methyl ester o f S- 
(pentach loro-l:3 -butad ienyl) cysteine. The two peaks were assumed
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Figure 3.4 Electron impact mass spectrum o f the methyl ester of
S - ( l ,1 ,2 ,3 ,4 -pentachloro-l:3-butadienyl)-L-cysteine obtained 
by hydrolysis and derivatisa tion  of the metabolite formed 
on incubation of [l^ClHCBD with male ra t hepatic microsomes 
and glutathione.
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Figure 3.5 Chemical ion isation mass spectrum of the methyl ester of 
S - ( l ,1 ,2 ,3 ,4-pentachloro-l:3-butadienyl)-L-cysteine obtained 
as in figure 3.4.
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to be isomers. The Cl and El spectra are shown fo r  the major isomer 
Figures 3.4 and 3.5. The o rig in a l conjugates before hydrolysis were 
assumed to be isomers of S -(pentach loro-l:3-butad ienyl) g lu tath ione. 
The assignment of the conjugate was S -(pentach loro-l:3 -butad ienyl) 
glutathione was subsequently confirmed by comparison of chemically
synthesised HCBD-glutathione conjugate on TLC.
3.3 Metabolism of HCBD in the Rat a fte r Oral Dosing.
The iso la tio n  and id e n tif ic a tio n  o f b i l ia r y  and urinary metabolites 
is  described.
a) B il ia ry  metabolites
The excretion studies showed tha t the faeces was the major route o f 
excretion o f HCBD in the ra t.  Iso la tion  of metabolites from faeces 
would have been a d i f f ic u l t  task and since excretion data had 
indicated tha t the b i l ia r y  route was the primary source o f faecal
metabolites i t  was decided to use th is  as the source o f m etabolites.
Prelim inary investigations were aimed at devising su itab le 
chromatographic methods fo r  the iso la tio n  of metabolites from b ile .  
The various methods tr ie d  included anion and cation exchange 
chromatography, TLC, normal and reverse phase HPLC. Out o f these 
methods arose the f in a l method fo r  analysis o f HCBD b i l ia r y  
metabolites.
Thin layer chromatography of b ile  revealed a number of rad ioactive  
components (Fig 3 .6). The b i l ia r y  metabolites were isolated by
- 61 -
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Figure 3.6
TLC radiochromatogram of 24 hr b ile  from rats given a single oral dose o f 
E^C] hexachloro-1:3-butadiene (200 mg/kg). Solvent system ethyl acetate : 
acetic acid : methanol : water (60 : 15 : 15 : 10). Id e n tifie d  metabolites are: 
X, 5 - ( l ,1 ,2 ,3 ,4 -pen ta-ch lo ro -l:3 -bu tad ieny l) -g lutath ione (Rf 0.46), and Y, S- 
( l,l,2 ,3 ,4 ,-p e n ta ch lo ro -l:3 -b u ta d ie n y l)-cys te in y l glycine (Rf 0.73).
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preparative HPLC methods. The b ile  sample was freeze dried w ith no 
loss of ra d io a c tiv ity  and dissolved in ethylacetate: acetic acid: 
methanol: water (60:15:15:10). This extract was compared w ith the 
o rig in a l b ile  on TLC using two d iffe re n t solvent systems. The plate 
scans and autoradiograms demonstrated tha t the extract contained a ll 
the components o r ig in a lly  present in b ile .  Chromatography on a 
preparative Lobar column fractionated the b i l ia r y  metabolites in to  
three bands w ith re tention times of .92, 174 and 204min. 
Chromatographic re p ro d u c ib ility  was ± 1 tube. Concentrates o f these 
bands were compared on TLC (Fig 3 .7).
The most polar band (Retention time 204min) contained 55% of the 
ra d io a c tiv ity  present in b ile  as determined by s c in t i l la t io n  
counting. TLC of th is  band revealed the presence of two radioactive 
components (Fig 3 .7). The major component (40%) at Rf 0.36 and the 
minor component (15%) at Rf 0.52 (butanol: acetic acid: water). The 
Rf of the major component corresponded to the Rf of the major 
component in the o rig in a l b ile  sample. This band was hydrolysed 
with HC1 and methylated with diazomethane. Gas chromatographic 
analysis of th is  sample fa ile d  to provide a good separation from 
endogenous m ateria ls. The sample was fu rth e r derivatised and 
analysis of the methylated and triflu o ro a ce ty la te d  sample by GC-RCD 
resulted in a good separation of the peak o f in te res t from 
endogenous m ateria ls. The peak of in te res t had a re tention time of 
9.0min on the 0.9m x 2mm 5.2% 0V101 columns programmed from 150°C (3 
min) to  250°C at 10°C/min. GC-MS of th is  peak gave Cl (methane) and 
El spectra as shown in Figures 3.8 and 3.9. In te rp re ta tion  o f these 
spectra indicated th is  peak to be the methylester of N - tr if lu o ro -
-  63 -
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originfront
92min
-•--------1--------1--------1------- 1____ I____ L
1-0 0-9 0 8  0-7 0*6 0*5 0*4 0*3 0*2 0*1 0*0
Butanol:Acetic acid: Water 1 2 : 3 : 5
Figure 3.7 TLC radiochromatograms of fractions obtained from preparative 
column chromatography of b ile  from rats given [1^C]HCBD.
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acety l-S -(1 ,1 ,2 ,3 ,4-pentach1oro-1: 3-butadi enyl) -L-cyste i ne. Wh i ch 
was consistent with the metabolite p r io r to hydrolysis being the 
glutathione conjugate of HCBD.
Synthesis of S -(l,l,2 ,3 ,4 -pen tach lo ro -l:3 -bu tad ieny l)g lu ta th ione  and 
subsequent TLC demonstrated tha t th is  had an iden tica l Rf to  the 
major b i l ia r y  m etabolite. In addition the in v itro  microsomal 
product also had the same Rf (Fig 3.10 (a) and (b )).
The band e lu ting  from the HPLC column at 174min contained two 
components (Fig 3 .7 ). The major component at Rf 0.59 accounted fo r  
\Z% o f the ra d io a c tiv ity  in b ile .  The Rf o f th is  component was 
s im ila r to tha t fo r  the y-g lutam yltransferase-treated 
in v it ro  microsomal metabolite and was therefore te n ta tiv e ly  
id e n tif ie d  as the cyste iny lg lyc ine  conjugate o f HCBD. Hydrolysis 
w ith 6 M HC1, in an attempt to remove the glycine residue and aid gas 
chromatographic analysis, gave a sample which when e ithe r methylated 
or methylated and triflu o ro a ce ty la te d  was la b ile  under the 
chromatographic conditions used. Incubation o f the authentic 
glutathione conjugate o f HCBD with Y-glutamyltransferase produced 
two n inhydrin -positive  spots on th in  layer chromatograms. The lower 
spot at Rf 0.18 corresponded to a glutamic acid standard, while the 
second at Rf 0.60 which was also u.v absorbing, was assumed to be 
the cyste inyl glycine conjugate o f HCBD. Control incubations 
without Y-glutamyltransferase gave only a single n inhydrin -pos itive  
component at Rf 0.37 which corresponded to a fresh ly  prepared 
authentic standard of the glutathione conjugate of HCBD.
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Figure
(A)
microsomal
GSH-CONJ
0 - 2 4  hr. 
BILE
origin
Ethyl acetate : Methanol : Acetic acid : Water (60:15:15:10)
front
(B)
microsomal
GSH-CONJ
0 - 2 4  hr. 
BILE
origin
Butanol: Acetic acid: Water (12:3:5)front
—t  _1------- 1--- :__ I--- :--- 1____ I____ 1____ i
0*7 0-6 0 5  0*4 0-3 0-2 0-1 0-0
L
1 0
.10 TLC radiochromatograms comparing the Rf values of the in  v it ro  
HCBD-glutathione conjugate with components in b ile  from rats 
treated with [1^C]HCBD.
-  6& .
Co-chromatography on TLC in two solvent systems of the Y -  
glutamyltransferase hydrolysed authentic glutathione conjugate of 
HCBD with the 174min HPLC band demonstrated a rad ioactive , 
n inhydrin -positive  spot corresponding to the Rf 0.60 spot in the 
enzymic hydrolysate, confirming tha t the major component in the 
174min HPLC band was the cyste inylg lyc ine  conjugate o f HCBD.
Gas chromatographic analysis of the two components in the least 
polar HPLC band e lu ting  at 92min (Fig 3.7) e ithe r underivatised or 
as methylesters was unsuccessful due to degradation under the 
chromatographic conditions used.
b) Sulphur-containing metabolites in b ile
Thin layer chromatography of b ile  from rats dosed with
[ S lcysteine, [ S] cysteine and 'co ld ' HCBD and rats dosed with 
14[ C]HCBD gave an autoradiogram as seen in Fig 3.11. In th is
experiment, corresponding radioactive areas in both the
[^S ]cys te in e /co ld  HCBD and [^C]HCBD chromatograms w ith no
35coincident radioactive area in the [ Slcysteine chromatogram are 
HCBD metabolites which contain sulphur. Radioactive areas in the 
[■^CjHCBD group with no corresponding area in the [^ S ]/c o ld  HCBD 
chromatogram are non-sulphur containing metabolites. I t  cannot be 
determined fo r  those radioactive areas which are coincident in a l l  
three chromatograms whether the metabolites contained sulphur or 
not.
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front
origin
Figure 3.11
#
I
T 1 0
0-9
0-8
0-7
- 0-6
- 0-5
- 0-4
- 0-3
- 0-2
- 0-1
-LOO
[35s ] CYS NCYS  
+
unlabelled
HCBD
fi 4  1
L c J h c b d
Determination of sulphur containing metabol ites in b i le .
An autoradiogram of a TLC plate showing the chromatography 
of samples of b i le  obtained from rats dosed e i the r  [ *5$ ] -  
cysteine ip or [L^C]-HCBD o ra l ly  and samples obtained from 
a ra t dosed [^^S]-cysteine ip and non-radioactive HCBD o ra l l y .  
The metabolites which contain sulphur are indicated.
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Radioactive areas at R f's 0.25, 0.30 and 0.40 contained sulphur.
The area at Rf 0.40 also chromatographed with the in v it ro  
glutathione-HCBD conjugate standard on th is  plate and therefore was 
fu rth e r evidence fo r  the in v it ro  formation of a glutathione HCBD 
conjugate. The fa in t  radioactive areas at 0.26, 0.33, 0.63, 0.67 
and 0.72 possibly contained sulphur. No non-sulphur containing 
metabolites could be id e n tif ie d .
c) Urinary metabolites
A small proportion o f the urinary ra d io a c tiv ity  {6%) was lo s t on 
protein p re c ip ita tio n . Diethyl e ther-extraction  of urine at neutral 
pH gave 2% of the to ta l urinary ra d io a c tiv ity . No fu rth e r analysis 
was carried out on e ithe r of these samples.
Extraction of urine at pH 1 w ith d ie thy l ether libera ted 30% o f the 
to ta l urinary ra d io a c tiv ity  and represented acid ic metabolites o f 
HCBD. Fractionation of th is  extracted material on reverse phase 
HPLC gave three radioactive bands. The least polar band accounted 
fo r  9% o f the ra d io a c tiv ity  in urine, 1% o f the dose o f HCBD. GC- 
RCD o f th is  band on a 29% 0V101 column gave a trace with a small 
radioactive peak associated w ith the solvent peak, which was 
probably due to sample breakdown and a large mass peak associated 
with ra d io a c tiv ity  at a retention time of 4.5min. GC-MS analysis of 
th is  peak in the Cl(methane) and El modes gave the spectra shown in 
Figures 3.12 and 3.13. The Cl spectrum shows the M+l ion at 221 
with a four chlorine isotope pattern. Assuming from b i l ia r y  
metabolite data tha t th is  metabolite was derived from conjugation o f
- 71 -
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12 Electron impact mass spectrum of the underivatised urinary 
metabolite showing the major fragment ions and the interpreted 
structure, that of tetrachlorothiophene.
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Figure 3.13 Chemical ion isation mass spectrum of the underivatised urinary 
metabolite obtained with methane as the reagent gas.
M + 1 = 221.
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HCBD with glutath ione, i t  seemed l ik e ly  tha t sulphur would be 
present. Analysis o f the El spectrum resulted in assignment o f the 
fragment ions as shown in Figure 3.12. The spectrum was in terpreted 
as tha t o f tetrachlorothiophene. Further evidence fo r  th is  
structure was obtained on inspection of the e ight peak index o f mass 
spectra (1974). Spectrum D1629 lis te d  the ions 222, 220, 224, 149, 
185, 187, 141 and 143 which agreed c losely with the most intense 
ions obtained from th is  sample: 222, 220, 224, 187, 185, 141, 143, 
79, 103 and 71. The structure was confirmed when an authentic 
sample o f tetrachlorothiophene was shown to have the same gas 
chromatographic retention time and iden tica l mass spectra to th a t o f 
the b io log ica l sample (Fig 3.14).
Tetrachlorothiophene is known to  be extremely soluble in ether but 
not water-soluble. This suggested tha t th is  compound was not 
present in urine as a metabolite o f HCBD, but was an a r t i fa c t  
produced under the conditions o f GC analysis. In addition the 
urinary metabolite had acid ic properties shown by its  extraction 
in to  ether at pH 1, which were not consistent with i t  being 
tetrachlorophene.
In an attempt to prevent sample breakdown, the TMS-derivative was 
prepared. GC-RCD analysis of the de riva tive  demonstrated a s ing le 
mass peak with associated ra d io a c tiv ity . I t  was observed tha t the 
derivatised sample was only stable when stored in the d e riva tis in g  
agent. Cl (methane) and El spectra were obtained . Cl gave an M+l 
of 345 (Fig 3.15). The El spectrum gave M+ 344 with a f iv e  ch lorine  
pattern (Fig 3.16). The metabolite was te n ta tiv e ly  assigned
- 75 -
RE
LA
TI
VE
 
IN
TE
NS
IT
Y
M+1
L
O m
Figure 3.15 Chemical ion isa t ion (methane) mass spectrum o f  the
tr imethyl si l y l  derivat ive of l , l , 2 ,3 ,4 -p e n ta c h lo ro - l : 3 -  
butadienyl sulphenic acid showing the M + 1 = 345.
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Figure 3.16 Electron impact mass spectrum o f the trim ethyl s i ly l  derivative  of 
1 ,1 ,2 ,3,4-pentachloro-l:3-butadienyl sulphenic acid.
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the structure l,l,2 ,3 ,4 -p en tach lo ro -l:3 -b u ta d ien y l sulphenic acid. 
High resolution GC-MS o f th is  sample having a re tention time o f 12 
minutes and gave accurate mass measurements on the M and M-Cl ions 
which were consistent w ith th is  structu re .
The computer output fo r  the strongest ions in the 309 and 344 
isotope clusters are shown in Table 3.3. The e rror column shows the 
deviation from the calculated accurate mass in m illimass un its based 
on : -
C = 12.0000
H = 1.00782
N = 14.00307
0 = 15.99491
Cl3 5  = 34.96884-
S = 31.97206
Si = 27.97692
35For the two Cl ions at nominal masses 309 and 344 the resu lts  
were;-
Table 3.3
Deviation
Calculated Accurate Mass Measured Mass mmu ppm 
308.8896 308.8921 +2.5 + 8
343.8585 343.8551 -3.2 -10
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Since accurate mass measurements w ith in  lOppm or less are considered 
to be acceptable at the resolution used (5000) th is  data supported 
the assigned structure o f the metabolite to be 1 ,1 ,2 ,3 ,4- 
pentachloro-l:3-butadienyl sulphenic acid.
The second band obtained on reverse phase HPLC separation o f the 
ether extract represented 5% of the to ta l urinary ra d io a c tiv ity  and 
accounted fo r  less than 1% of the dose. Rechromatography of th is  
band using a gradient RP- 8  system fa ile d  to achieve any fu rth e r 
frac tiona tion  of ra d io a c tiv ity . The p o la r ity  o f th is  band compared 
w ith the least polar band suggested tha t i t  could be a stronger acid 
than the sulphenic acid id e n tif ie d  in the least polar band, and may 
possibly be a su lphin ic acid. The sample was therefore treated w ith 
BSTFA in an attempt to make i t  more amenable to GC. GC-RCD analysis 
of the BSTFA-treated sample fa ile d  to  produce a detectable 
radiochemical peak. Attempts to prepare the sulphonyl chloride 
derivative  were more successful in tha t upon GC-RCD analysis a 
radiochemical peak was produced. However th is  radiochemical peak 
was only associated with a small mass peak which was in s u ff ic ie n t 
fo r  GC-MS analysis. This mass peak had a re tention time o f 9min and 
eluted at 140°C from a 20% 0V101 column (1.5m x 2mm).
Rechromatography o f the most polar fra c tio n  from the HPLC separation 
of the ether extract on a reverse phase gradient system, 
fractionated the ra d io a c tiv ity  in to  f iv e  bands representing 6 , 2, 3, 
3 and 3% of the to ta l urinary ra d io a c tiv ity . Each band being less 
than 1% of the dose of HCBD. Although treatment of the samples w ith
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BSTFA in some instances produced material tha t was amenable to GC 
analysis and GC-MS analysis, no good mass spectral data was 
obtained.
3.4 T ox ic ity  studies
Excretion studies have shown b ile  to be the major route o f excretion 
o f ra d io a c tiv ity  derived from [^C]HCBD. Since the id e n tif ic a tio n  
of nephrotoxic metabolites o f HCBD was the primary objective o f th is  
study, i t  was necessary to determine whether the nephrotoxic 
m etabolite(s) or precursor o f the nephrotoxic m etabolite(s) was 
excreted in b ile . This section is  concerned with the demonstration 
o f the nephrotoxic po tentia l o f the glutathione-derived b i l ia r y  
metabolites of HCBD. Information was also gained on metabolite 
re c ircu la tio n .
a) The to x ic ity  o f o ra lly  administered b i l ia r y  metabolites o f HCBD
Q ualita tive  assessment of the b i l ia r y  metabolite pattern on TLC 
demonstrated no differences before and a fte r concentration o f the 
b ile .  Gross quan tifica tion  revealed no loss o f ra d io a c tiv ity . 
Animals dosed e ithe r control b ile  or corn o i l  displayed no signs o f 
nephrotoxicity or hepatotoxic ity as assessed biochemically or 
h is to lo g ic a lly  (Tables 3.4 and 3 .5). Animals dosed with the R e ­
labelled b i l ia r y  metabolites (107mg/kg equivalents) or HCBD 
(lOOmg/kg) produced marked changes in kidney:body weight ra tio  
(Table 3 .4 ). The kidney damage produced by HCBD was less severe 
than tha t produced by dosing o f the b i l ia r y  metabolites as 
demonstrated by elevated plasma urea concentrations.
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This observation was supported by h is to log ica l data (Table 3 .5), 
which demonstrated tubular necrosis in a ll metabolite-dosed animals, 
one o f which showed casts and several fo c i o f c a lc if ic a tio n  in the 
inner medulla of the kidney. The animals dosed HCBD also displayed 
tubular necrosis but th is  was less severe than in animals, dosed 
with b i l ia r y  metabolites.
The e ffects  on the l iv e r  o f b i l ia r y  metabolites was minimal; only 
the live ribody weight ra tio  increased over con tro l. This may also 
have occurred in the HCBD dosed animals. H isto log ica l data 
demonstrated no detectable damage which was consistent w ith the 
biochemical data which demonstrated no increase in the l iv e r  enzymes 
aspartate aminotransferase, a lka line  phosphatase and alanine 
aminotransferase.
Animals dosed with e ithe r the ^C -la b e lle d  b i l ia r y  metabolites or 
[ 1 4 C] HCBD excreted 6.17 ± 1.52% and 4.62 ± 0.07% respective ly o f 
the administered ra d io a c tiv ity  in urine. The appearance of 
ra d io a c tiv ity  in urine o f animals dosed with the b i l ia r y  metabolite 
is ind ica tive  o f absorption from the gastro in testina l tra c t w ith 
c ircu la tio n  to and excretion via the kidneys.
b) Nephrotoxicity of Synthetic Conjugates of HCBD
( i ) Dose dependency
Single oral doses o f N -a ce ty l-S -(l,l,2 ,3 ,4 -p e n ta ch lo ro -l,3 - 
butadienyl)-L-cysteine at 10,25 and 50mg/kg fa ile d  to produce an 
elevation in plasma urea, the parameter used to assess kidney
- 81 -
Ta
ble
 
3.4
 
The
 
to
xi
ci
ty
 
of 
bi
lia
ry
 
m
et
ab
ol
ite
s 
of 
he
xa
ch
lo
ro
-1
:3
-b
ut
ad
ie
ne
o P J=
H H • 00 •r— +-> II
CM H o • 3^" O rH 2 •r—fmm • • • CO CM rH • • 3: C
r— ‘ 1— o o rH • O o >>
O o +1 CO r
J- +1 +1 +1 +1 +1 +1 1 CD o •
+-> e O +1 CO i— 00
c s- co o CT) o • rH CO S_ •r— P
o o • lO CO • CT) r'» CO o o JO +1 to
o o • • *3* CO • • • CD
i» LO CO o r^. iH vo CM CO -o to P
CD o c 1to S- CO P
o 4-» fl)
¥ TO c gE
* ¥ o rHr—» KO * rH VO to CJ CD O
o H o • CM O p s- O
.x • • • o VO to • rH CO M- CO
rH o o CM • o • S_ O O
Q CT) +t CM o to
CQ e +! +1 +1 +1 +1 E H-> +■> V
o +t co +1 o c
3C o CO o CT) VO • o vo &. 3 3 o .o • o • o C - *3* O) vo M- O to
rH CD • • 00 CM • • » • E CD 0%
r^. O CM vo CM CO <3- T3 CO C£ 0)
CD c
+J ■P o
O e •
CD CD CO
r“ CT)
r— cO JJo > •f—
co o •f— f— o
<u 3 Er—» CT e
•1— a CD to s_
jo CO «— • o
LD t—1 r*. to CM o C CJr— • to CO • to to CO rH 3= CO CD
O IT) • • to O) • • • C c
S- VO CO o 1— rH CT) CM CO 1 CT) -C o CD
+-> JX +J r— >
c •r— COo O) CT)
o E CD■CT r~ to
CD U r—o to •r~ CO
rH o SZ E■o CD •r*• o > C
0) > * ¥ -t-> 0) CO•r— ¥ ¥ s_ r—•r— 3 * H CO CO * +-> CD •r— t—
JO O ' * o O VO 00 o * c 2 O o
a) LT> • • • O) CM • H to CD i-
O o O CO • o • • r— to c p
CQ CT) +1 +1 rH o rH (O +-> i - c
C_3 +1 +1 +1 +! > CO o o
x : o +i +1 +i •j— CJ CJ
r—i CT) • LO to o • rH 3
CJ E rH CO *3* • •3" co <3- r^. CM CT" <H- J= E
«3- VO • • CT) VO • • • • CD o ■p o
T---I r-. rH <3- O vo CO r^. CM CO VO s-
1—1 o to 2 p
<—i CD o.
r— 3 s- p
•r— o o c
JO S- CD
CT) r— &-
«3" •r- CD
rH S- o P
1 CD P
o J= c •r“
+-> <—* +-> s- "CT
2 4-> XT s_ o
2 4-> 3 C_) > )
>> *r— Li.
u c P
■a V •r— C-— . -CT CD >> • <oCT) o r—* C r~ o
o CT) o •t— r— CT) CT) •r—
Q. o i-H o s_ CO JC JX P
3 CM o f-H 3 &. •r—
O X X CM o CT) CT) C
s- * or X C E E O)
CD CT> CT) r— f— 1— •r— •a •r—
E -—< p V, **>, \ CT) CD o O CO
2 13 DO 3 —- P > ) to o Os- C. -«—» 2 +-> s- o CM rH ■K
<u CO cd >» S_ •r- J= •CT r ■X
p CD p -a 1— a . H- <1) >> >  «3-
<u S- CO o CO P ■a •r- CM CD o o
E 3 jO < < < <3 o P  \ S. CQ CO •
<0 • • JO CJ CD CD O o CM
s- cO >> >> (TJ CO to • • CO tO 3D DC
CO E cd CD E E E S- S- O  O r—i i— i II
a . to c £= to to to a> <D •r- "CT to o o
03 ■a ■ct 03 fl3 CO > > *CT +-> •O’ Cr— •r— •r— r— r— T— •r— •r— CO CO rH rH
Q_ a. a. Q_ _1 O ' oc i__i UH CO
-  82 -
AST
 
- 
As
pa
rta
te
 
am
in
ot
ra
ns
fe
ra
se
 
ALP
 
- 
Al
ka
lin
e 
ph
os
ph
at
as
e 
ALT
 
- 
Al
an
in
e 
am
in
ot
ra
ns
fe
ra
se
Table 3.5 The to x ic ity  of b il ia ry  metabolites of hexachloro-1:3-butadiene:
Histopathology findings
Rat
Number
Group Kidney Liver
1 CONTROL NAD NAD
2 (CORN OIL) NAD NAD
3 NAD NAD
4 CONTROL BILE NAD NAD
5 NAD NAD
7 Tubular necrosis++ minimal hepatocyte 
vacuolation
8 HCBD Tubular necrosis+++ NAD
9 lOOmg/kg Tubular necrosis++ NAD
1 0 B ile  collected Tubular necrosis+++ NAD
1 1 from C1 4 C3HCBD Tubular necrosis+++ NAD
1 2 treated rats 
107mg/kg equiv
Tubular necrosis++++ 
with casts and 
several foci c a lc i­
f ica tio n  in inner 
medulla
NAD
+ - severity of necrosis
NAD - No abnormalities detected
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damage. However a dose of lOOmg/kg produced a s ig n ifica n t r ise  in 
plasma urea (Fig 3.17) over the control value.
Single oral doses of S -(l,l,2 ,3 ,4 -p e n ta ch lo ro -l:3 -b u ta d ie n y l)-  
glutathione o f 50, 100, 150 and 200mg/kg produced a dose-dependent 
increase in plasma urea (Fig 3.18). S ign ifican t elevations in 
plasma urea were observed at 100, 150 and 200mg/kg.
These dose responses allowed the selection of an equimolar dose of 
each compound which would produce a nephrotoxic response and could 
be used to carry out more deta iled comparison o f th e ir  
nephrotoxic ities using biochemical and h is to log ica l parameters. The 
doses chosen were 100 and 138mg/kg fo r  N -acetyl-S -(1 ,1 ,2 ,3 ,4 - 
pentachloro-l:3 butadienyl)-L-cyste ine and S - ( l ,1 ,2 ,3 ,4-pentachloro- 
l:3 -bu tad ieny l)-g lu ta th ione  respective ly.
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Figure 3.17
200 t
150
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10 100C 5025
DOSE ( m g / kg)
Nephrotoxicity of single oral doses of N -a c e ty l-S -( l, l,2 ,3 ,4 - 
pentachloro-l:3-butadienyl)-L-cysteine in  the ra t as assessed 
by the kidney damage marker, plasma urea. Means ± S.D, n=3 
except the control group; n=4. * S ign ifican t a t p <  0.02
( t  - te s t).
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Figure 3.18 Nephrotoxicity of single oral doses of S-(1 ,1 ,2 ,3 ,4 -
pentachloro-l:3-butadienyl)-g lutathione in  the ra t as assessed 
by the kidney damage marker, plasma urea. Means ± S.D, n=3 
except the control group; n=4 and the 50 mg/kg group; n=2.
* S ign ifican t at p <: 0.02 ( t  - te s t) .
( i i ) T o x ic ity  o f o ra lly  administered syn the tic  m etabolites
A single oral dose of HCBD (200mg/kg) produced marked changes in a ll 
of the biochemical parameters used to assess kidney damage (Tables 
3.6 and 3 .7 ). Increases in plasma urea, urinary glucose and prote in 
indicated a s ig n ifica n t e ffe c t on glomerular f i l t r a t io n  and tubular 
re-adsorption. The concentration of N -acetyl-8 -D-glucosaminidase, 
an enzyme with greatest a c t iv ity  in the renal cortex increased 
s ig n if ic a n tly  as did urinary a lka line  phosphatase and the proximal 
tubule brush border marker enzymes Y-glutamyltranferase and alanine 
aminopeptidase. The increases in y-glutam yltransferase and alanine 
aminopeptidase were p a rtic u la r ly  marked. HCBD also produced a 
s ig n ifica n t increase in kidneyrbody weight ra tios  which was 
associated w ith an increase in tissue water content. H isto log ica l 
examination of the kidneys showed marked renal tubular necrosis 
which was seen as a d is t in c t band of damage in the outer s tr ip e  of 
the outer medulla (Fig 3.19 ), which is  associated with the s tra ig h t 
portion of the proximal tubules. L iver damage caused by HCBD was 
minimal, no s ig n ific a n t h is to log ica l changes could be observed under 
the lig h t  microscope and the only biochemical marker to change was 
plasma alanine aminotransferase the concentrations of which 
decreased. The reasons fo r  th is  decrease are unknown, l iv e r  damage 
usually being indicated by an increase in the plasma concentrations 
o f th is  enzyme.
When the glutathione and N-acetyl cysteine conjugates of HCBD were 
dosed o ra lly  to rats at equimolar doses of 138 and lOOmg/kg 
respective ly, a remarkably s im ila r pattern o f changes to  tha t
-  87 -
observed with HCBD was seen with a ll o f the kidney biochemical 
markers (Tables 3.6 and 3 .8).
H is to log ica l examination of the kidneys from these rats confirmed 
tha t the conjugates o f HCBD produced iden tica l kidney damage to  HCBD 
i t s e l f  (Tables 3.7 and 3.9 and Figure 3.19). As with HCBD there was 
no h istopathological or biochemical evidence to suggest any 
hepatotoxic ity .
- 88 -
Control (Polyethylene glycol 400)
HCBD 200mg/kg
Figure 3.19 Rat kidney, 24hr a f te r  the administrat ion of 
polyethylene glycol 400 (5ml/kg p.o .)  or HCBD (200mg/kg p .o . ) .  The 
kidney from the ra t  given HCBD showed a d is t in c t  band of tubular  
necrosis in the outer s t r ipe  of the outer medulla. Haematoxylin and 
eosin x 40. Cortex l e f t  hand side medulla r ig h t  hand side.
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S -( l , l ,2 ,3 ,4 -P en ta ch lo ro - l :3 -bu tad ieny l ) -g lutath ione
, . ;  • ■ -  :
N-ace ty l -S -( l , l ,2 ,3 ,4 -Pentach lo ro- l :3 -bu tad ieny l ) -L -cys te ine
Figure 3.19 cont. Rat kidney, 24hr a f te r  the administrat ion of S- 
( l , l ,2 ,3 ,4 -P en ta ch lo ro - l :3 -bu tad ie ny l ) -g luta th ione (138mg/kg p .o . ) 
or N -ace ty l -S -( l , l ,2 ,3 ,4 -Pentach lo ro- l :3 -bu tad ieny l ) -L -cys te ine  
(lOOmg/kg p.o .)  showing a d is t in c t  band of damage necrosis in the 
outer s t r ipe  of the outer s t r ipe  of the outer medulla. Haematoxylin 
and eosin x 40.
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Table 3.8 Assessment of N -ace ty l-S -(l,l,2 ,3 ,4 -P en tach lo ro -l:3 -bu tad ieny l)-L - 
cysteine fo r kidney and l iv e r  to x ic ity :  Biochemical parameters .
Parameter Mean ± S.D (n)
Group
N-acetyl cysteine  
HCBD Conjugate 
lOOmg/kg
PEG 400 Control HCBD
200mg/kg
Plasma Urea (mg%) 147 + 23 ( 6 ) * * 51 ± 15 (6) 108 ± 23 ( 6 ) * *
Plasma ALP (U / l ) 394 + 46 (6) 303 ± 112 (6) 383 ± 9 2 ( 6 )
Plasma ALT (U / l ) 7 + 2 (6 ) * 12 ± 2 (6) 6 ± 1 ( 6 ) * *
Plasma AST ( U / l ) 39 + 10 (6) 39 ± 8 (6) 47 ± 11 (6)
Urine Glucose (mg/24h) 33.9 + 1 8 .8 (6 )* 2.1 ± 0 .4  (6) 51.5 ± 1 1 .2 ( 6 ) * *
Urine Protein (mg/24h) 71.8 + 1 9 .2 (6 ) * * 9.4 ± 5.2 (5) 62.1 ± 17 .6 (6 )+
Urine ALP (ymol/h/24h) 12.61 + 6.9 (6 )+ 0.71 ± 0 .25(6 ) 17.43 ± 7 .7 6 (6 ) *
Urine NAG (pmol/h/24h) 7.67 + 1 .0 8 (6 ) * * 2.18 ± 1 .09(6) 7.46 ± 1 .8 7 (6 ) * *
Urine GGT (umol/h/24h) 17,869 6879(6 )** 647 ± 377 (6) 12,209 ± 4787(6 )*
Urine AAP (pmol/h/24) 422.6 + 8 4 .3 ( 5 ) * * 32.7 ± 18 .0 (5 ) 329.9 ± 9 1 .4 ( 6 ) * *
Kidney water (gH20/g 
dry wt) 3.93 ± 0 .2 8 ( 6 ) * * 3.21 ± 0 . 2 3 ( 6 ) 3.85 ± 0 .1 8 ( 6 ) * *
Kidney: body wt x 100 1.04 ± 0 .0 9 ( 6 ) * * 0.79 ± 0 . 0 4 ( 6 ) 0.96 ± 0 .0 9 (6 ) *
L iver water (gH20/g 
dry wt) 2.43 + 0.04(6 ) 2.37 ± 0 .05(6 ) 2.62 dt 0 .62(6 )
L iver: body wt x 100 4.19 + 0 .17 (6 ) 4.70 ± 0 .47 (6 ) 4.24 dt 0 .20 (6 )
Groups of rats were dosed o ra l ly  with N -a c e ty l -S - ( l , l ,2 ,3 ,4 -P e n ta c h lo ro b u ta d ie n y l ) -L -  
cysteine (lOOmg/kg) or HCBD (200mg/kg) as pos it ive  contro l.  Control rats were given 
vehicle alone (Polyethylene glycol 400). The animals were sacr i f ic e d  24 hr a f t e r  
treatment and the biochemical parameters measured. Results are means ± S .D (n).
S ig n if ic n t ly  d i f fe re n t  from control group given PEG 400 alone ( t - t e s t )  a t  * * ,p  < 0 . 0 0 1 ;
* ,p  < 0 .01; + ,p < 0 .02.
AST, Aspartate aminotransferase; ALP, A lkaline  phosphatase; ALT, Alanine aminotransferase; 
NAG, N-acetyl-3-D-glucosaminidase; GGT, Y-glutamyltransferase; AAP, alanine ami nopeptidase.
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c ) The e ffe c t o f b i l ia r y  cannulation on the ne ph ro to x ic ity  o f HCBD
in the ra t
Complete protection from HCBD nephrotoxic ity was observed in ra ts 
tha t had been f i t t e d  with a b i l ia r y  cannula p r io r to being given a 
single oral dose of 200mg/kg HCBD (Table 3.10). This group o f 
animals displayed concentrations o f glucose, prote in ,
Y-glutamyltransferase and alanine ami nopeptidase in th e ir  urine 
which were comparable to  the control values o f cannulated ra ts  given 
vehicle alone. The concentrations of these markers in both groups 
were g rea tly  reduced from values obtained from the non-cannulated 
HCBD (200mg/kg) group.
The surgical procedure fo r  implanting the b i l ia r y  cannula resulted 
in abnormally high concentrations o f aspartate aminotransferase and 
plasma urea and precluded th e ir  use in th is  experiment as useful 
markers in assessing liv e r  and kidney damage. The concentrations o f 
the markers in the sham-operated HCBD group were lower than those 
obtained previously with HCBD-dosed animals, the reason fo r  th is  is 
not known.
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Table 3.10 The e ffe c t of b ilia ry  cannulation on the to x ic ity  of 
hexachloro-1:3-butadiene in the ra t
Parameter
Group
Cannulated + 
HCBD 
(200 mg/kg)
Cannulated + 
PEG 400
HCBD 
(200 mg/kg)
Plasma ALP (U /l) 275 ± 73 264/437 342 ± 13
Plasma ALT (U /l) 8 ± 3 7/11 8 ± 3
Plasma AST (U /l) 67 ± 17 86/116 57 ± 6
Urine glucose
(mg/24hr) 1.0 ± 0.3 0.8 ± 0.3 25.4 ± 13.1
Urine protein
(mg/24hr) 2.4 ± 1.7 3.3 ± 3.2 27.7 ± 16.7
Urine GGT
(umol/hr/24hr) 688 ±272 1139 ± 909 8104 ± 6584
Urine AAP .
. (pmol/hr/24hr) 49 ± 17 37/80 109/187
Rats (n = 3) were b ilia ry  cannulated and given a single oral dose of HCBD 
(200 mg/kg). Control rats were cannulated and dosed with the vehicle alone 
(polyethylene glycol 400). A th ird  group were not cannulated but were given 
HCBD (200 mg/kg) as a positive control. Results are means ± SD or when n = 2 
both values are given.
AST, Aspartate aminotransferase; ALP, A lkaline phosphatase;
ALT, Alanine aminotransferase; GGT, y-glutamyltransferase;
AAP, alanine ami nopeptidase.
DISCUSSION
Although the nephrotoxicity o f HCBD had been recognised fo r  many 
years (Chapter 1), l i t t l e  or nothing was known about the metabolic 
fa te  o f th is  compound, or the relevance or otherwise of metabolism 
to the renal to x ic ity  seen in experimental animals. HCBD was known 
to be metabolised to  unknown water soluble metabolites (Davis et a l , 
1980) which were excreted in urine and faeces. In 1981 Lock and 
Ishmael observed a dose-dependent depletion of hepatic g lutathione 
in the ra t on dosing HCBD. These workers suggested tha t the 
depletion may be due to the formation of a reactive metabolite of 
HCBD, by hepatic metabolism, which is  subsequently scavenged by 
g lutath ione. The depletion o f g lutathione in animal tissues a fte r 
adm inistration of compounds which are known to be tox ic  is 
frequently associated with the inac tiva tion  of tox ic  metabolites 
formed by cytochrome P-450-mediated monooxygenase reactions 
(Chasseaud, 1979; M itchell et a l , 1976; Jollow et a l , 1977).
However, i f  a to x ic  metabolite was generated in the liv e r  from HCBD 
one might expect to see l iv e r  damage, (especia lly  i f  the glutath ione 
pool was depleted) one does not, a point which was not eas ily  
explained at the time. The damage produced by HCBD is directed 
exclusive ly towards the kidney where paradoxically in male ra ts  no 
glutathione depletion can be observed (Lock and Ishmael, 1981). The 
mechanism of HCBD-induced glutathione depletion was investigated in 
male ra t l iv e r  preparations in v it ro  (Wolf et a l , 1984) on the 
assumption tha t HCBD would be metabolised in a s im ila r manner to 
analogous chlorinated compounds (see In troduction ). HCBD caused a
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marked reduction in glutathione concentration when incubated w ith
male (or female) hepatic microsomal or cy toso lic  frac tions  fo r t i f ie d
with g lutathione. In the present study, id e n tif ic a tio n  of the
microsomal product came from in te rp re ta tion  o f the mass spectrum of
i ts  acid-hydrolysed and derivatised product as that o f the
methylester o f S -(pentach loro-l:3-butad ienyl) cysteine, th is  being
the expected product from hydrolysis of the corresponding
glutathione conjugate. Further evidence fo r  the correct
in te rp re ta tion  o f the spectra and assignment o f the o rig in a l
conjugate as that o f a glutathione adduct came from dual label
experiments (Wolf et al 1984) where a 1:1 ra tio  of [^H -]g lu ta th ione 
1 4
to [ C-1HCBD was demonstrated in the microsomal product.
HCBD has s ix  chlorine substituents any one of which could be subject 
to displacement by g lutath ione. I t  has been demonstrated tha t the 
apparently single microsomal product (by TLC) when subjected to GC- 
MS analysis as the derivatised acid hydrolysate consists o f two 
isomeric forms, in tha t two d is t in c t mass peaks gave s im ila r mass 
spectra. These were assumed to  be c is -  and trans-isomers formed 
from o rig ina l c is -  and trans-g lutath ione conjugates of HCBD. On 
s te ric  grounds the trans-isomer was expected to  predominate.
The evidence suggests tha t the glutathione depletion observed in 
v it ro  by Wolf et al (1984) was due to  a d ire c t conjugation reaction 
o f g lutathione with HCBD with loss of one atom of ch lo rine . The 
reaction was shown not to be cytochrome P-450-mediated because no a- 
hydroxy substituent was evident and the o le f in ic  bonds remained
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in ta c t. The lack of involvement o f cytochrome P-450-dependent 
metabolism, the p rin c ip le  route fo r  s tru c tu ra lly  re lated chlorinated 
ethylenes, was fu rth e r demonstrated by Wolf et a l , (1984) in tha t 
the formation o f product was not inh ib ited  by carbon monoxide or 
nitrogen in place o f oxygen, and was independent of the presence of 
NADPH.
The formation of glutathione conjugates by glutathione transferase 
enzymes is  well documented and u n til recently conjugations o f th is  
type have been thought to be mediated by cytoso lic  transferases, 
however, Morgenstern et al (1979 and 1980) and Friedberg et al 
(1980) have now recognised the presence of hepatic microsomal 
glutathione S-transferases. For most substrates the a c t iv ity  o f the 
microsomal transferases is normally low when compared with cy toso lic  
transferases; less than 10% on a m illigram  o f protein basis. In the 
case of HCBD th is  appears not to be true , the rate of HCBD - 
glutathione conjugation in microsomal frac tions  being up to  twice 
tha t found in cytosol (Wolf et a l , 1984). One possible explanation 
fo r  the high microsomal transferase(s) a c t iv ity  may be the 
1ipophi1ic i t y  o f the HCBD molecule favouring p a rt it io n  in to  the 
microsomal l ip id  membranes.
M u ltip le  forms of both microsomal and cytoso lic  glutathione-S- 
transferases ex is t (Friedberg et a l , 1980; Habig et a l , 1974) and in 
the case of the cytoso lic  enzymes these proteins are known to have 
d iffe re n t substrate s p e c if ic it ie s . Certain s im ila r it ie s , such as 
the iso e le c tric  point and immunochemical c ro ss -re a c tiv ity  between 
some of the microsomal glutathione S-transferases and those in the
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cytosol, are known (Friedberg et a l , 1980). However, Morgenstern et 
a l , (1982) have demonstrated tha t at least one form o f microsomal 
transferase is c le a rly  d istinguishable from those in the cytosol. 
Which transferase(s) is  responsible fo r  the conjugation reaction 
with HCBD is  unknown.
The in vivo studies described in th is  thesis indicated tha t the main 
route o f excretion o f ra d io a c tiv ity  a fte r a nephrotoxic dose o f HCBD 
was in the b ile , 17% o f the dose being excreted in both 24hr and 24- 
48hr respective ly. In the ra t e f f ic ie n t  b i l ia r y  excretion usually
requires a molecular weight greater than 325-350 and the presence of 
a strong polar group (Hirom et a l , 1976; Levine, 1978). HCBD (M.W.
261) possessing neither o f these characte ris tics  is  not excreted in
b ile  unchanged but has been reported to be extensively metabolised
and excreted as unknown polar metabolites (Davis et al 1980). In
th is  thesis two metabolites have been id e n tif ie d  in b ile  which
possess the necessary characte ris tics  fo r  b i l ia r y  excretion, S-
pentachlorobutadienyl-glutathione (M.W. 531) and also a product o f
i ts  fu rth e r metabolism by the mercapturic acid synthesis pathway, S-
pentachlorobutadienyl-cysteinylglycine (M.W. 384). Both these
conjugates together accounted fo r  over 50% of the ra d io a c tiv ity  in
b ile .
The presence of a glutathione conjugate which is  formed in the liv e r  
is  consistent with the glutathione depletion observed in vivo in 
male ra ts (Lock and Ishmael, 1981), and also with the formation and 
id e n tif ic a tio n  of g lutathione conjugates in v it ro  (Wolf et al 1984). 
The formation of the cyste inylg lycine conjugate of HCBD can be 
explained by the c lass ica l degradation pathway fo r  glutathione
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conjugates. Y-glutamyltransferase present in the b ile  duct 
canniculi in the l iv e r  or secreted in to  the common b ile  duct by the 
pancreas via  the pancreatic ducts may be responsible fo r  the 
degradation as demonstrated fo r  methyl mercury glutathione (H irata 
and Takahashi, 1981). Cysteinylglycine hydrolase is also present in 
b ile  and may fu rth e r degrade the cyste inylg lyc ine conjugate to  S- 
pentach1 orobutad i eny1 -cyste i ne.
A dd itio na lly , the small in tes tine  also possesses the necessary 
degradative ca p a b ility , as does the kidney i t s e l f .  The degradative 
ca p a b ility  o f the kidney w il l  be discussed la te r.
P a rtia l degradation of S-pentachlorobutadienyl-glutathione to lower 
molecular weight conjugates w ith greater l ip o p h il ic ity  would 
fa c i l i ta te  reabsorption from the in te s tin e . Comparison o f b i l ia r y  
excretion w ith tha t in faeces suggested extensive reabsorption and 
enterohepatic re c ircu la tio n  o f HCBD metabolites. The reabsorption 
of HCBD metabolites has been demonstrated fu rth e r in these studies. 
When radio labelled b ile  collected from one group o f [^C]HCBD-dosed 
ra ts was dosed to a second group of ra ts , s ix  per cent o f the dose 
was excreted in the urine in the f i r s t  twenty four hours. This 
experiment was also important in tha t i t  demonstrated tha t in 
addition to enterohepatic re c ircu la tio n  and faecal excretion, part 
of the dose eliminated in i t i a l l y  in b ile ,  is  subsequently excreted 
by the kidneys. This experiment also established a lin k  between 
hepatic metabolism, b i l ia r y  metabolites and kidney damage. The ra ts 
dosed with b ile  containing HCBD metabolites showed marked kidney 
damage in comparison to rats dosed with control b ile , ind ica ting  the
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hepatic production of a nephrotoxic metabolite. Further experiments 
demonstrated th a t, when e ithe r the chemically synthesised 
glutathione conjugate or i ts  mercapturate deriva tive  were dosed to 
ra ts they each produced an iden tica l pattern o f kidney damage to 
tha t found fo r  HCBD i t s e l f ,  without producing liv e r  damage. The 
absolute ro le  o f hepatic metabolism in the to x ic ity  o f HCBD was 
established when b i l ia r y  cannulated ra ts  dosed with HCBD were 
completely protected from kidney damage. This experiment c le a rly  
established tha t although the kidney possesses a ll o f the enzymes 
necessary to synthesise the glutathione and other mercapturic acid 
pathway metabolites in s itu  (Chasseaud, 1973) th is  does not occur at 
least not to an extent which leads to kidney damage. The 
conjugation of HCBD with glutathione in the liv e r  is therefore the 
c r i t ic a l  in i t ia l  event in the production o f HCBD nephrotoxic ity .
Further evidence supporting the necessary involvement o f hepatic- 
mediated glutathione conjugation in the nephrotoxicity o f HCBD came 
from reassessment of the data of Lock et al (1979) who demonstrated 
tha t HCBD when added in v it ro  to kidney co rtica l s lices fa ile d  to 
produce a decrease in PAH or TEA accumulation (ind ica to rs of damage 
to the kidney anion and cation transport systems respective ly ). 
However, renal s lices prepared from ra ts previously dosed in vivo 
w ith HCBD showed selective damage to the renal anion transport 
system without damaging the cation system when tested in v i t r o .
This difference between the in v it ro  and in vivo treatment w ith HCBD 
was suggested at the time to be due to the fa c t tha t in vivo tubu lar 
c e ll necrosis could occur as a re su lt of ischaemia and/or as a 
re su lt of prolonged contact of HCBD with the tubular c e lls .
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However, in the l ig h t  of current work i t  is now known tha t HCBD 
requires hepatic metabolism in i t i a l l y  to the glutathione conjugate 
as a c r i t ic a l event in the manifestation of i ts  to x ic ity ,  a reaction 
which the renal co rtica l s lices treated d ire c tly  with HCBD in v it ro  
appear unable to  undertake to any s ig n ific a n t extent.
The exact nature of the reabsorbed HCBD hepatic metabolites is  
unknown, but they are thought to be degradation products o f the 
in i t ia l  glutathione-HCBD conjugate.
Irrespective  o f the exact nature o f the reabsorbed hepatic 
metabolites, once delivered to the kidney, the kidney has the 
a b i l i t y  to  degrade a ll of these conjugates to the cysteine 
conjugate. For certa in  glutathione conjugates the kidney is  known 
to play a major ro le  in th is  metabolism (Meister and Tate, 1976).
One such example is  the metabolism by isolated kidney ce lls  o f 
paracetamol-glutathione, to the corresponding cysteine and N- 
acetylcysteine derivatives via the cyste inylg lyc ine  intermediate 
(Moldeus et a l; 1978 and Jones et a l ; 1979). HCBD-glutathione would 
be expected to be degraded in a s im ila r manner, by the enzymes y -  
glutamyltransferase (Y-glutamyltranspeptidase) and cyste iny lg lyc ine  
hydrolase. Within the kidney, Y-glutamyltransferase is  p rim a rily  
associated with the brush-border membrane of the proximal tubule 
ce lls  (Glossman and N ev ille , 1972). The asymmetric o rien ta tion  o f 
i ts  a c t iv ity  suggests tha t glutathione metabolism occurs in the 
tubular lumen (Tsao and Curthoys, 1980). Aminopeptidase is  also 
located on the brush border o f the tubular e p ith e lia l ce lls  (Okajima 
et al 1981) and is  thought to  metabolise cyste inylg lyc ine  conjugates
-  103 -
to cysteine conjugates. In add ition, a pa rticu la te  renal 
dipeptidase which catalyses the hydrolysis o f cyste iny lg lyc ine  has 
also been recently reported in ra t renal brush border membrane 
(McIntyre and Curthoys, 1982) and may also hydrolyse 
cyste inylg lycine conjugates.
Following the id e n tif ic a tio n  of the glutathione and cyste iny lg lyc ine  
conjugates in b ile ,  and the ca p a b ility  o f the kidney fo r  glutath ione 
degradation and mercapturic acid synthesis (Hughey et a l , 1978) one 
may have expected the mercapturic acid deriva tive  of HCBD to  be 
present in urine, as was observed fo r  S -(D ich loroviny l)-cyste ine  
(Derr and Schultze, 1963). Although no d ire c t attempt to  id e n tify  
the mercapturic acid deriva tive  o f HCBD was made, synthesis of th is  
metabolite demonstrated tha t i t  had extreme water in s o lu b il i ty  and 
therefore may not be excreted in urine.
The glutathione or cysteine conjugates o f HCBD per se would not be 
expected to be reactive species capable of causing kidney damage. 
Therefore some fu rth e r metabolic event must be occurring in the 
'ta rg e t organ1, the kidney. The cysteine conjugate o f HCBD would 
have a structure analogous to tha t o f the renal tox in  S -( tra n s - l,2 -  
d ich lo rov iny l)-L -cyste ine  (DCVC) and the metabolic events which are 
occuring in the kidney may be s im ila r to those documented fo r  DCVC.
DCVC was f i r s t  synthesised by McKinney et al (1957) and shown to 
produce renal tubular necrosis in ra ts  (Schultze et al 1962; 
Terracin i and Parker, 1965) and in several animal species (Terracin i 
and Parker, 1965). In ra ts a single in traperitonea l in je c tio n  o f
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DCVC (lOOmg/kg) was s u ff ic ie n t to produce necrosis of renal tubules 
in the inner cortex w ith in  24hr (Terracin i and Parker, 1965). The 
area of damage was defined fu rth e r as a d is t in c t band in the pars 
recta of the proximal tubules, the same area in  which HCBD-induced 
damage occurs (Ishmael et a l , 1982).
Metabolic studies with DCVC demonstrated tha t the major components 
in ra t urine were unchanged DCVC, i ts  N-acetyl derivative  
(mercapturic acid), an un iden tified  component and inorganic sulphate 
(Derr and Schultze, 1963a). In v it ro  work led to the recognition of 
an additional metabolic step, the enzymatic cleavage o f the in tra ­
cysteine C-S bond o f DCVC by bovine l iv e r  and kidney preparations 
(Anderson and Schultze 1965b and Bhattacharya and Schultze, 1967). 
The enzyme responsible, a 8 -lyase, was isolated and p u rifie d  by 
these workers, and is  probably the same enzyme recently iso la ted and 
characterised by Tateishi et al (1978) and tha t isolated by Stevens 
and Jackoby (1983). 8 -Lyase a c t iv ity  has been demonstrated in ra t 
l iv e r  mitochondrial and cytoso lic  frac tions  (Stonard and Parker, 
1971a; Stonard, 1973). The products of the cleavage reaction are 
sto ich iom etric quantities o f ammonia and pyruvate, chloride ions and 
a reactive fragment which contains sulphur and the v iny l carbon 
atoms of DCVC.
The l iv e r  enzyme was shown to  be only active w ith the L-isomer o f 
DCVC. L-DCVC sulphoxide also served as substrate but the apparent 
Km was higher than w ith L-DCVC (Anderson and Schultze, 1965b). 
Anderson and Schultze also suggested tha t formation of a sulphoxide 
was not a prerequ is ite  fo r 8 -lyase cleavage of DCVC. Several other
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halo-alkene cysteine conjugates have been shown to be metabolised by 
th is  enzyme (Bonhaus and Gandolfi, 1981; Green and Odum, in press). 
8 -Lyase is  inactive  towards glutathione conjugates or N-acetyl 
cysteine conjugates, and the free amino group of the cysteine moiety 
appears to be essential fo r  a c t iv ity  (Tateishi et al 1978; Anderson 
and Schultze, 1965(b)). HCBD conjugates have also been tested with 
p u rifie d  8 -lyase. 8 -lyase fa ile d  to  metabolise S-pentachloro- 
butadienylglutathione or N-acetyl-S-(pentachlorobutadienyl)-L- 
cysteine to y ie ld  ammonia and pyruvate, but could metabolise S- 
(pentachlorobutadienyl)-cysteine. The mercapturic acid conjugate 
was metabolised by 8 -lyase a fte r incubation with an acylase enzyme 
(Green and Odum, in press; Nash et a l , 1983). In to x ic ity  
experiments where the N-acetyl-cysteine-HCBD conjugate was dosed to 
animals and produced to x ic ity ,  the conjugate was assumed to  be de­
acetyl ated in the ta rget organ or elsewhere to libe ra te  S- 
(pentachlorobutadienyl)-cysteine which can serve as a substrate fo r  
8 -lyase.
Work fo r  th is  thesis id e n tif ie d  a urinary metabolite o f HCBD, 
l,l,2 ,3 ,4 -p en tach lo ro -l:3 -bu tad ie n y l sulphenic acid (Figure 3.12) 
which is consistent with cleavage of a cysteine - HCBD conjugate by 
8 -lyase. The sulphenic acid metabolite of HCBD is  unusual in tha t 
i t  is one of very few stable sulphenic acids known to e x is t, 
anthraquinone-l-sulphenic acid and purine sulphenic acids being 
other examples (Kuhle, 1973; Abraham and Jardine, 1982). A s im ila r 
although more trans ien t sulphenic acid has been id e n tif ie d  in plants 
fo llow ing the action of 8 -lyase on S -(p rop -l-eny l) cysteine 
sulphoxide (Spare and Virtanen, 1963).
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Two possible routes by which the sulphenic acid metabolite may arise
are shown in Figure 4.1. (1) Cleavage of the HCBD-cysteine
conjugate (pentachlorobutadienyl-cysteine) by renal 8 -lyase to form 
a th io l followed by oxidation to give the sulphenic acid. ( 2 ) 
A lte rn a tive ly  oxidation of the sulphur to form 
pentachlorobutadienyl-cysteine sulphoxide, which is  subsequently 
cleaved by 8 -lyase to produce the sulphenic acid.
Both routes seem equally feas ib le  and w i l l  be considered:
(1) A ll organic th io ls  and th io l derivatives are quite susceptible 
to aerobic oxidation y ie ld ing  a va rie ty  o f oxy deriva tives. The
only th io l oxidation reaction to  oxy derivatives of general 
endogenous biochemical sign ificance is  tha t o f cysteine to alanine 
3-sulphin ic acid (cysteine su lphin ic acid), the main pathway fo r  the 
u t i l is a t io n  o f cysteine sulphur fo r  sulphate production (Patai, 
1974a). Thiols are also known to dimerise (a well known reaction 
fo r  g lu ta th ione), and in the case of pentachlorobutadienyl-cysteine 
th is  reaction could give r ise  to sulphenic acid by subsequent
hydrolysis o f the disulphide as shown in Figure 4.2 (reaction 1). A
reactive th io l generated by 8 -lyase cleavage of 
pentachlorobutadienyl-cysteine could more l ik e ly  react with 
glutathione to form a mixed disulphide which could give r ise  to
sulphenic acid in a s im ila r manner.
Figure 4.2 also shows tha t the disulphide can th e o re tic a lly  give 
r ise  to a th iosulphinate and thiosulphonate, both of which by 
subsequent hydrolysis can give sulphenic acids (reaction 2  and 3 ).
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Figure 4.1
A scheme showing two possible routes from S-pentachlorobutadienyl 
cysteine to pentachlorobutadienyl-sulphenic acid via S-oxidation 
and 3-lyase reactions.
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Figure 4.2 Possible reactions giving rise  to sulphenic, sulphinic 
and sulphonic acid derivatives (Capozzi and Modena 
taken from Patai 1974),
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The th io l which may be generated from 8 -lyase cleavage of 
pentachlorobutadienyl-cysteine may also undergo S-methylation by 
methyl transferases present in l iv e r  and kidney. This mechanism may 
be the o rig in  o f the many S-methyl metabolites reported fo r  a wide 
range of compounds in recent years (M ille r , 1970; Tateishi and 
Shimizu, 1976; Jenner and Testa, 1978).
(2) S-oxidation to form sulphoxides is  documented fo r  a wide range 
of sulphur-containing substrates, one example is  the S-oxidation o f 
propylcysteine formed from 1-bromopropane (Baines et a l , 1977). S- 
oxidation appears to  be catalysed by both cytochrome P-450-dependent 
monooxygenases and flavopro te in  mixed-function amine oxidase 
(Poulsen et a l , 1979). However, which enzyme is  responsible fo r  a 
p a rticu la r substrate is not e n tire ly  c lear. Sulphoxides have been 
shown to  be substrates fo r  8 -lyase (Anderson and Schultze, 1965(b)).
Regardless o f which route to the sulphenic acid is applicable there 
exists the p o s s ib ility  fo r  fu rth e r sulphur oxidation products such 
as sulphin ic (RSC^H) and sulphonic acids (RSOgH). This type of 
sequential oxidation has been shown to be enzymic fo r phenylthiourea 
and ethylenethiourea. The formation of th e ir  sulphin ic acid 
derivatives (phenylformidine- and ethyleneformidine su lph in ic acids) 
being catalysed by microsomal FAD-containing monooxygenase. Further 
oxidation to the sulphonic acids is  at least in part enzymatic 
(Poulson et a l, 1979).
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In the case of HCBD two other more polar components were present in 
urine samples and could have been fu rth e r oxidation products o f the 
sulphenic acid. These components were derivatised on th is  
assumption but were not id e n tif ie d  due to the small quan tities of 
material or fa ilu re  in attempts to make chromatographically su itab le  
derivatives fo r  mass spectral analysis.
Sulphenic acids are also known to cyclise  to thiophenes (a reaction 
used to id e n tify  the sulphenic acid o f HCBD). I f  a s im ila r reaction 
occurred b io lo g ic a lly  in the kidney a product, tetrachlorothiophene 
which is  insoluble in water would be produced and might well be 
reabsorbed, fu rth e r complicating the biodegradation of HCBD.
HCBD s p e c if ic a lly  damages the kidney and the pathological lesion 
produced resembles c lose ly tha t produced by DCVC. Recent work has 
shown tha t DCVC and S-(pentachlorobutadienyl)-cysteine and also the 
glutathione and mercapturic acid conjugates o f HCBD decrease the 
accumulation o f the organic ions PAH and TEA when incubated in v it ro  
w ith kidney s lice s . This damage to  the renal organic ion uptake 
system is  presumed to be mediated in both cases by a reactive th io l 
generated by 8 -lyase cleavage of the cysteine conjugates (Nash et 
a l , 1983). The th io v in y l moiety generated in v it ro  from DCVC has 
been shown to be a very reactive a lky la ting  agent in tha t i t  w i l l  
re ad ily  a lky la te  4 -(p -n itrobenzy l)-pyrid ine  (NBP) (Stonard and 
Parker, 1971a) a widely recognised acceptor fo r  a lky l groups 
(Epstein et a l, 1965). The th io v in y l moiety can combine with 
proteins (Anderson and Schultze, 1965a), g lutathione (Anderson and 
Schultze, 1965a) and DNA (Bhattacharya and Schultze, 1972). In the
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cases of the glutathione and mercapturic acid conjugates of HCBD the 
kidney appears to degrade them to the cysteine conjugates in order 
to  serve as substrates fo r  renal 8 -lyase.
As the data above is  s im ila r fo r  HCBD and DCVC i t  is  suggested tha t 
the biochemical ta rget fo r  HCBD w ith in  the kidney ce lls  may be 
the same as tha t proposed fo r  DCVC (Stonard, 1973). Biochemical 
studies with DCVC have shown tha t DCVC inh ib ited  both DNP-stimulated 
(DNP; 2 ,4-d in itropheno l, an agent uncoupling oxidative 
phosphorylation) and unstimulated resp ira tion  of ra t l iv e r  and 
kidney mitochondria in v i t r o . When DCVC (50mg/kg) was in jected 
in tra p e rito n e a lly  in to  rats DNP-stimulated resp ira tion  of ra t kidney 
mitochondria was substan tia lly  inh ib ite d  2-4hr a fte r adm inistration 
(Parker, 1965), and also delayed stim ulation o f ATP hydro lysis, both 
in vivo and in v it ro  (Stonard and Parker, 1971). These e ffec ts  were 
thought to be related to production o f a reactive metabolite. Like 
l iv e r  and kidney fra c tio n s , ra t l iv e r  mitochondrial frac tions  have 
the a b i l i t y  to degrade DCVC to pyruvic acid and ammonia and at least 
one other un iden tified  metabolite, which has the characte ris tics  o f 
an a lky la ting  agent (Stonard, 1971; Stonard and Parker, 1971b). The 
s ites o f action o f DCVC are thought to be the multienzyme complexes, 
2-oxoacid dehydrogenases (Stonard and Parker, 1971b). I t  has been 
shown tha t lip o y l dehydrogenase (NADH2  : lip o ic  acid oxidoreductase
E C 1.6.4.3) an enzyme present in both the pyruvate and 2- 
oxoglutarate dehydrogenase complexes and glutathione reductase (an 
extramitochondrial cytoso lic  enzyme) are inh ib ited  in v it ro  
(Stonard, 1973). The active s ites of lip o y l dehydrogenase and 
glutathione reductase are both thought to  contain FAD and a redox-
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disulphide grouping (Massey 1963). A mechanism fo r  the action of 
DCVC is  shown in Figure 4.3.
The in h ib it io n  of mitochondrial events may lead to the observed 
mitochondrial swelling observed with HCBD (Lock and Ishmael 1982) 
and eventually to c e ll death. A scheme fo r  the hepatic conjugation 
and renal activa tion  of HCBD is  shown in Figure 4.4.
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N-acetylation
Figure 4.3
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Work contained in th is  thesis has established a number o f important 
p rinc ip les  fo r  HCBD-induced nephrotoxicity which may be applicable 
to  other haloethylene-produced nephro tox ic ities.
Conjugation o f HCBD with glutathione in the l iv e r  is the in i t ia l  
cruc ia l event and probably accounts fo r  the reduction in glutathione 
concentrations seen in vivo (Lock and Ishmael, 1981) on dosing HCBD 
to ra ts . Experiments using b i l ia r y  cannulation techniques have 
demonstrated in d ire c tly  tha t the kidney cannot produce glutath ione 
conjugates of HCBD at least not to an extent which can cause 
nephrotoxic ity. Although other workers have synthesised various 
glutathione and cysteine conjugates (Bonhaus and Gandolfi (1981), 
Gandolfi et a l , (1981), Green and Odum (1985), in order to 
demonstrate th e ir  nephrotoxicity in v it ro  or occasionally in vivo 
the present study provides the f i r s t  evidence fo r  the production of 
a metabolite in vivo which leads to nephrotoxic ity. I t  has been 
demonstrated conclusively tha t the glutathione conjugate is  
elim inated in b ile  and tha t degradation and reabsorption o f 
subsequent metabolites occurs. I t  is  the glutathione conjugate 
which is  a precursor of the ultim ate nephrotoxic metabolite produced 
by B-lyase cleavage of the proximate nephrotoxin S- 
(pentachlorobutadienyl)-cysteine. The id e n tif ic a tio n  of the 
sulphenic acid metabolite o f HCBD constitu tes the only published 
evidence to date o f the id e n tif ic a tio n  o f a B-lyase cleavage product 
from a halocarbon-cysteine conjugate.
HCBD is  therefore an example of a glutathione conjugation reaction 
which subsequently leads to a tox ic  metabolite rather than a non­
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to x ic , less b io lo g ic a lly  active metabolite. The spec ific  region of 
damage produced in the kidney nephron is  probably a consequence of 
the kidney possessing a ll the necessary enzymes fo r glutathione 
conjugate degradation in close proxim ity to the enzyme B-lyase. In 
th is  case, the enzymes are used fo r  xenobiotic degradation y ie ld in g  
a reactive metabolite. No evidence has been obtained fo r  the 
production of to x ic ity  v ia  epoxide formation as seen with 
chloroethylene -induced liv e r  damage.
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The Metabolism and Disposition of Hexachloro-1:3-butadiene in 
the Rat and Its Relevance to Nephrotoxicity
Jo h n  A . N a s h , L a u r e n c e  J. K in g ,*  E d w a r d  A . L o c k , a n d  T r e v o r  G r e e n 1
Biochemical Toxicology Section, Central Toxicology Laboratory, Imperial Chemical Industries PLC, Alderley 
Park, Macclesfield, Cheshire SK10 4TJ, England, and *  Department o f Biochemistry,
University of Surrey, Guildford, Surrey GU2 5XH, England
Received August 31, 1983; accepted November 3, 1983
The Metabolism and Disposition of Hexachloro-1:3-butadiene in the Rat and Its Relevance 
to Nephrotoxicity. N a s h ,  J. A., K i n g ,  L. J., L o c k ,  E. A., a n d  G r e e n ,  T. (1984). Toxicol. Appl. 
Pharmacol. 73, 124-137. Following po administration of a nephrotoxic dose (200 mg/kg) of 
hexachloro-1:3-butadiene (HCBD) to male rats, the principal route of excretion was biliary, 17- 
20% of the dose being eliminated on each of the first 2 days. Fecal excretion over this period 
was less than 5% of the dose per day, suggesting enterohepatic recirculation of biliary metabolites. 
Urinary excretion was small, not exceeding 3.5% of the dose during any 24-hr period. The major 
biliary metabolite was a direct conjugate between glutathione and HCBD itself. The cysteinylglycine 
conjugate of HCBD has also been found in bile. Evidence was obtained to show that biliary 
metabolites of HCBD are reabsorbed and excreted via the kidneys. The glutathione conjugate, 
its mercapturic acid derivative, and bile containing HCBD metabolites were all nephrotoxic 
when dosed orally to rats. In common with HCBD, these metabolites caused localized damage 
to the kidney with minimal effects in the liver. Rats fitted with a biliary cannula were completely 
protected from kidney damage when dosed with HCBD, demonstrating that hepatic metabolites 
were solely responsible for the nephrotoxicity of this compound. It is proposed that the hepatic 
glutathione conjugate of HCBD was degraded to its equivalent cysteine conjugate which was 
cleaved by the renal cytosolic enzyme /3-lyase to give a toxic thiol which caused localized kidney 
damage. A urinary sulphenic acid metabolite of HCBD has been identified which is consistent 
with this hypothesis. The mode of activation of HCBD conjugates in the kidney is believed to 
be analogous to that proposed for S-( 1,2-dichlorovinyl)-L-cysteine.
Hexachloro-1:3-butadiene (HCBD) is used 
commercially in small quantities as a vineyard 
fumigant and in the recovery o f chlorine gas 
in the chemical industry. More significant 
amounts o f HCBD are found in industrial 
wastes, generated mainly from the manufac­
ture o f tetra- and trichloroethylene and carbon 
tetrachloride (I.A.R.C., 1979). The toxicity o f  
HCBD is directed almost exclusively toward 
the kidney (Gradiski et al., 1975; Kociba et 
al., 1977; Lock and Ishmael, 1979), and in 
the rat it specifically damages the pars recta 
o f the proximal tubule (Ishmael et al., 1982).
1 To whom all correspondence should be addressed.
Although HCBD is metabolized in rats to 
unidentified water soluble metabolites (Davis 
et al., 1980) which are excreted in urine and 
bile, the relevance o f these metabolites to the 
toxicity o f HCBD is unknown. The dose-de­
pendent depletion o f hepatic glutathione levels 
observed in male rats dosed with HCBD (Lock 
and Ishmael, 1981) is consistent with the pos­
sible formation o f  reactive electrophilic ep­
oxides in com m on with the metabolism o f  
other chloro-alkenes (Henschler and Greim, 
1976). However, the toxicity o f HCBD in vivo 
does not seem to be affected by inducers or 
inhibitors o f hepatic and renal mixed function 
oxidases (Lock and Ishmael, 1981; H ook et
0041-008X/84 $3.00
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al., 1982), the enzymes associated with epoxide 
formation, nor do these observations explain 
the organ specificity o f HCBD. Recent work 
in this laboratory with renal and hepatic in 
vitro preparations (W olf et a l,  1984) has 
shown that depletion o f hepatic glutathione 
is a result o f a direct glutathione ^-transferase 
mediated reaction between HCBD and glu­
tathione. The same study failed to find any 
role for cytochrome R-450 in the hepatic me­
tabolism o f HCBD in vitro. These observations 
formed the basis o f this in vivo investigation 
o f the mechanism o f activation o f HCBD to 
toxic, organ specific metabolites. We carried 
out experiments to elucidate the structure o f  
HCBD metabolites, to determine their site of  
formation, and by means o f detailed toxicity 
studies, their relevance to the nephrotoxicity 
o f hexachloro-1 ;3-butadiene.
METHODS
Materials. Hexachloro-l:3-butadiene (Spectrosol grade, 
>99% purity) was obtained from BDH Chemicals Ltd, 
Poole, Dorset, UK. [U-I4C]Hexachloro-l:3-butadiene, 
specific activity 10.1 mCi/mmol, was supplied by Physics 
and Radioisotope Services, Imperial Chemical Industries
PLC, Billingham, Cleveland, UK. The Chemical and ra­
diochemical purity which exceeded 99% was assessed by 
gas chromatography with radiochemical detection and by 
gas chromatography-mass spectrometry. All other chem­
icals and reagents were obtained from commercial sources 
at the highest purity available.
Synthesis o f conjugates o f hexachloro-13-butadiene. N- 
Acetyl-5'-( 1,1,2,3,4-pentachloro-1:3-butadienyl)-L-cyste- 
ine: Dry iV-acetyl-L-cysteine (50 g, 0.3 mol) was added to 
a solution of sodium (0.6 mol) in methanol (1 liter). Hex­
achloro-l:3-butadiene ( 8 8  g, 0.33 mol) was added slowly 
with stirring over 30 min. After 90 min, the solution was 
evaporated to approximately 500 ml, 300 ml water was 
added, and the pH was adjusted to 5-6. Unchanged hex­
achloro-l:3-butadiene was removed by extracting four 
times with equal volumes of n-hexane. The aqueous so­
lution was then adjusted to pH 1 with sulfuric acid and 
extracted 4 times with ethyl acetate. The ethyl acetate 
extracts were washed twice with water and evaporated to 
dryness. The residue was recrystallized from acetonitrile 
after treatment with decolorizing charcoal to yield 38 g 
of product; the melting point was 70°C. (Found C, 29.9; 
H, 2.6; N, 5.7; S, 7.7; Cl, 41.2%, C9H 80 3NSC15 requires 
C, 27.9; H, 2.1; N, 3.61; S, 8.3; Cl, 45.8%). The probe 
insertion mass spectrum of the product was consistent 
with the expected structure (Fig. 1).
iS'-( 1,1,2,3,4-Pentachloro-1:3 -butadienyl)-glutathione. 
This conjugate was prepared from hexachloro-1 ^ -buta­
diene and glutathione in the presence of sodium and liquid 
ammonia by a method analogous to that described by 
McKinney and Biester (1959). The crude product was
100 -
NHCOCH,I 3CHCH2S \( 
COOH C l ' '
8a
>>
60-
40-
20 -
m+
33 200 300 400
Fig . 1. Probe insertion mass spectrum of A-acetyl-5'-( 1,1,2,3,4-pentachloro-1:3-butadienyl)-L-cysteine.
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recrystallized from ethanol/water to give a white crystalline 
material with a melting point of 186-187°C. (Found C, 
32.0; H, 3.2; N, 7.7; S, 6.3; Cl, 33.1%, C14H 160 6N 3SCl5 
requires C, 31.6; H, 3.0; N, 7.9; S, 6.0; Cl, 33.4%). The 
field desorption mass spectrum was consistent with the 
expected structure (Fig. 2).
Animals. Male, Alderley Park (Wistar derived) rats, 170 
to 200 g body weight, were housed in temperature (22 °C) 
and humidity (50%) controlled rooms equipped with a 
12-hr lighting cycle. Feed (PCD diet, Special Diet Services 
Ltd, Witham, Essex, UK) and water were provided ad 
libitum throughout all experiments unless otherwise stated.
Excretion studies. Six rats were dosed orally with 
[14C]HCBD (200 mg/kg) as a solution in com oil (5 ml/ 
kg). Each dose contained 9.28 nCi of radiolabeled HCBD. 
The rats were housed singly in plastic metabolism cages 
designed for the separate collection of urine and feces. 
Excreta were collected frozen in dry ice at 24-hr intervals 
for 5 days and analyzed for radioactivity. Aliquots of urine 
(1  ml) were mixed with 1 0  ml of standard liquid scintil­
lation fluid (Fisofluor, Fisons Ltd.) and assayed by liquid 
scintillation counting with a Packard Tri-Carb Model 460 
CD spectrometer. Fecal samples were freeze dried and 
ground to a homogeneous powder; samples ( 1 0 0  mg) were 
quantified as 14C02 in a Packard tissue oxidizer and liquid 
scintillation spectrometer.
Additional studies were carried out with three rats with 
exteriorized bile flow. Following recovery from the surgical 
implantation of a biliary cannula, each rat was given a 
single po dose of [14C]HCBD (200 mg/kg: 50 /*Ci) as a 
solution in com oil (5 ml/kg). The rats were restrained 
for the collection of bile and urine (Bollman, 1948), but 
had access to pelleted laboratory diet and drinking water 
containing 1% w/v dextrose, 0.9% w/v sodium chloride, 
and 0.05% w/v potassium chloride. Bile and urine samples 
were collected at 24-hr intervals for 2 days. Aliquots of 
bile (0 .1  ml) and urine (1  ml) were mixed with a standard 
scintillation fluid and assayed for radioactivity.
Distribution studies. The tissue distribution of radio­
50 100 150 200 250 300
15.00 
%
. 0.00
350 400 450 500 550 600
%
Fig. 2. Field desorption mass spectrum of 5'-( 1,1,2,3,4- 
pentachloro- 1:3-butadienyl)glutathione.
activity was studied 2, 4, 8 , and 16 hr after a single po 
dose of [14C]HCBD (200 mg/kg: 42.6 fiCi) as a solution 
in com oil (5 ml/kg). A single rat was killed at each time 
point by exposure to excess halothane BP, and rapidly 
frozen in a hexane/solid C02 mixture. The frozen carcass 
was embedded in 2 % w/v carboxymethylcellulose, and 
20-/zm longitudinal sagittal sections cut with an LKB PMV 
type 450 MP cryomicrotome. Apposition autoradiograms 
were prepared from the freeze-dried sections (Ullberg, 
1962).
Identification o f biliary metabolites. A 24-hr bile sample 
from a rat dosed with [14C]HCBD (200 mg/kg: 50 y d )  
was freeze dried; the residue was dissolved in ethyl ace- 
tate:acetic acid:methanol:water (EAMW 60:15:15:10) and 
chromatographed on thin layer plates (Silica Gel GF) with 
the same solvent system (Fig. 6 ). Areas of radioactivity 
were located by a thin-layer radiochromatogram scanner 
(Berthold Model LB 2723). Preparative separation of larger 
amounts of bile was achieved by column chromatography 
with a Lobar size B Si 60 column (E. Merck, Darmstadt) 
with the same solvent system at a flow rate of 1 ml/min. 
The eluate was monitored with a radiochemical detector 
(Berthold Model LB 503) and collected in 2-ml fractions. 
Three bands of radioactivity were eluted with retention 
times of 92, 174, and 204 min. Fractions corresponding 
to each of these bands were pooled and concentrated under 
reduced pressure. The most polar fraction (RT 204 min) 
containing the major metabolite on thin layer chromato­
grams (R/0.46) was hydrolyzed overnight with 6  M HC1 
at 100°C. The hydrolysate was evaporated to dryness, and 
the methyl ester, A-trifluoroacetyl derivative was prepared 
with ethereal diazomethane and trifluoroacetic anhydride 
successively. The derivatized sample was analyzed by gas 
chromatography and by gas chromatography-mass spec­
trometry (GC-MS).
The material eluting from the column with a retention 
time of 174 min was analyzed by thin-layer chromatog­
raphy alongside an authentic sample of ^ (l.l^ ^ ^ -p en - 
tachloro-l:3-butadienyl)-cysteinylglycine. Silica gel GF 
thin layer plates were used with either the previously de­
scribed solvent system (EAMW) or a mixture of n-butanol: 
acetic acid:water (BAW 12:3:5 v/v). The standard was 
prepared by treating S-{ 1,1,2,3,4-pentachloro-1:3-buta- 
dienyl) glutathione (2.5 mM) with 7 -glutamyl transpep­
tidase (20 units) in Tris-HCl buffer (50 mM, pH 8.5) for 
16 hr at 25 °C. Spots on chromatograms were located 
under uv light, by spraying with ninhydrin solution or by 
radiochromatogram scanning.
Identification of urinary metabolites. Observations by 
Davis et al. (1980) and in this laboratory have shown a 
dose-dependent urinary excretion of HCBD metabolites. 
In order to optimize the recovery of radioactivity and 
mass from treated rats, both high and low doses of HCBD 
were used to generate metabolites. Twelve rats were dosed 
po with [14C]HCBD (200 mg/kg: 50 yCi) and a further 
four rats at a dose level of 20 mg/kg: 50 fiCi. Urine was 
collected for 24 hr (200 mg/kg) or 48 hr (20 mg/kg), and
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the total urine samples were combined. Two volumes of 
ice-cold ethanol were added to the combined urine sample, 
and the precipitated protein was removed by centrifugation 
at 10,000g. The supernatant fraction was removed, evap­
orated under reduced pressure to approximately half vol­
ume, and extracted four times with equal volumes of 
diethyl ether at neutral pH. The aqueous fraction was 
then adjusted to pH 1 with 3 M HC1 and extracted re­
peatedly with equal volumes of diethyl ether until no 
further radioactivity was extracted. The pH 1 ether extract 
was evaporated to dryness; the residue was dissolved in 
distilled water and chromatographed on a Lobar size B 
Lichroprep RP8  reverse phase column with metha- 
nol:water:formic acid (60:40:1 v/v) as the eluting solvent. 
Fractions corresponding to individual peaks of radioac­
tivity were combined and evaporated to dryness under 
reduced pressure; their silyl derivatives were prepared with 
a mixture of BSTFA/1% TMCS in dry pyridine. Samples 
were analyzed by radiochemical gas chromatography and 
by high-resolution gas chromatography-mass spectrom­
etry.
Gas chromatography. Radioactive metabolites were an­
alyzed by gas chromatography with a Pye series 104 in­
strument equipped with flame ionization and radiochem­
ical detection (ESI Nuclear 504 Radiogas Detector). The 
column effluent was split in the ratio of 1 0 :1  between the 
radiochemical detector and the flame ionization detector. 
In each case the carrier gas was a mixture of Argon/C02 
(95:5) at a flow rate of 30 ml/min. Biliary metabolites 
were analyzed on a 0.9 m X 2 mm glass column packed 
with 5.2% OV101 on 100-200 mesh Supelcoport, tem­
perature programmed from 150°C (3 min) to 250°C at 
10°C/min. Urinary metabolites were analyzed on a 1.5 
m X 2 mm glass column packed with the same material 
and programmed from 100 to 300°C at 15°C/min. Mass 
peaks corresponding to radioactivity were identified and 
analyzed by GC-MS with the same columns and con­
ditions, but with a helium carrier gas ( 2 0  ml/min).
Mass spectrometry. An LKB 2091 EI/CI gas chro­
matograph-mass spectrometer was used to obtain spectra 
of metabolites. Accurate mass measurement and field de­
sorption spectra were obtained on a Jeol D300 GC-MS. 
This instrument was fitted with a 2.7 m X 2 mm glass 
column packed with 3% OV101 on Supelcoport (100- 
120 mesh) and programmed from 150 to 300°C at 
15°C/min.
The toxicity of biliary HCBD metabolites and HCBD  
conjugates. Bile was collected from 13 rats fitted with 
biliary cannulae for 24 hr after a single po dose of 
[I4C]HCBD (200 mg/kg). The bile samples were pooled, 
freeze dried, and reconstituted in a small volume of distilled 
water (10 ml). Control bile obtained from com oil dosed 
rats was concentrated in the same way.
A group of three rats was dosed po with the reconstituted 
bile collected from [14C]HCBD-treated rats at a dose level 
equivalent to 107 mg/kg HCBD based on the radioactivity 
content of the bile. Further groups of three rats were dosed
po with an equivalent amount of control bile, with 
[14C]HCBD (100 mg/kg) in com oil, or with com oil 
vehicle alone (5 ml/kg). The rats were housed individually 
in metabolism cages for the separate collection of urine 
and feces. Twenty four hours after dosing, the rats were 
killed with halothane, and blood and the 24-hr urine sam­
ples were taken for biochemical analysis. Urine was also 
assayed for radioactivity. Kidneys and liver were removed 
for the measurement of organ body weight ratios and 
water content and for histopathological assessment. Por­
tions of liver and kidney were fixed in 1 0 % formol saline, 
and paraffin sections (5 ^m) were cut and stained with 
hematoxylin and eosin.
The toxicity of equimolar doses of the A-acetyl cysteine 
and glutathione conjugates of HCBD (100 and 138 mg/ 
kg, respectively) was assessed in groups of six rats following 
single po doses of the test compounds. A third group of 
six rats received po doses of HCBD (200 mg/kg). The 
conjugates of HCBD were found to be insoluble in com 
oil, the vehicle chosen for the earlier studies with HCBD 
itself. It was considered preferable to dose these conjugates 
as solutions in polyethylene glycol 400 (PEG) or water 
rather than as suspensions in com oil. When direct com­
parisons with HCBD were made, this administration was 
also dosed in PEG. The A-acetyl cysteine conjugate and 
HCBD were therefore dosed as solutions in polyethylene 
glycol 400 (5 ml/kg); the glutathione conjugate was dosed 
as the hydrochloride in aqueous solution. Control rats 
received polyethylene glycol alone. Twenty-four hour 
blood and urine samples and liver and kidneys were taken 
for the procedures described above.
The effect o f biliary cannulation on HCBD toxicity. 
Two groups of rats, three per group, were fitted with ex­
teriorized biliary cannulae as previously described. One 
group was dosed with HCBD (200 mg/kg) as a solution 
in polyethylene glycol 400 (5 ml/kg); the other group 
received the vehicle alone. A third group of three rats 
underwent part of. the surgical procedure in that the ab­
dominal cavity was opened under anesthesia and im­
mediately closed again with sutures. A biliary cannula 
was not fitted to these rats; the bile duct was not disturbed 
and remained fully functional. These rats then received 
a single po dose of HCBD (200 mg/kg) in PEG 400. 
Twenty-four hour blood and urine samples were taken 
for biochemical analysis and liver and kidney for histo- 
pathology as described above.
Biochemical assays. Plasma urea, alkaline phosphatase, 
alanine aminotransferase, aspartate aminotransferase, and 
urinary glucose were all determined by commercially 
available methods (Smith Kline Instruments; Boehringer 
Corporation Limited) in conjunction with Vitatron An­
alyzers. Urinary protein was determined by a modification 
of the method of Pesce and Strande (1973). The activities 
of urinary alanine aminopeptidase and 7 -glutamyl trans­
ferase were measured by the methods of Mondorf et al. 
(1978) and Szasz (1969), respectively. Urinary alkaline 
phosphatase was determined by the method of Femley
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and Walker (1965) and A-acetyl-/3-D-glucosaminidase by 
the method of Leaback and Walker (1961).
RESULTS 
Excretion and Tissue Distribution
Over the 5-day period studied, the major 
route o f elimination o f a single po dose o f 2 0 0  
mg/kg o f [14C]HCBD was in the feces (39%), 
the bulk o f the radioactivity being excreted 
on Days 3 to 5 (Fig. 3). Experiments with rats 
fitted with a biliary cannula demonstrated that 
35% of the dose was excreted in bile during 
the first 48 hr (Fig. 3), suggesting that biliary 
metabolites accounted for most if  not all o f 
the radioactivity in feces. The fecal excretion 
over this period was low (5.4%) suggesting ex­
tensive reabsorption and enterohepatic recir­
culation o f biliary metabolites. However fecal 
output on Days 1 and 2 was reduced, and this 
reduced output may contribute to the low ex­
cretion o f radioactivity over this period. The 
excretion o f radioactivity in urine was low, a 
maximum o f 3.5% o f  the dose being elimi­
nated in any 24-hr period over the 5 days 
(Fig. 3).
Tissue Distribution o f  Radioactivity
Autoradiograms o f  longitudinal sagittal 
sections taken sequentially through whole an­
imals dosed po with [14C]HCBD at 200 mg/ 
kg and killed after various times were quali­
tatively similar at all time points and only the
4-hr whole body autoradiogram is presented 
as being representative (Fig. 4). Quantitation 
with a densitometer demonstrated low levels 
o f radioactivity in the stomach, but higher 
levels in the small intestine indicated either 
rapid absorption o f HCBD followed by ex­
cretion via the bile into the gut or passage of 
HCBD directly from the stomach to the in­
testine. Extraction o f the gut and its contents 
with hexane at this time point indicated that 
both hexane (85%) and water (15%)-soluble 
forms o f radioactivity were present suggesting 
that some metabolism had occurred but that 
most o f the radioactivity was present as un­
changed HCBD (85%). Similar experiments 
at 8  and 16 hr showed that by 16 hr absorption 
was virtually complete and that the radioac­
tivity present in the gut at this time was mainly 
due to water-soluble metabolites. The auto-
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F ig .  3. The daily excretion of radioactivity following a single po dose of [14C]hexachloro-l:3-butadiene 
(200 mg/kg). The values shown are the means ±  SD.
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Fig. 4. Whole body autoradiogram of a longitudinal sagittal section showing distribution of radiolabel 
in the rat after a single po dose of [14C]hexachloro-l:3-butadiene in corn oil (200 mg/kg: 250 jtCi/kg) and 
killed after 4 hr.
radiogram showed a definite intrarenal dis­
tribution of radioactivity, the outer medulla, 
the site of damage produced by HCBD being 
particularly well labeled.
Biliary Metabolites
Preparative column chromatography of a 
freeze dried extract of bile fractionated the 
biliary metabolites into three bands, the most 
polar of which (RT 204 min) contained over 
half of the radioactivity (55%) in bile. Thin 
layer chromatograms of this band revealed the 
presence of a major component (40%) at Rf  
0.46 which corresponded to synthesized S- 
(1,1,2,3,4-pentachloro-1:3-butadienyl) gluta­
thione, together with a minor component 
(15%) at R/ 0.64. Hydrolysis, methylation, and 
trifluoroacetylation of the major component 
gave a product which was identified by G C - 
MS as the O-methyl ester of A-trifluoroacetyl-
S- (1,1,2,3,4 - pentachloro -1:3- butadienyl) - L - 
cysteine. Figure 5 shows the electron impact 
mass spectrum together with the interpreted 
structure.
Incubation of the glutathione conjugate of 
hexachloro-1:3-butadiene with 7 -gIutamyl 
transpeptidase produced 2 ninhydrin-positive 
spots on thin-layer chromatograms. The spot 
at R j0. 18 (BAW system) corresponded to glu­
tamic acid while the second at R/0.60, which 
was uv absorbing, was assumed to be the cys- 
teinyl glycine conjugate of HCBD. When this 
conjugate was cochromatographed in two sol­
vent systems (BAW and EAMW) with the col­
umn chromatography band with a retention 
time of 174 min, the cysteinyl glycine con­
jugate of HCBD was shown to be the major 
component of this band, accounting for 12% 
of the radioactivity in bile. The remaining bil­
iary metabolites (Fig. 6) accounting for ap­
proximately 45% of the radioactivity in bile 
have not been identified.
Urinary Metabolites
Ether extraction of pooled urine samples 
from [l4C]HCBD dosed rats yielded 1.6% of 
the total urinary radioactivity at neutral pH 
and 29.5% at pH 1. When the pH 1 ether
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F ig . 5. E lectron im pact m ass spectrum  o f  th e 0 -m eth y l ester o f  A-trifluoroacetyl-( 1,1,2 ,3 ,4-pentachloro- 
1 ;3-butadienyl)-L-cysteine obtained  by hydrolysis and derivatization  o f  th e m ajor biliary m etabolite.
extract was chromatographed on a reversed 
phase column, three bands o f radioactivity 
were isolated. Gas chromatography o f the tri- 
methylsilyl derivative o f the least polar o f these 
bands gave a single radiolabeled peak eluting 
at 240°C with a retention time o f 9.4 min. 
This metabolite was subsequently identified 
by mass spectrometry as the trimethylsilyl de­
rivative o f  l,l,2 ,3 ,4-pentachloro-l:3-buta- 
dienyl sulphenic acid (Fig. 7) and accounted 
for 8.9% of the radioactivity in urine, 1% o f  
the dose o f HCBD. The structure was con­
firmed by accurate mass measurement o f the 
molecular and M — Cl ions (Fig. 7). If this 
metabolite were not stabilized by esterification, 
it readily cyclized in the gas chromatograph 
to give tetrachlorothiophene, which was iden­
tified by comparison o f its mass spectrum with 
that of an authentic sample. The identification 
o f  this cyclization product is consistent with 
the urinary metabolite being the sulphenic acid 
structure assigned from the high-resolution 
mass spectrum o f its trimethylsilyl ester. The 
two remaining ether extractable bands rep­
resenting 15.9 and 4.7% o f the radioactivity 
in urine and the non-ether-soluble material 
(70%) are the subject o f further investigation.
The Toxicity o f  HCBD and HCBD Conjugates
A single po dose o f hexachloro-1 ^ -buta­
diene ( 1 0 0  to 2 0 0  mg/kg) produced marked 
changes in all o f the parameters used to assess 
kidney damage 24 hr after dosing (Tables 1 
and 2). Increases in plasma urea, urinary glu­
cose, and protein indicated a significant re­
duction o f glomerular filtration and tubular
ORIGINSF
F ig .  6 . TLC radiochromatogram of 24-hr bile from rats 
given a single po dose of [14C]hexachloro-l:3-butadiene 
(200 mg/kg). Solvent system ethyl acetate:acetic 
acidrmethanol:water (60:15:15:10). Identified metabolites 
are X, £-( 1,1,2,3,4-penta-chloro-1:3-butadienyl)-glutathi- 
one (Rf  0.46), and Y, tS'-( 1,1,2,3,4,-pentachloro-1:3-bu- 
tadienyl)-cysteinyl glycine (Rf 0.73).
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Fig . 7. Electron impact mass spectrum of the trimethylsilyl derivative of l,l,2,3,4-pentachloro-l:3- 
butadienyl sulphenic acid. Mass measurement of the M +  and M  — Cl ions by high resolution mass 
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reabsorption (Table 2). The high urinary glu­
cose levels which are believed not to be as­
sociated with high plasm a glucose levels 
(Gradiski et al., 1975) also indicated damage 
to the proximal tubule as did the marked in­
crease in the enzymes alkaline phosphatase 
and Y-glutamyl transferase. Hexachloro-1:3- 
butadiene also produced a significant increase 
in kidney to body weight ratio (26%) which 
was associated with an increase in kidney water 
content (Table 1). There was no histopatho- 
logical or biochemical evidence (Table 2) to 
suggest any hepatic damage.
A single po dose o f bile containing radio- 
labeled HCBD metabolites also caused marked 
renal toxicity (Table 1). N o increase in liver 
enzyme markers was seen, the only significant 
change was an increase in liver/body weight
ratio (Table 1). Control bile showed no signs 
of toxicity to either kidney or liver in these 
experiments. It was shown by thin-layer chro­
matography that the freeze drying and recon­
stitution in distilled water produced no qual­
itative or quantitative changes in the radio­
activity content o f the original bile samples. 
Rats given bile containing radioactive HCBD  
metabolites excreted 6 % o f the radioactivity 
in urine compared to 4.6% in rats given 
[14C]HCBD (Table 1).
When the glutathione or iV-acetyl cysteine 
conjugates o f HCBD were dosed po to rats at 
equimolar doses o f 138 and 1 0 0  mg/kg, re­
spectively, a remarkably similar pattern o f  
changes was seen in all o f  the biochemical 
markers (Table 2). Each parameter was af­
fected with a clear quantitative correlation be-
132 NASH ET AL.
TABLE 1
T h e  T o x ic it y  o f  B il ia r y  M et a bo lite s  o f  H e x a c h l o r o -1 :3-b u t a d ie n e
[14C]HCBD bile Control HCBD Control
Parameter (107 mg/kg equiv.) bilec ( 1 0 0  mg/kg) (Com oil)
Plasma urea (mg%) 161.7 ±  5** 65.5 79.3 ±  1.76 57.3 ±  4.2
Kidney water (g H 20/g dry wt) 4.35 ±  0.01** 3.51 4.00 ±0 .1 ** 3.50 ±  0.1
Kidney: body w t(X  100) 0.45 ±  0.03** 0.37 0.49 ±  0.01** 0.39 ±  0.01
Plasma AST (U/liter) 69.0 ±  3.6 75.5 78.6 ±  20.6 74.0 ±13.1
Plasma ALP (U/liter) 364.0 ±  98 195 220.7 ±  52 189.0 ±  24.0
Plasma ALT (U/liter) 7.3 ±  1.2 9.5 6.7 ±  2.5 6.7 ±  3.1
Liver water (g H 20/g dry wt) 2.41 ±  0.03 2.32 2.40 ±  0.04 2.31 ±  0.04
Liver: body wt (X100) 3.7 ±0 .1 ** 3.1 3.95c 3.03 ±0.18
Radioactivity in urine
(% dose/24 hr) 6.2 ±  1.5 — 4.6 ±0.1 —
a AST, Aspartate aminotransferase; ALP, alkaline phosphatase; ALT, alanine aminotransferase.
* Rats were dosed po with 14C bile (equivalent to 107 mg/kg HCBD) collected from rats dosed po with [14C]HCBD 
(200 mg/kg). Further groups of rats were dosed with an equivalent amount of control bile, with [14C]HCBD (100 
mg/kg) in corn oil or with com oil vehicle alone (5 ml/kg). Results are means ±  SD (n = 3). 
cn = 2 .
** Significantly different from control animals given com oil alone, p <  0.001 (t test).
tween the conjugates and HCBD itself, sug- nephrotoxicity. The conjugates were also sim-
gesting that hepatic glutathione conjugates o f ilar to HCBD in that they showed no histo-
HCBD were involved in HCBD-mediated pathological or biochemical evidence o f liver
TABLE 2
T h e  T o x i c i t y  o f  S y n t h e s i z e d  H e x a c h lo r o - 1 :  3 -B u t a d ie n e  C o n j u g a t e s  a 'b
Parameter Controle
HCBD 
( 2 0 0  mg/kg)
Glutathione 
HCBD 
conjugate 
(138 mg/kg)
A-Acetyl 
cysteine-HCBD 
conjugate 
( 1 0 0  mg/kg)
Plasma urea (mg%) 51 ±  15 108 ±  23** 95 ±  11** 147 ±  23**
Plasma ALP (U/liter) 303 ±  112 383 ±  92 406 ±  65 394 ±  46
Plasma ALT (U/liter) 12  ±  2 6  ±  1** 7 ±  0.5** 7 ±  2*
Plasma AST (U/liter) 39 ±  8 47 ±  11 36 ±  2 39 ±  10
Urine glucose (mg/24 hr) 2.1 ±  0.4 51.5 ±  11.2** 48.8 ±  14.7** 33.9 ±  18.8*
Urine protein (mg/24 hr) 9.4 ±  5.2 62.1 ±  17.6* 37.3 ±  6.4** 71.8 ±  19.2**
Urine ALP (^mol/hr/24 hr) 0.7 ±  0.25 17.4 ±  7.76* 17.4 ±  5.1** 12.6 ±  6.9*
Urine NAG (Mmol/hr/24 hr) 1.9 ±  0.47 7.56 ±  1.87** 4.0 ±  0.7** 7.77 ±  1.08**
Urine GGT (Mmol/hr/24 hr) 647 ±  377 12209 ±  4787* 15965 ±  5105** 17869 ±  6879**
Urine AAP (Mmol/hr/24 hr) 33 ±  18 330 ±  91.4** 327 ±  8 8 ** 422 ±  84**
a ALP, Alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; NAG, iV-acetyl-/8 - 
D-glucosaminidase; GGT, -y-glutamyltransferase; AAP, alanine aminopeptidase.
b Rats were dosed po with equimolar doses of 5'-( 1,1,2,3,4-pentachloro-1:3-butadienyl)-glutathione (138 mg/kg) or 
Ar-acetyl-5’-( 1,1,2,3,4-pentachloro-1:3-butadienyl-L-cysteine (100 mg/kg). A further group was dosed HCBD (200 mg/ 
kg) in polyethylene glycol 400 as positive control. 
c The control group received polyethylene glycol 400. Results are means ±  SD (n = 6 ).
* p <  0 .0 1  (r test).
** Significantly different from control, p <  0.001.
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damage. Histopathological examination o f the 
kidneys from these rats confirmed that the 
conjugates o f HCBD caused an identical lesion 
to that already described for HCBD itself (Ish­
mael et a l, 1982).
Complete protection from HCBD neph­
rotoxicity was observed in rats that had been 
fitted with a biliary cannula before being given 
a single po dose o f 200 mg/kg HCBD (Table 
3). Each o f the parameters measured was 
comparable to control values from cannulated 
rats given the vehicle alone. Because o f the 
surgical procedures involved, only a limited 
number o f animals were used in this study 
and statistical evaluation o f the results was 
not meaningful. However, the marked differ­
ences in glucose, protein, GGT, and AAP lev­
els (Table 3) between cannulated and non- 
cannulated HCBD treated rats clearly indicate 
that cannulation and loss o f bile prevents 
HCBD-mediated nephrotoxicity. Although 
the enzymes, AST, ALP, and ALT, used to 
detect liver toxicity were unchanged, the sur­
gical procedure for implanting the biliary can­
nula resulted in abnormally high levels o f  
plasma urea in rats given the vehicle alone 
and precluded the use o f this marker in as­
sessing kidney damage. The third group o f  
rats which had undergone part o f the surgical 
procedure but had been left with the bile duct 
intact displayed typical kidney damage when
given a single po dose o f HCBD (Table 3). 
N o evidence was found for the dosing vehicle 
having an effect on any o f the parameters 
measured in these studies (Tables 1, 2, and 3).
DISCUSSION
The organ selectivity o f HCBD suggests that 
metabolism may be a prerequisite for the 
nephrotoxicity o f this chemical. A direct in­
teraction between HCBD and target tissue 
would be less selective and hence unlikely to 
account for the organ and site specificity o f  
the damage (Ishmael et a l,  1982). In common  
with most xenobiotics, the principal site o f  
metabolism o f HCBD would be expected to 
be the liver rather than the kidney. One o f  
the objectives o f this study was to investigate 
whether hepatic metabolites o f HCBD had a 
role in kidney damage or whether unique m e­
tabolism o f HCBD in the kidney was the crit­
ical event.
It has been known for several years that 
HCBD causes a depletion o f  hepatic gluta­
thione levels in the rat (Lock and Ishmael, 
1981). More recent in vitro studies in this lab­
oratory have shown this depletion to be a result 
of direct conjugation o f HCBD with gluta­
thione mediated primarily by a microsomal 
glutathione transferase (W olf et a l,  1984), an 
observation now confirmed in vivo. The same
TABLE 3
T h e  Effec t  o f  B il ia r y  Ca n n u l a t io n  o n  t h e  T o x ic it y  o f  H e x a c h l o r o -1:3-b u t a d ie n e  in  t h e  R a t "
Parameter
Cannulated 
+  HCBD 
( 2 0 0  mg/kg)
Cannulated 
+  PEG 400
HCBD 
( 2 0 0  mg/kg)
Plasma ALP (U/liter) 275 ±  73 264/437 342 ±  13
Plasma ALT (U/liter) 8  ±  3 7/11 8  ±  3
Plasma AST (U/liter) 67 ±  17 86/116 57 ±  6
Urine glucose (mg/24 hr) 1.0 ±  0.3 0.8 ±  0.3 25.4 ±13.1
Urine protein (mg/24 hr) 2.4 ±  1.7 3.3 ±  3.2 27.7 ±  16.7
Urine GGT (^mol/hr/24 hr) 6 8 8  ±  272 1139 ±  909 8104 ±  6584
Urine AAP (/*mol/hr/24 hr) 49 ±  17 37/80 109/187
a Rats (n = 3) were biliary cannulated and given a single po dose of HCBD (200 mg/kg). Control rats were cannulated 
and dosed with the vehicle alone (polyethylene glycol 400). A third group were not cannulated but were given HCBD 
(200 mg/kg) as a positive control. Results are means ±  SD or when n = 2 both values are given.
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study failed to find any evidence for cyto­
chrome P-450-dependent m etabolism, the 
principal route for structurally related chlo­
rinated ethylenes (H enschler and G reim ,
1976). The identification o f a glutathione con­
jugate in vitro (W olf et a l,  1984) and the 
known high biliary excretion o f HCBD me­
tabolites (Davis et a l ,  1980) suggested that 
the po route o f administration was the most 
appropriate for this current study. The use of 
this route when dosing chemically synthesized 
biliary metabolites more closely represents the 
way in which biliary metabolites are intro­
duced into the small intestine in vivo, than 
does the ip route used by other workers (Davis 
et a l,  1980; Lock and Ishmael, 1979, 1981). 
Intraperitoneal injection is also unsuitable for 
whole body autoradiography studies and hence 
the po route was used throughout.
In the present study, hepatic metabolites o f  
HCBD are excreted mainly in the bile, 17% 
o f the dose being excreted on each o f the first 
2 days. In the rat, biliary excretion is usually 
associated with the formation o f polar con­
jugates with a molecular weight greater than 
300 (Hirom et a l,  1976) and would be the 
preferred route o f elimination o f the gluta­
thione conjugate o f HCBD (molecular weight 
>  500). This conjugate and its cysteinyl glycine 
derivative accounted for over 50% of the ra­
dioactivity in bile.
A comparison o f biliary excretion o f radio­
activity over 2 days with that in feces over 5 
days (Fig. 3) suggests extensive reabsorption 
o f biliary metabolites and enterohepatic re­
circulation. Reabsorption frequently occurs as 
a result o f hydrolysis or partial degradation o f  
conjugates by enzymes in the bile duct or small 
intestine. Evidence for partial degradation has 
been obtained by the identification o f the cys- 
teinyl-glycine conjugate o f HCBD in rat bile. 
This metabolite which accounts for 12% o f  
the radioactivity in bile is possibly produced 
by the action o f  7 -glutamyl transferase o f  pan­
creatic origin as demonstrated for methyl 
mercury glutathione by Hirata and Takahashi 
(1981), or by the action o f this enzyme in the 
liver.
Degradation o f the glutathione conjugate 
o f HCBD to either the cysteinylglycine or cys­
teine conjugate will markedly increase the li- 
pophilicity o f the molecule, thus favoring 
reabsorption. A significant quantity o f reab­
sorbed metabolites particularly o f reduced 
molecular weight may be excreted via the 
bloodstream and the kidneys. Experiments in 
this study support this view, and in addition 
to demonstrating that biliary metabolites are 
reabsorbed and passed to the kidney, it has 
also been demonstrated that such metabolites 
are toxic to the kidney. In these experiments 
bile collected from HCBD-treated rats was 
dosed to a second group o f rats. Six percent 
of the dose was excreted in urine in the first 
24 hr and the rats showed marked kidney 
damage in comparison to rats dosed with con­
trol bile. These experiments established a link 
between hepatic metabolism, biliary metab­
olites, and kidney damage. Subsequently, 
when either the glutathione conjugate or its 
mercapturate derivative was dosed to rats, they 
each produced an identical pattern o f kidney 
damage to that found for HCBD (Table 2). 
Thus it appears that the glutathione conjugate 
o f HCBD or one o f its degradation products 
excreted in bile and reabsorbed from the gut 
is responsible for the renal toxicity o f HCBD. 
This thought was confirmed when biliary- 
cannulated rats dosed with HCBD were com ­
pletely protected from kidney damage, an ob­
servation essential in establishing the role of 
hepatic metabolism in the nephrotoxicity o f  
this compound. Although kidneys possess all 
o f the enzymes necessary to synthesise these 
conjugates in situ (Chasseaud, 1973), this study 
has established that this action does not occur, 
at least not to an extent that leads to kidney 
damage. Thus, although only just over 50% 
o f hepatic biliary metabolites have been iden­
tified, evidence has been obtained to support 
the findings o f W olf et a l  (1984) that the prin­
cipal metabolic pathway for HCBD is by direct 
conjugation with glutathione.
Reabsorption o f the glutathione conjugate 
of HCBD from the gut is more likely to occur 
after degradation to  the lower m olecular
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weight, more lipophilic, cysteinylglycine, or 
cysteine conjugates. However, irrespective o f  
the exact nature o f the reabsorbed metabolites, 
the kidney has the potential to degrade all o f  
them to the cysteine conjugate by means of* 
the enzymes 7 -glutamyl transferase and cys- 
teinylglycinase present in the brush border 
(Hutson, 1976). Following V-acetylation in 
renal tubular cells, the mercapturic acids are 
then excreted in urine. Work with the renal 
toxin S-( 1 ,2 -dichlorovinyl) cysteine (DCVC) 
has led to the recognition o f an . additional 
enzyme C-S or /3-lyase, which metabolizes 
cysteine conjugates o f several halo-alkenes 
(Anderson and Schultze, 1965a; Bonhaus and 
Gandolfi, 1981). The enzyme will cleave cys­
teine but not glutathione or TV-acetyl cysteine 
conjugates to form ammonia, pyruvate, and 
a reactive fragment containing sulfur which 
is believed to be a thiol (Anderson and 
Schultze, 1965b). Because o f the substrate 
specificity o f /6 -lyase, we presume that in our 
experiments the glutathione and TV-acetyl cys­
teine conjugates o f HCBD are metabolized to 
the free cysteine conjugate in order to become 
substrates for this enzyme.
Evidence has been obtained to suggest that
the reaction o f the thiol fragment derived from 
DCVC with dithiols and sulfhydryl groups in 
proteins, and with glutathione itself, may lead 
to renal toxicity (Anderson and Schultze, 
1965a; Stonard and Parker, 1971; Stonard, 
1973).
A scheme for the hepatic conjugation and 
renal activation o f HCBD is shown in Fig. 8 . 
The structure o f the cysteine conjugate o f  
HCBD is analogous to that o f DCVC sug­
gesting a similar mechanism o f action. Fur­
thermore dichlorovinyl cysteine and HCBD  
(or its conjugates) both produce a lesion to 
the pars recta o f the proximal tubule in the 
rat (Terracini and Parker, 1965; Ishmael et 
al., 1982), an area o f the renal tubule which 
contains high concentrations o f peptidase and 
cysteinyl glycinase enzymes (Hughey et al., 
1978) and presumably /6 -lyase. We have iden­
tified a urinary metabolite which is consistent 
with cleavage o f a cysteine-HCBD conjugate 
by /3-lyase. This metabolite, 1 ,1,2,3,4-pen- 
tachloro-l:3-butadienyl sulphenic acid (Fig. 8 ) 
is the first evidence to be presented for this 
type o f cleavage occurring in vivo. Oxidation 
o f the sulfur atom o f this metabolite may have 
occurred prior to cleavage since cysteine sulf-
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Fig. 8 . Proposed mechanism for hexachloro-l:3-butadiene elicited nephrotoxicity.
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oxide conjugates are also known to be sub­
strates for /6 -lyase (Anderson and Schultze, 
1965b). Alternatively oxidation o f a thiol to 
a sulphenic acid and subsequently to sulphinic 
and sulphonic acids is likely to occur and may 
constitute a detoxification pathway for this 
type o f thiol. Compounds o f this type are also 
known to cyclize to thiophenes and to di- 
merize to thiosulfinates (Spare and Virtanen, 
1963). During the identification o f  the sul­
phenic acid metabolite o f HCBD, it was found 
that unless this metabolite was stabilized by 
ester formation, it readily cyclized to give tet- 
rachlorothiophene. Similar reactions occur­
ring in the kidney would give products in­
soluble in water which would readily be reab­
sorbed. This type o f reaction may partly 
account for the proliferation o f HCBD m e­
tabolites found while there is apparently only 
a single metabolic event occurring in the liver. 
The sulphenic acid metabolite o f HCBD is 
unusual in that it is one o f very few stable 
sulphenic acids known to exist, anthraqui- 
none-1-sulphenic acid and purine sulphenic 
acids being the other examples (Kuhle, 1973; 
Abraham and Jardine, 1982). A similar al­
though more transient sulphenic acid has been 
identified in plants following the action o f /3- 
lyase on ^-(prop-l-enyl) cysteine sulfoxide 
(Spare and Virtanen, 1963).
We suggest that thiols generated by cleavage 
of cysteine conjugates by /3-lyase could account 
for the stable thiol metabolites found for 
chemicals such as hexachlorobenzene (Koss 
et al., 1976). Subsequent methylation o f thiols 
by hepatic methyl transferases may be related 
to the formation o f  the S-methyl metabolites 
that have been found for a wide range o f  
chemicals (Miller, 1970; Tateishi and Shimizu, 
1976; Jenner and Testa, 1978).
It is concluded from this study that deple­
tion o f glutathione in the liver is not a response 
to the formation o f a reactive metabolite of  
HCBD but results from a simple conjugation 
reaction that is not associated with hepato- 
toxicity. It is only when this conjugate is de­
graded to its cysteine equivalent that it be­
comes a substrate for renal /3-lyase and a toxic
metabolite is formed (Fig. 8 ). Although this 
enzyme is widely distributed in the rat, the 
highest concentrations are found in the kidney 
(Tateishi et al., 1978; Tateishi and Shimizu,
1981), the principal organ responsible for the 
formation and excretion o f cysteine conjugates 
and hence the target organ for these chemicals.
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ABSTRACT
The mechanism of hexachloro-1:3-butadiene (HCBD)-induced 
glutathione depletion in male and female rats has been investi­
gated in rat liver and kidney preparations in vitro in order to 
characterize the enzymes involved and to study the relationship 
between this effect and the nephrotoxic action of this compound. 
HCBD caused a marked reduction in glutathione concentration 
when incubated with male or female hepatic microsomal or 
cytosolic fractions fortified with glutathione. In contrast with that 
reported for other halo-olefin’s, the depletion of glutathione in 
the microsomal fraction is not related to the formation of metab­
olites via cytochrome P-450. The microsomal rate of depletion 
appeared to be due to a direct reaction catalyzed by a micro­
somal glutathione S-transferase. A glutathione adduct of HCBD 
was isolated by thin-layer chromatography and mass spectral
analysis strongly indicates the structure to be as S-(1,1,2,3,4- 
pentachloro-1,3-butadienyl)glutathione, confirming a direct sub­
stitution reaction without prior oxidation. This conjugate was 
formed at a faster rate by the hepatic microsomal fraction than 
by the cytosolic fraction suggesting a major role for the micro­
somal glutathione S-transferases in the disposition of this com­
pound. A second more polar glutathione-dependent adduct 
which may be a double conjugate was formed with cytosol. 
Glutathione adducts were also formed by male and female kidney 
cytosol and microsomal fractions but at a slower rate than in 
liver fractions. It is suggested that the glutathione conjugate of 
HCBD may be converted to the cysteine derivative, the structure 
of which is similar to that of S-dichloro-vinyl-L-cysteine and 
therefore may be nephrotoxic by a similar mechanism.
It has been known for some time that glutathione plays an 
important role in the elimination of potentially toxic foreign 
compounds (Chasseaud, 1979). Many exogenous chemicals are 
known to be metabolized by the cytochrome P-450-dependent 
monooxygenase system (present predominantly in the liver, but 
also in other organs, e.g., kidney and lung) to electrophilic 
products, e.g., epoxides (Jollow et al., 1977) and these poten­
tially toxic products then either react with glutathione directly 
or are conjugated via a reaction catalyzed by the glutathione S- 
transferases. Such reactions represent a detoxification path­
way. As a consequence of these studies, any observed depletion 
of tissue glutathione after the administration of a toxic com­
pound has been taken as indicative of the formation of poten­
tially toxic metabolites (Mitchell et al., 1976). Although there 
are possible alternative explanations for a decrease in tissue 
glutathione concentration, the correlation between glutathione 
depletion and toxic metabolite formation for many compounds 
has been reasonably good (Mitchell et al., 1976).
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HCBD is a relatively potent nephrotoxin in rodents (Lock 
and Ishmael, 1979; Berndt and Mehendale, 1979) but has little 
effect on the liver (Lock et al., 1982b). It is therefore interesting 
that a marked depletion of hepatic glutathione is observed in 
male rats after HCBD administration (Lock and Ishmael,
1981), whereas in the kidney no depletion can be measured. In 
contrast, in female animals which are more susceptible to the 
nephrotoxic effects of this compound (Hook et al., 1983) the 
depletion of hepatic glutathione is not as marked in the liver, 
but significant depletion in the kidney can be measured. Deple­
tion of hepatic glutathione with diethylmaleate before HCBD 
administration did not produce any hepatotoxicity (Hook et al.,
1982). Therefore, there seemed to be no direct correlation 
between glutathione depletion and toxicity. We have investi­
gated 1 ) in vitro whether HCBD-mediated glutathione deple­
tion is due to the formation of reactive, potentially toxic me­
tabolites and 2 ) the relative roles of cytochrome P-450 and the 
glutathione S-transferases in this reaction. The relationship 
between these reactions and the mechanism of HCBD-induced 
nephrotoxicity is discussed. Preliminary observations on this 
work have been reported by Wolf et al. (1982) and Lock et al. 
(1982a).
ABBREVIATIONS: HCBD, hexachloro-1:3-butadiene; av, avoidupois.
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Materials and Methods
M aterials. HCBD (spectroscopic grade >  99% pure), l-chloro-2,4- 
dinitrobenzene and 5,5'-dithiobis(2-nitrobenzoic acid) were purchased 
from BDH Chemicals Ltd. (Poole, Dorset, UK). Glutathione ([3H] 
glycine labeled), specific activity 1 mCi/mmol, was purchased from 
New England Nuclear (Boston, MA). HCBD, uniformly [14C] -labeled 
was synthesized by Physics and Radioisotope Services, Imperial Chem­
ical Industries PLC (Billingham, UK). The specific activity was 9.9 
mCi/mmol and the radiochemical and chemical purity >  99%. All other 
reagents were obtained from commercial sources and were of the 
highest purity available.
Preparation o f hepatic and renal microsomal and cytosolic 
fractions. Hepatic and renal cytosolic and microsomal fractions were 
prepared from male or female Alderley Park (Wistar-derived) rats of 
170 to 210 g b.wt. which had been fasted for 24 hr before use. The rats 
were killed by cervical dislocation, tissues were removed and a 25% w/ 
v homogenate made in ice-cold 0.154 M  KC1 (adjusted to pH 7.4 with 
0.1 M  phosphate buffer) using a Potter type homogenizer. The homog­
enate was then centrifuged at 11,000 x  g (av) for 20 min at 4°C, the 
supernatant was transferred to fresh tubes and centrifuged at 160,000 
x g (av) for 40 min at 4°C. The fatty layer on the top of the samples 
was discarded and the supernatant (cytosolic fraction) removed and 
stored at —70°C. The microsomal pellet was washed once by resus- 
pending in ice-cold 0.154 M  KC1 and then centrifuged at 80,000 x  g 
(av) for 30 min. Finally the pellet was resuspended in 20 mM Tris-HCl 
buffer (pH 7.4) containing 0.25 M  sucrose and 5.4 mM EDTA at a 
protein concentration of 20 to 30 mg/ml. Samples were either used 
immediately or for some experiments stored at —70°C for up to 2 weeks. 
Protein concentrations were determined by the method of Lowry et al. 
(1951). A sample of hepatic or renal cytosol from each rat was dialysed 
overnight at 4°C against 0.1 M  phosphate buffer (pH 7.4), to reduce 
the glutathione concentration to <  0.1 mM.
Determ ination of glutathione depletion. The interaction of 
HCBD with glutathione was assessed by measuring the loss of sulphy- 
dryl group reactivity with 5,5'-dithiobis(2-nitrobenzoic acid) by the 
following procedure. Incubations were carried out in 0.1 M  phosphate 
buffer (pH 7.4) containing hepatic microsomes (1-2 mg of protein per 
ml) or dialyzed cytosol (5-9 mg of protein per ml), reduced glutathione 
(10 mM), glutathione reductase (1.2 U/ml) and for some experiments 
a NADPH generating system (NADP, 6 mM; MgCl2, 12 mM; glucose- 
6-phosphate, 7.5 mM and glucose-6-phosphate dehydrogenase, 1 U / 
ml). The final incubation volume was 10 ml. The depletion of glutathi­
one was followed after the addition of [14C]HCBD (2.8 mM and 1 pCi/ 
ml) as a solution in ethanol (0.05 ml). Incubations were carried out at 
37°C in air and samples were removed (0.3 ml) at 30, 60, 90 and 120 
min. The reaction was stopped by the addition of ice-cold 0.6 M  
trichloroacetic acid (0.3 ml). Glutathione concentration was determined 
on the protein-free solution by the method of Sedlak and Lindsay 
(1968). For some experiments the enzyme concentration (microsomal 
protein) and substrate concentration(s) (HCBD or glutathione) were 
varied to determine the kinetics of the reaction.
Measurement of glutathione conjugate formation. Liver glu­
tathione conjugate formation was determined on the samples obtained 
from the glutathione depletion studies. Kidney glutathione conjugate 
formation was determined by incubating microsomal or dialyzed cyto­
solic fractions at a protein concentration of 0.9 to 1.5 or 2.2 to 2.7 mg/ 
ml, respectively, under the conditions described for measuring hepatic 
glutathione depletion. At the end of 2 hr incubation samples were 
quickly cooled in ice-cold water and the remaining unchanged HCBD 
removed by extraction with diethyl ether (6 x  10 ml). The aqueous 
phase was then freeze dried and the microsomal fraction reformed in 1 
ml of water and the cytosolic fraction in 1.2 ml. Aliquots of the clear 
supernatant (40-60 /d) were then applied to silica gel GF thin-layer 
chromatography plates (20 x  5 cm) and the plates developed in n- 
butanol-acetic acid-water mixture (12:3:5). Areas of radioactivity were 
determined quantitatively using a Berthold model I I  thin-layer chro­
matograph scanner linked to a PET Commodore computer. For some
hepatic experiments l-chloro-2,4-dinitrobenzene (1 mM), a competitive 
substrate for glutathione transferases, was present as a solution in 
ethanol at a final concentration of 0.5% v/v. In other experiments, 
[3H] glutathione (1 ^Ci/ml) was used to replace the radiolabeled HCBD 
to help identification of the conjugate. The dependance of the reaction 
on cytochrome P-450 and molecular oxygen was measured in samples 
gassed with CO-02 (80:20) or nitrogen for 1 min before HCBD addition, 
these latter experiments were done in stoppered tubes.
Identification of the glutathione conjugate. To enable isolation 
and identification of the HCBD metabolite the incubation conditions 
were modified as follows: HCBD (5 mM), reduced glutathione (4 mM), 
[14C]HCBD (10 pCi) and microsomal protein (7.5 mg/ml). The total 
incubation volume was 40 ml and the incubations were carried out for 
75 min at 37°C. At the end of the incubation unchanged HCBD was 
removed by extracting 3 times with hexane (40 ml). Two volumes of 
ice-cold ethanol were then added to the aqueous fractions and the 
precipitated microsomal protein removed by centrifugation at 10,000 
X g for 30 min. The supernatant was decanted and evaporated under 
reduced pressure at 25°C to a volume of 0.5 ml. This concentrate was 
then chromatographed on silica gel GF thin-layer chromatography 
plates using n-butanol-acetic acid-water (12:3:5 v/v) as the developing 
solvent. The major radioactive band (Rf 0.33) was removed and eluted 
from the silica with water. The eluate was again concentrated (1 ml) 
and hydrolyzed with 6 M  HC1 at 100°C for 20 hr. Under these conditions 
complete hydrolysis of the material with Rf 0.33 occurred to give a 
single radioactive product Rf 0.57 in the same system. The hydrolyzate 
was evaporated to dryness and methylated with an ethereal solution of 
diazomethane. The methylated sample was further chromatographed 
on thin-layer plates (silica gel GF) using chloroform methanol (9:1 v / 
v) as the solvent system. The major radioactive band Rf 0.75 which 
was strongly UV absorbing and ninhydrin positive was eluted with 
ether, concentrated and analyzed by gas chromatography. The gas 
chromatograph (Pye Series 104) was fitted with flame ionization and 
radiochemical detection (ESI Nuclear 504 Radiogas detector). The 
effluent from the 5 foot x  2 mm glass column which was packed with 
5.2% OV101 on 100 to 120 mesh Supelcoport was split equally between 
the two detectors. The column was operated at 200°C with an Argon- 
C02 (95:5) carrier gas flow rate of 25 ml/min. Two radiolabeled mass 
peaks were identified using an LKB 2091 E I/C I gas chromatograph 
mass spectrometer operated with the same chromatographic conditions.
Synthesis o f glutathione and cysteine conjugates o f H C BD. 1.
S-(l,l,2,3,4-pentachloro-l:3-butadienyl)-L-cysteine. HCBD was re­
acted with the sodium salt of N-t-BOC-S-benzyl-L-cysteine in liquid 
ammonia at —70°C for 1 hr. The ammonia was allowed to evaporate 
and the residue treated with a solution of approximately 1 M  HC1 in 
ethyl acetate for 30 min at room temperature. The resulting white solid 
(m.p. 180-182°C) was removed by filtration and shown to be S- 
(l,l,2,3,4-pentachloro-l:3-butadienyl)-L-cysteine by mass spectrome­
try and by [13C]NM R (—COOH, 168.156 ppm; —CH, 51.680 ppm; 
—CH2S, 32.882 ppm; — C = C —C =C — , 133.159, 125.358, 124.383 
and 119.724 ppm).
2. iS-( 1,1,2,3,4-pentachloro-l:3-butadienyl)-glutathione. This conju­
gate was prepared from HCBD and glutathione by a method analogous 
to that described by McKinney and Biester (1959). The crude product 
was recrystallized to give a white crystalline material m.p. 186-187°C. 
Microanalysis, the field desorption mass spectrum and [13C]NM R  
spectrum were consistent with the expected structure.
Results
HCBD-mediated glutathione depletion by hepatic m i­
crosom al and cytosolic fractions from  m ale and fem ale  
rats. Initial experiments were designed to establish suitable 
incubation conditions for investigating HCBD-mediated glu­
tathione depletion in vitro and were based on the premise that 
a cytochrome P-450-dependent activation reaction was required 
before conjugation would occur. Male rat liver microsomal
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samples, fortified with glutathione and an NADPH generating 
system, were incubated with HCBD and a time-dependent loss 
of glutathione measured (fig. 1 ). A small reduction in glutathi­
one occurred in samples incubated in the absence of HCBD or 
with heat-inactivated microsomes (fig. 1). Glutathione deple­
tion catalyzed by HCBD was proportional to microsomal pro­
tein concentration and was linear up to 4 mg of protein per ml. 
The rate of depletion was also dependent on the concentration 
of glutathione (fig. 2A) and a K m of 290 yuM and a V max of 1.38 
nmol/min/mg of microsomal protein was obtained. The K m 
value for HCBD was 550 yuM with a V max of 0.91 nmol/min/mg 
of microsomal protein (fig. 2B). Incubations carried out in the 
absence of the NADPH generating system produced a similar 
rate of HCBD-mediated glutathione loss to that in the presence 
of NADPH (fig. 1 ; table 1). When male rat liver cytosol was 
used instead of microsomes a lower rate of loss was measured 
(fig. 1; table 1). The depletion of glutathione by microsomes or 
cytosol from female liver was similar to that obtained with 
male samples (table 1 ).
Experiments using the above incubation system with kidney 
subcellular fractions were not feasible due to the rapid loss of 
added glutathione in the presence and absence of HCBD. This 
is presumably due to the presence of high concentrations of 
glutathione metabolizing enzymes.
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Fig. 1. HCBD-mediated glutathione loss by male rat liver microsomes 
and cytosol. A, rat liver microsomes (10-12 mg of protein) or B, cytosol 
(50-90 mg of protein) were incubated in 0.1 M phosphate buffer (pH 7.4) 
containing glutathione (10 mM), glutathione reductase (12 U) and were 
indicated an NADPH generating system and HCBD (2.8 mM). Samples 
were removed from the incubation at the times shown and glutathione 
measured in a protein-free extract. For some experiments the micro­
somes were heated to 100°C for 5 min before use (O) or alternatively 
the reaction contained no HCBD (O). With NADPH (•). Minus NADPH 
(A).
Glutathione concentration
B. HCBD
HCBD concentration (mM
Fig. 2. Double reciprocal plot of the rate of HCBD-mediated glutathione 
depletion vs. glutathione or HCBD concentration using male hepatic 
microsomal fractions. A, glutathione. Incubations were made in 0.1 M 
phosphate buffer (pH 7.4, 10 ml) containing male rat liver microsomal 
protein (11 mg), glutathione reductase (12 U), HCBD (2.7 mM) and 
glutathione at the concentrations shown. Incubations were for 2 hr at 
37°C with samples taken at several time points to determine the initial 
reaction rate. B, HCBD. Incubations were made in 0.1 M phosphate 
buffer (pH 7.4; 1 ml) containing rat liver microsomal protein (4 mg), 
glutathione reductase (0.25 U), glutathione (2.5 mM), an NADPH gener­
ating system and HCBD at the concentrations shown. Incubations were 
for 30 min at 37°C. Results are shown as the mean of two experiments 
for each substrate.
TABLE 1
Rate of HCBD-mediated glutathione depletion by male and female 
hepatic microsomal and cytosolic fractions
Rat liver fractions were incubated as described under “Materials and Methods” in 
the presence of glutathione (10 mM), [14C]HCBD (2.8 mM and 1 ^Ci/ml), glutathione 
reductase (12 U) and an NADPH generating system where indicated. Samples (0.3 
ml) were removed at 30, 60, 90 and 120 min for glutathione measurement and the 
rate of loss calculated. Values are shown as mean ±  S.E. with the number of 
animals in parentheses.
Fraction Glutathione Depletion
Male
Microsomes +  HCBD 
Microsomes +  NADPH +  HCBD 
Microsomes alone 
Cytosol +  HCBD 
Cytosol alone 
Female 
Microsomes +  HCBD 
Cytosol +  HCBD
nmol/min/mg protein
0.592 ±  0.038 (5) 
0.524 ±  0.034 (5) 
0.006 ±  0.006 (4) 
0.349 ±  0.020 (6) 
0.061 ±  0.032 (3)
0.604 ±  0.047 (6) 
0.368 ±0 .012 (5)
Form ation o f HCBD-mediated glutathione conjugates 
by microsom al and cytosolic fractions from male and 
fem ale rat liver and kidney. To establish whether the 
hepatic glutathione depletion due to HCBD was the result of 
the formation of a glutathione conjugate, radiolabeled HCBD 
was incubated with microsomal fractions fortified with gluta­
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thione. The deproteinized incubation medium was then chro­
matographed on thin-layer plates and the results of a typical 
experiment are shown in figure 3. A radioactive metabolite (Rf 
0.33) was observed on scanning the thin-layer chromatogram. 
The formation of this product was independent of the presence 
of NADPH but dependent on the presence of reduced glutathi­
one and an enzymatically active microsomal preparation. When 
[3H] glutathione was used instead of [14C]HCBD a peak of 
radioactivity with an identical Rf value to the [14C]HCBD 
metabolite was observed (data not shown). The material of Rf 
0.33 which was isolated and characterized by gas chromatog­
raphy and mass spectrometry after hydrolysis and methylation 
gave a mass spectrum consistent with that of the methyl ester 
of S-(l,l,2,3,4-pentachloro-l:3-butadienyl)cysteine (fig. 4). 
Two radiolabeled mass peaks in the ratio of 9:1 were detected 
with retention times of 2.4 and 2.7 min. Both peaks gave 
identical mass spectra and are therefore assumed to be the cis- 
and trans-isomers of this conjugate. The identification of this 
cysteine derivative, after hydrolysis, using conditions known to 
hydrolyze glutathione (Hutson, 1976) is consistent with the 
metabolite Rf 0.33 being the corresponding glutathione conju­
gate. This is further supported by 1 ) experiments using [3H] 
glutathione which gave an identical product to that isolated, 2 ) 
chemically synthesized S -(l,1,2,3,4-pentachloro-l:3-buta- 
dienyl) glutathione had an identical Rf value in the thin-layer 
chromatographic system to the metabolite and 3) the mass 
spectrum of the chemically synthesized methyl ester of the 
cysteine conjugate was identical to the derivatized metabolite. 
The [13C]NMR spectrum of the synthesized product showed 
the structure to be S-(l,l,2,3,4-pentachloro-l:3-butadienyl) 
cysteine. As well as substantiating the structure of the metab-
4
5
origin
Fig. 3. Thin-layer chromatography scan of radiolabeled metabolites re­
sulting from the incubation of [14C]HCBD and glutathione with male 
hepatic microsomes or cytosol. Incubations were carried out as de­
scribed in figure 1. After incubation samples were cooled to 4°C, centri­
fuged and 40 jul of the supernatant run on silica gel plates in butanol- 
acetic acid-water (12:3:5). Plates were scanned using a radiochromato­
gram scanner. Scan: 1, microsomes plus NADPH, 2, microsomes minus 
NADPH; 3, cytosol; 4, microsomes minus GSH; 5, microsomes boiled at 
100°C for 5 min; 6, microsomes plus oxidized glutathione to replace 
GSH.
TABLE 2
Rate of HCBD-glutathione conjugate formation by male and female 
hepatic microsomal and cytosolic fractions
Rat liver fractions were incubated as described in the legend to table 1. After 2 hr 
the reaction was stopped, the excess HCBD extracted into diethyl ether and a 
sample of the aqueous phase taken for radioactivity determination and for thin- 
layer chromatography. The amount of conjugate formation was calculated from the 
area under the radiochromatogram scans. Results are mean ±  S.E. with the
number of animals shown in parentheses.
Fraction Conjugate Formation
nmollminlmg protein
Male
Microsomes +  HCBD 0.715 ±  0.055 (4)
Microsomes +  NADPH +  HCBD 0.576 ±  0.036 (6)
Microsomes alone 0.025 ±  0.008 (5)
Cytosol +  HCBD 0.290 ±0 .014 (6)
Cytosol alone 0.034 ±  0.009 (6)
Female
Microsomes +  HCBD 0.575 ±  0.021 (5)
Microsomes +  NADPH +  HCBD 0.601 ±  0.037 (6)
Cytosol +  HCBD 0.168 ±0 .009 (6)
TABLE 3
Effect of 1-chloro-2,4-dinitrobenzene on the formation of HCBD- 
glutathione conjugates by male rat liver microsomal and cytosolic 
fractions
Male rat liver microsomal fraction (9 mg of protein) or cytosol fraction (25 mg of 
protein) was incubated with glutathione (4 mM) and [14C]HCBD (1 mM and 1 t iC \/  
ml) as described under “Materials and Methods” for 60 min at 37°C in the presence 
or absence of 1-chloro-2,4-dinitrobenzene (CDNB) (1 mM). The reaction was then 
cooled to 4°C, centrifuged and an aliquot of the supernatant chromatographed on 
a thin-layer chromatogram and the conjugate formation calculated from the area 
under the radioactive peaks. A, the product with R( 0.14 and B, the pentachloro- 
butadienyl-glutathione conjugate with an R, 0.33. Results are shown as mean ±  
S.E. of three animals.
Fraction Conjugate Formation
nmoljmin/mg protein
Microsomes 0 .3 0 9  ±  0 .0 4 7
Microsomes +  CDNB 0 .2 3 1  ±  0 .0 2 7
Cytosol 0 .0 9 8  ± 0 . 0 1 0  0 .2 8 6  ±  0 .0 3 3
Cytosol +  CDNB 0 .0 5 3 *  ±  0 .0 0 5  0 .2 1 0 *  ±  0 .0 1 6
* Significantly different from control. P <  .05 using Student f test.
olite these data also demonstrate that the product of Rf 0.33 
does not contain positional isomers of the HCBD-glutathione 
adduct.
To quantitate the rate of metabolite formation the thin-layer 
plates were scanned using a computer-linked radiochromato­
gram scanner and the peak areas were determined. The results 
for male and female hepatic microsomal and cytosolic fractions 
are shown in table 2. In addition to the major metabolite (Rf 
0.33) a second smaller and more polar metabolite (Rf 0.14) was 
observed in the incubation with female hepatic microsomes and 
with male and female hepatic cystosolic fractions (fig. 3). The 
ratio of the metabolite at R f 0.14 compared with R f 0.33 was 
0.4 to 0.5. Incubation of male hepatic microsomes plus NADPH 
under an atmosphere of carbon monoxide or nitrogen did not 
reduce the rate of HCBD-mediated glutathione conjugate for­
mation [control, 100 ±  18% (3); 20% 0 2 in CO, 95 ±  18% (3); 
nitrogen, 123 ±  8 % (3)]. l-Chloro-2:4-dinitrobenzene, a sub­
strate for glutathione »S-transferase enzymes reduced the for­
mation of the HCBD-conjugate when present at an equimolar 
concentration to HCBD (1  mM) in male microsomal and cy­
tosolic fractions (table 3).
When male and female kidney microsomal fractions were 
incubated with [14C]HCBD and glutathione a radioactive prod­
uct was formed which had an Rf of about 0.35 on the thin-layer 
chromatography plates. This peak was not observed in incu-
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Fig. 4. Mass spectrum of the derivatized metabolite formed on incubation of HCBD with male hepatic microsomes and glutathione. The incubation 
conditions and derivatization conditions are described under “Materials and Methods.”
TABLE 4
Rate of HCBD-glutathione conjugate formation by male and female 
renal microsomal and cytosolic fractions
Rat kidney fractions were prepared as described under “Materials and Methods" 
and incubated at 37°C for 2 hr in the presence of glutathione (10 mM), HCBD (2.8 
mM) and glutathione reductase (12 U). Protein concentrations were microsomal (8 - 
13 mg) and cytosol (21-27 mg). An aliquot was then chromatographed on a thin- 
layer plate and the plate scanned using a radiochromatogram scanner. Results are 
shown as mean ±  S.E. with the number of animals in parentheses.
Fraction Conjugate Formation
nmol/minlmg protein
Male
Microsomes +  HCBD 0.089 ±  0.008 (6)
Microsomes alone 0.009 ±  0.003 (3)
Cytosol +  HCBD 0.049 ±  0.010 (5)
Cytosol alone <.005 (3)
Female
Microsomes +  HCBD 0.122 ±0 .010  (5)
Cytosol +  HCBD 0.143 ±  0.026 (6)
bations made in the absence of glutathione. The rate of for­
mation of this product was similar for male and female micro­
somal fractions (table 4). Incubation of male or female renal 
cytosolic fractions with radiolabeled HCBD and glutathione 
led to the formation of two radiolabeled products which on 
thin-layer chromatography had Rf values of 0.14 and 0.33, 
similar to that found with liver cytosol. The ratio of these 
metabolites was about 1 :1 . The rate of formation of these 
radiolabeled products was dependent on glutathione and was
about 3 times faster in cytosol from female kidney compared 
with male kidney (table 4).
Discussion
The depletion of glutathione in animal tissues after the 
administration of compounds which are known to be toxic is 
usually associated with the inactivation of toxic metabolites 
formed by cytochrome P-450-mediated monooxygenase reac­
tions (Ghasseaud, 1979; Mitchell et al., 1976; Jollow et al., 1977). 
It has been proposed that when the concentration of glutathi­
one became too low to effectively deactivate these metabolites, 
they react with proteins and other macromolecules which re­
sults in cellular damage (Mitchell etal., 1973; Jollow and Smith,
1977). We have shown previously that HCBD administration 
to rats causes a marked depletion in hepatic nonprotein sul- 
phydryl content (mainly glutathione) in males (Lock and Ish­
mael, 1981), whereas in female animals both hepatic and renal 
glutathione levels are reduced (Hook et al., 1983).
In the present study we have examined this effect in vitro 
and shown that HCBD does cause glutathione depletion and 
that the product formed is as a result of direct conjugation of 
HCBD with glutathione. The reaction is catalyzed by micro­
somal glutathione S-transferases and is not related to the 
formation of metabolites via cytochrome P-450. The rate of 
formation of the conjugate in microsomes compared closely 
with the rate of glutathione depletion, supporting a 1 :1  stoichi­
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ometry of HCBD with glutathione. Gas chromatography-mass 
spectrum indicates the presence of two isomeric forms of this 
conjugate, one of which predominates. The two isomers could 
not be distinguished by their mass spectra, but on steric grounds 
the trans-isomer might be expected to predominate.
The presence of hepatic microsomal glutathione S-transfer- 
ase(s) has only recently become apparent (Morgenstern et al., 
1979, 1980; Friedberg et al., 1980). Multiple forms of both 
microsomal and cytosolic glutathione S-transferases exist 
(Friedberg et a l, 1980; Habig et a l, 1974) and in the case of the 
cytosolic enzymes these proteins are known to have different 
substrate specificities. Certain similarities, for example isoelec­
tric point and immunochemical cross reactivity between some 
of the microsomal glutathione S-transferases and those in the 
cytosol, are known (Friedberg et al., 1980). However, Morgen­
stern et al. (1982) have clearly demonstrated that at least one 
form of microsomal transferase is clearly distinguishable from 
those in the cytosol. However, in the case of HCBD, these 
enzymes appear to play a major role, the rate of formation of 
the HCBD-glutathione conjugate in the microsomal fraction 
being up to twice that found in cytosol. The activity of these 
enzymes with a variety of substrates under normal conditions 
is low compared with the activity of the hepatic cytosolic 
glutathione S-transferase(s), less than 10% on a milligram of 
protein basis (Glatt and Oesch, 1977; Morgenstern et a l, 1980; 
Friedberg et a l, 1980). Therefore, the microsomal enzyme(s)
did not appear to play an important role in the conjugation of 
most foreign compounds.
The major microsomal glutathione conjugate of HCBD also 
appeared to be formed by rat liver cytosol, but at a slower rate. 
This suggests that either the enzyme (s) responsible for HCBD 
conjugation in the cytosol are different, present at a lower 
concentration or that HCBD preferentially partitions into the 
lipid membranes of the microsomes and results in more sub­
strate being available to the microsomal transferase (s) than to 
those in the cytosol. A second more polar metabolite (Rf 0.14) 
has not been identified but some support for a double conjugate 
is the finding that more glutathione is consumed than product 
formed, suggesting a stoichiometry of greater than 1:1. The 
formation of an HCBD glutathione conjugate by the micro­
somal transferase will result in a significantly less lipophilic 
metabolite than HCBD itself. A water soluble conjugate of this 
nature is unlikely to be retained by the lipophilic membranes 
thus reducing the opportunity for a second conjugation with 
glutathione. In the case of the transferases present in the 
cytosol, although less substrate (HCBD) is available the con­
jugate when formed is likely to be a better substrate for the 
soluble enzymes than the membrane bound transferases. Thus, 
conjugation with 2 mol of glutathione is likely to be favored in 
the cytosol fraction if such an event is occurring.
The overall activities of the male and female hepatic micro­
somal and cytosolic enzymes were not significantly different to
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Fig. 5. Conjugation of HCBD with glutathione (GSH) and its possible nephrotoxic mechanism by analogy with S-dichlorovinyl-L-cysteine and S- 
difluorochlorovinyl-L-cysteine.
208 Wolf et al. Vol. 228
explain convincingly why HCBD-mediated glutathione deple­
tion is more marked in males (Hook et al., 1983).
Kidney microsomal and cytosolic fractions from both male 
and female animals contain enzymes capable of conjugating 
HCBD with glutathione, although their activity is lower than 
that of the liver. Female kidney cytosol appeared to be about 3 
times more active than male kidney cytosol and this may in 
part account for the marked glutathione depletion observed in 
female but not male kidney after HCBD administration (Hook 
et al., 1983).
Unlike other halo-olefins such as trichloroethylene or te- 
trachloroethylene which are almost exclusively metabolized via 
cytochrome P-450 (Henschler and Bonse, 1977), HCBD is not. 
This is substantiated by the finding that the formation of the 
major metabolite in microsomes was independent of the pres­
ence of NADPH and was not affected by carbon monoxide, a 
potent cytochrome P-450 inhibitor, or by anaerobosis, and is 
in agreement with the in vivo studies in which prior treatment 
of rats with inducers or inhibitors of cytochrome P-450 did not 
modify the nephrotoxicity of HCBD (Lock and Ishmael, 1981; 
Hook et al., 1982).
We have isolated the glutathione conjugate of HCBD and 
evidence is presented indicating a direct substitution reaction, 
with the loss of a chloride ion and without the incorporation of 
oxygen. This glutathione conjugate formed in the liver or 
directly in the kidney will be converted by conventional path­
ways in the kidney to give a cysteine conjugate (Bray et al., 
1959). The structure of the HCBD-cysteine conjugate would be 
analogous to that of S-dichlorovinyl-L-cysteine, a known neph- 
rotoxin (Terracini and Parker, 1965). S-dichlorovinyl-L-cys- 
teine is metabolized by the enzyme C-S or /3-lyase, which is 
present in high concentrations in the kidney, to yield a reactive 
alkylating moiety, pyruvate and ammonia (Anderson and 
Schultze, 1965). Activation by this C-S lyase enzyme has also 
been proposed to account for the nephrotoxicity of the cysteine 
conjugates of chlorotrifluoroethylene and chlorodifluoroethy- 
lene (Gandolfi et a l, 1981). Thus, by analogy we suggest that 
HCBD may exert its nephrotoxicity via a similar mechanism 
(fig. 5). This hypothesis is supported by the finding that the 
N-acetylcysteine conjugate of HCBD is nephrotoxic to rats and 
the finding that a glutathione conjugate equivalent to that 
identified here is excreted in the bile after HCBD administra­
tion to rats (Green et al., 1982).'
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